<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1407245569
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Elbag
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ELTROMBOPAG OLAMINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4610.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Synthon Hispania SL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Synthon Hispania SL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 389]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Arabian Japanese Pharmaceutical Co. Ltd.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02BX05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Elbag contains eltrombopag, which belongs to a group of medicines<br />called thrombopoietin receptor agonists. It is used to help increase<br />the number of platelets in your blood. Platelets are blood cells that<br />help to reduce or prevent bleeding.<br />&bull; Elbag is used to treat a bleeding disorder called immune<br />)idiopathic( thrombocytopenic purpura )ITP( in patients aged<br />1 year and above who have already taken other medicines<br />)corticosteroids or immunoglobulins(, which have not worked.<br />ITP is caused by a low blood platelet count )thrombocytopenia(.<br />People with ITP have an increased risk of bleeding. Symptoms<br />patients with ITP may notice include petechiae )pinpoint-sized<br />flat round red spots under the skin(, bruising, nosebleeds, bleeding<br />gums and not being able to control bleeding if they are cut or<br />injured.<br />&bull; Elbag can also be used to treat low platelet count<br />)thrombocytopenia( in adults with hepatitis C virus )HCV(<br />infections, if they have had problems with side effects while<br />on interferon treatment. Many people with hepatitis C have low<br />platelet counts, not only as a result of the disease, but also due<br />to some of the antiviral medicines that are used to treat it. Taking<br />Elbag may make it easier for you to complete a full course of<br />antiviral medicine )peginterferon and ribavirin(.<br />&bull; Elbag may also be used to treat adult patients with low blood<br />counts caused by severe aplastic anaemia )SAA(. SAA is a disease<br />in which the bone marrow is damaged, causing a deficiency of<br />the red blood cells )anaemia(, white blood cells )leukopenia( and<br />platelets )thrombocytopenia(.<br />&bull; For the first-line treatment of acquired severe aplastic anaemia<br />)SAA( in combination with standard immunosuppressive therapy<br />in adult and paediatric patients aged 2 years and over who are<br />unsuitable for haematopoietic stem cell transplantation at the<br />time of diagnosis.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take Elbag</strong><br />&bull; <strong>if you are allergic </strong>to eltrombopag or any of the other ingredients of<br />this medicine )listed in section 6 under &lsquo;What Elbag contains&rsquo;(.<br /><strong>Check with your doctor </strong>if you think this applies to you.<br /><strong>b. Take special care with Elbag</strong><br />Talk to your doctor before taking Elbag:<br />&bull; if you have <strong>liver problems</strong>. People who have low platelet counts as<br />well as advanced chronic )long-term( liver disease are more at risk of<br />side effects, including life-threatening liver damage and blood clots. If<br />your doctor considers that the benefits of taking Elbag outweigh the<br />risks, you will be closely monitored during treatment.<br />&bull; if you are at risk of <strong>blood clots </strong>in your veins or arteries, or you know<br />that blood clots are common in your family.<br />You may be at <strong>higher risk of blood clots</strong>:<br />- as you get older<br />- if you have had to stay in bed for a long time<br />- if you have cancer<br />- if you are taking the contraceptive birth control pill or hormone<br />replacement therapy<br />- if you have recently had surgery or received a physical injury<br />- if you are very overweight )obese(<br />- if you are a smoker<br />- if you have advanced chronic liver disease<br />If any of these apply to you, <strong>tell your doctor </strong>before starting<br />treatment. You should not take Elbag unless your doctor considers<br />that the expected benefits outweigh the risk of blood clots.<br />&bull; if you have <strong>cataracts </strong>)the lens of the eye getting cloudy(<br />&bull; if you have another <strong>blood condition</strong>, such as myelodysplastic<br />syndrome )MDS(. Your doctor will carry out tests to check that you do<br />not have this blood condition before you start Elbag. If you have MDS<br />and take Elbag, your MDS may get worse.<br />Tell your doctor if any of these apply to you.<br /><strong>Eye examinations</strong><br />Your doctor will recommend that you are checked for cataracts. If you<br />do not have routine eye-tests your doctor should arrange regular<br />testing. You may also be checked for the occurrence of any bleeding<br />in or around your retina )the light-sensitive layer of cells at the back<br />of the eye(.<br /><strong>You will need regular tests</strong><br />Before you start taking Elbag, your doctor will carry out blood tests<br />to check your blood cells, including platelets. These tests will be<br />repeated at intervals while you are taking it.<br /><strong>Blood tests for liver function</strong><br />Elbag can cause blood test results that may be signs of liver damage<br />- an increase of some liver enzymes, especially bilirubin and alanine<br />/ aspartate transaminases. If you are taking interferon-based<br />treatments together with Elbag to treat low platelet count due to<br />hepatitis C, some liver problems can get worse.<br />You will have blood tests to check your liver function before you start<br />taking Elbag and at intervals while you are taking it. You may need to<br />stop taking Elbag if the amount of these substances increases too<br />much, or if you get other signs of liver damage.<br /><strong>Read the information &lsquo;</strong>Liver problems<strong>&rsquo; in section 4 of this leaflet.<br />Blood tests for platelet count</strong><br />If you stop taking Elbag, your blood platelet count is likely to become<br />low again within several days. The platelet count will be monitored,<br />and your doctor will discuss appropriate precautions with you.<br />A very high blood platelet count may increase the risk of blood<br />clotting. However blood clots can also form with normal or even low<br />platelet counts. Your doctor will adjust your dose of Elbag to ensure<br />that your platelet count does not become too high.<br /><strong>Get medical help immediately </strong>if you have any of these signs of<br />a <strong>blood clot</strong>:<br />&bull; <strong>swelling</strong>, <strong>pain </strong>or tenderness in <strong>one leg</strong><br />&bull; <strong>sudden shortness of breath </strong>especially together with sharp pain in<br />the chest or rapid breathing<br />&bull; abdominal )stomach( pain, enlarged abdomen, blood in your stools<br /><strong>Tests to check your bone marrow</strong><br />In people who have problems with their bone marrow, medicines like<br />Elbag could make the problems worse. Signs of bone marrow changes<br />may show up as abnormal results in your blood tests. Your doctor<br />may also carry out tests to directly check your bone marrow during<br />treatment with Elbag.<br /><strong>Checks for digestive bleeding</strong><br />If you are taking interferon-based treatments together with Elbag<br />you will be monitored for any signs of bleeding in your stomach or<br />intestine after you stop taking Elbag.<br /><strong>Heart monitoring</strong><br />Your doctor may consider it necessary to monitor your heart during<br />treatment with Elbag and carry out an electrocardiogram )ECG( test.<br /><strong>Children and adolescents</strong><br />Elbag is not recommended for children aged under 1 year who have<br />ITP. It is also not recommended for people under 18 years with low<br />platelet counts due to hepatitis C or severe aplastic anaemia.<br /><strong>c. Taking other medicines, herbal or dietary supplements</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or<br />might take any other medicines.<br /><strong>Some everyday medicines interact with Elbag </strong>&ndash; including<br />prescription and non-prescription medicines and minerals. These<br />include:<br />&bull; antacid medicines to treat <strong>indigestion</strong>, <strong>heartburn </strong>or <strong>stomach<br />ulcers </strong>)see also &lsquo;When to take it&rsquo; in section 3(<br />&bull; medicines called statins, to <strong>lower cholesterol</strong><br />&bull; some medicines to treat <strong>HIV infection</strong>, such as lopinavir and/or<br />ritonavir<br />&bull; ciclosporin used in the context of <strong>transplantations </strong>or <strong>immune<br />diseases</strong><br />&bull; minerals such as iron, calcium, magnesium, aluminium, selenium and<br />zinc which may be found in <strong>vitamin and mineral supplements </strong>)see<br />also &lsquo;When to take it&rsquo; in section 3(<br />&bull; medicines such as methotrexate and topotecan, to treat <strong>cancer<br />Talk to your doctor </strong>if you take any of these. Some of them are not to<br />be taken with Elbag, or the dose may need adjusting, or you may need<br />to alter the timing of when you take them. Your doctor will review<br />the medicines you are taking, and suggest suitable replacements if<br />necessary.<br />If you are also taking medicines to prevent blood clots there is a<br />greater risk of bleeding. Your doctor will discuss this with you.<br />If you are taking <strong>corticosteroids, danazol, </strong>and/or <strong>azathioprine </strong>you<br />may need to take a lower dose or to stop taking them while you are<br />taking Elbag.<br /><strong>d. Taking Elbag with food and drink</strong><br />Do not take Elbag with dairy foods or drinks as the calcium in<br />dairy products affects the absorption of the medicine. For more<br />information, see &lsquo;When to take it&rsquo; in section 3.<br /><strong>e. Pregnancy and breast-feeding<br />Don&rsquo;t use Elbag if you are pregnant </strong>unless your doctor specifically<br />recommends it. The effect of Elbag during pregnancy is not known.<br />&bull; <strong>Tell your doctor if you are pregnant, </strong>think you may be pregnant,<br />or are planning to have a baby.<br />&bull; <strong>Use a reliable method of contraception </strong>while you&rsquo;re taking Elbag,<br />to prevent pregnancy<br />&bull; <strong>If you do become pregnant during treatment </strong>with Elbag, tell<br />your doctor.<br /><strong>Don&rsquo;t breast-feed while you are taking Elbag</strong>. It is not known<br />whether Elbag passes into breast-milk.<br /><strong>If you are breast-feeding </strong>or planning to breast-feed, tell your<br />doctor.<br /><strong>f. Driving and using machines<br />Elbag can make you dizzy </strong>and have other side effects that make<br />you less alert.<br /><strong>Don&rsquo;t drive or use machines </strong>unless you are sure you&rsquo;re not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check<br />with your doctor or pharmacist if you are not sure. Do not change the<br />dose or schedule for taking Elbag unless your doctor or pharmacist<br />advises you to. While you are taking Elbag, you will be under the care<br />of a doctor with specialist experience in treating your condition.<br /><strong>How much to take<br />For ITP<br />Adults </strong>and <strong>children </strong>)6 to 17 years( &ndash; the usual starting dose for ITP<br />is <strong>one 50 mg tablet </strong>of Elbag a day. If you are of East Asian origin<br />)Chinese, Japanese, Taiwanese, Thai or Korean( you may need to start<br />at a <strong>lower dose of 25 mg.<br />Children </strong>)1 to 5 years( &mdash; the usual starting dose for ITP is <strong>one 25<br />mg tablet </strong>of Elbag a day.<br /><strong>For hepatitis C<br />Adults - </strong>the usual starting dose for hepatitis C is <strong>one 25 mg tablet</strong><br />of Elbag a day. If you are of East Asian origin )Chinese, Japanese,<br />Taiwanese, Thai or Korean( you will start on the <strong>same 25 mg dose.<br />For SAA<br />Adults - </strong>the usual starting dose for SAA is <strong>one 50 mg tablet </strong>of Elbag<br />a day. If you are of East Asian origin )Chinese, Japanese, Taiwanese,<br />Thai or Korean( you may need to start at a <strong>lower dose of 25 mg.</strong><br />Elbag may take 1 to 2 weeks to work. Based on your response to<br />Elbag your doctor may recommend that your daily dose is changed.<br /><strong>How to take the tablets</strong><br />Swallow the tablet whole, with some water.<br /><strong>When to take it</strong><br />Make sure that &ndash;<br />&bull; in the <strong>4 hours before </strong>you take Elbag<br />&bull; and the <strong>2 hours after </strong>you take Elbag<br /><strong>you don&rsquo;t </strong>consume any of the following:<br />&bull; <strong>dairy foods </strong>such as cheese, butter, yoghurt or ice cream<br />&bull; <strong>milk or milk shakes, </strong>drinks containing milk, yoghurt or cream<br />&bull; <strong>antacids, </strong>a type of medicine for <strong>indigestion and heartburn</strong><br />&bull; some <strong>mineral and vitamin supplements </strong>including iron, calcium,<br />magnesium, aluminium, selenium and zinc<br />If you do, the medicine will not be properly absorbed into your body</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Take Elbag</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>NO dairy products,<br />antacids or mineral<br />supplements</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>For 4 hours before<br />you take Elbag</p></td><td><p>&nbsp;</p></td><td><p>and for 2 hours<br />after you take<br />Elbag</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>For more advice about suitable foods and drinks, talk to your<br />doctor.<br />a . If you take more Elbag than you should<br />Contact a doctor or pharmacist immediately</strong>. If possible show<br />them the pack, or this leaflet.<br />You will be monitored for any signs or symptoms of side effects and<br />given appropriate treatment immediately.<br /><strong>b . If you forget to take Elbag</strong><br />Take the next dose at the usual time. Do not take more than one dose<br />of Elbag in one day.<br /><strong>C . If you stop taking Elbag</strong><br />Don&rsquo;t stop taking Elbag without talking to your doctor. If your doctor<br />advises you to stop treatment, your platelet count will then be<br />checked each week for four weeks. See also &lsquo;Bleeding or bruising<br />after you stop treatment&rsquo; in section 4.<br />If you have any further questions on the use of this medicine, ask<br />your doctor or pharmacist.<br />*The Powder for oral solution supporting the age group from 1 to 5<br />years old is not registered</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br /><strong>Symptoms needing attention: see a doctor</strong><br />People taking Elbag for either ITP or low blood platelet counts due<br />to hepatitis C could develop signs of potentially serious side effects.<br /><strong>It is important to tell a doctor if you develop these symptoms</strong>.<br /><strong>Higher risk of blood clots</strong><br />Certain people may have a higher risk of blood clots, and medicines<br />like Elbag could make this problem worse. The sudden blocking of<br />a blood vessel by a blood clot is an uncommon side effect and may<br />affect up to 1 in 100 people.<br /><br />⚠ <strong>Get medical help immediately if you develop signs and<br />symptoms of a blood clot, such as</strong>:<br />&bull; <strong>swelling, pain, heat, redness, </strong>or tenderness in <strong>one leg</strong><br />&bull; <strong>sudden shortness of breath</strong>, especially together with sharp pain<br />in the chest or rapid breathing<br />&bull; abdominal )stomach( pain, enlarged abdomen, blood in your stools.<br /><strong>Liver problems</strong><br />Elbag can cause changes that show up in blood tests, and may be<br />signs of liver damage. Liver problems )increased enzymes showing<br />up in blood tests( are common and may affect up to 1 in 10 people.<br />Other liver problems )bile not flowing properly( are uncommon and<br />may affect up to 1 in 100 people.<br />If you have either of these signs of liver problems:<br />&bull; <strong>yellowing </strong>of the skin or the whites of the eyes )jaundice(<br />&bull; unusually <strong>dark-coloured urine<br />tell your doctor immediately</strong>.<br /><strong>Bleeding or bruising after you stop treatment</strong><br />Within two weeks of stopping Elbag, your blood platelet count will<br />usually drop back down to what it was before starting Elbag. The<br />lower platelet count may increase the risk of bleeding or bruising.<br />Your doctor will check your platelet count for at least 4 weeks after<br />you stop taking Elbag.<br /><strong>Tell your doctor </strong>if you have any bleeding or bruising after stopping<br />Elbag.<br />Some people have <strong>bleeding in the digestive system </strong>after they<br />stop taking peginterferon, ribavirin, and Elbag. Symptoms include:<br />&bull; black tarry stools )discoloured bowel movements are a uncommon<br />side effect that may affect up to 1 in 100 people(<br />&bull; blood in your stools<br />&bull; vomiting blood or something that looks like coffee grounds<br /><strong>Tell your doctor </strong>immediately if you have any of these symptoms.<br /><strong>The following side effects have been reported to be associated<br />with treatment with Elbag in adult patients with ITP:<br />Very common side effects</strong><br />These may affect <strong>more than 1 in 10 </strong>people:<br />&bull; common cold<br />&bull; feeling sick )nausea(<br />&bull; diarrhoea<br />&bull; cough<br />&bull; infection in the nose, sinuses, throat and upper airways, common<br />cold )upper respiratory tract infection(<br /><strong>Very common side effects that may show up in blood tests:</strong><br />&bull; increased of liver enzymes )alanine aminotransferase )ALT((<br /><strong>Common side effects</strong><br />These may affect <strong>up to 1 in 10 </strong>people:<br />&bull; muscle pain, muscle spasm, muscle weakness<br />&bull; back pain<br />&bull; bone pain<br />&bull; heavy menstrual period<br />&bull; sore throat and discomfort when swallowing<br />&bull; eye problems including abnormal eye test, dry eye, eye pain and<br />blurred vision<br />&bull; vomiting<br />&bull; flu )influenza(<br />&bull; cold sore<br />&bull; pneumonia<br />&bull; irritation and inflammation )swelling( of the sinuses<br />&bull; inflammation )swelling( and infection of the tonsils infection of the<br />lungs, sinuses, tonsils, nose and throat<br />&bull; inflammation of the gum tissue<br />&bull; loss of appetite<br />&bull; feeling of tingling, prickling or numbness, commonly called &rdquo;pins<br />and needles&ldquo;<br />&bull; feeling drowsy<br />&bull; ear pain<br />&bull; pain, swelling and tenderness in one of your legs )usually the calf(<br />with warm skin in the affected area )signs of a blood clot in a deep<br />vein(<br />&bull; localised swelling filled with blood from a break in a blood vessel<br />)haematoma(<br />&bull; mouth problems including dry mouth, sore mouth, sensitive tongue,<br />bleeding gums, mouth ulcers<br />&bull; runny nose<br />&bull; toothache<br />&bull; stomach pain and tenderness<br />&bull; liver problems<br />&bull; skin changes including excessive sweating, itching bumpy rash, red<br />spots, changes in appearance of the skin<br />&bull; hair loss<br />&bull; foamy, frothy or bubbly-looking urine )signs of protein in urine(<br />&bull; generally feeling unwell, high temperature, feeling hot<br />&bull; chest pain<br />&bull; problems sleeping, depression<br />&bull; migraine<br />&bull; decreased vision<br />&bull; spinning sensation )vertigo(<br />&bull; Digestive wind/gas<br /><strong>Common side effects that may show up in blood test:</strong><br />&bull; decreased number of red blood cells )anaemia(<br />&bull; decreased number of platelets )thrombocytopenia(<br />&bull; decreased number of white blood cells<br />&bull; decreased haemaglobin level<br />&bull; decreased number of eosinophils<br />&bull; increased number of white blood cells )leukocytosis(<br />&bull; increased levels of uric acid<br />&bull; decreased levels of potassium<br />&bull; increased levels of creatinine<br />&bull; increased levels of alkaline phosphatase<br />&bull; increase of liver enzymes )aspartate aminotransferase )AST((<br />&bull; increase in bilirubin )a substance produced by the liver(<br />&bull; increased levels of some proteins<br /><strong>Uncommon side effects</strong><br />These may affect <strong>up to 1 in 100 </strong>people:<br />&bull; interruption of blood supply to part of the heart<br />&bull; sudden shortness of breath, especially when accompanied with<br />sharp pain in the chest and /or rapid breathing, which could be signs<br />of a blood clot in the lungs )see &lsquo;Higher risk of blood clots&rsquo; earlier in<br />section 4(<br />&bull; the loss of function of part of the lung caused by a blockage in<br />the lung artery<br />&bull; liver problems, including yellowing of the eyes and skin )see &lsquo;Liver<br />problems&rsquo; earlier in section 4(<br />&bull; the loss of function of part of the lung caused by a blockage in<br />the lung artery<br />&bull; including yellowing of the eyes and skin )see &lsquo;Liver problems&rsquo; earlier<br />in section 4(<br />&bull; liver injury due to medication<br />&bull; heart beating faster, irregular heartbeat, bluish discolouration of<br />the skin<br />&bull; disturbances of heart rhythm )QT prolongation(<br />&bull; blood clot<br />&bull; painful swollen joints caused by uric acid )gout(<br />&bull; lack of interest, mood changes<br />&bull; problems with balance, speech and nerve function, shaking<br />&bull; eye problems including increased production of tears, cloudy lens in<br />the eye )cataract(, bleeding of the retina<br />&bull; problems with the nose, throat and sinuses, breathing problems<br />when sleeping<br />&bull; digestive system problems including frequent bowel movements,<br />food poisoning, blood in stool<br />&bull; rectal bleeding, blood in your stool, abdominal bloating, constipation<br />&bull; mouth problems, including dry or sore mouth, sensitive tongue,<br />bleeding gums<br />&bull; sunburn<br />&bull; redness or swelling around, a wound bleeding around a catheter )if<br />present( into the skin sensation of a foreign body<br />&bull; kidney problems including inflammation of the kidney, excessive<br />urination at night, kidney failure, white cells in urine<br />&bull; cold sweat<br />&bull; infection of the skin<br />&bull; skin changes including change in colour, peeling, redness, itching<br />and sweating<br /><strong>Uncommon side effects that may show up in laboratory tests:</strong><br />&bull; changes in the shape of red blood cells<br />&bull; increased number of platelets<br />&bull; decreased levels of calcium<br />&bull; decreased number of red blood cells )anaemia( cause by excessive<br />destruction of red blood cells )haemolytic anaemia(<br />&bull; increased number of myelocytes<br />&bull; increased band neutrophils<br />&bull; increased blood urea<br />&bull; increased levels of blood albumin<br />&bull; increased levels of total protein<br />&bull; decreased levels of blood albumin<br />&bull; increased pH of urine<br />&bull; increased haemaglobin level<br /><strong>The following additional side effects have been reported to be<br />associated with treatment with Elbag in children )aged 1 to 17<br />years( with ITP:</strong><br />If these side effects become severe, please tell your doctor,<br />pharmacist or nurse.<br /><strong>Very common side effects</strong><br />These may affect <strong>more than 1 in 10 </strong>children:<br />&bull; infection in the nose, sinuses, throat and upper airways, common<br />cold )upper respiratory tract infection(<br />&bull; diarrhoea<br />&bull; abdominal pain<br />&bull; cough<br />&bull; high temperature<br />&bull; feeling sick )nausea(<br /><strong>Common side effects</strong><br />These may affect <strong>up to 1 in 10 </strong>children:<br />&bull; difficulty in sleeping )insomnia(<br />&bull; toothache<br />&bull; pain in the nose and throat<br />&bull; itchy, runny or blocked nose<br />&bull; sore throat, runny nose, nasal congestion and sneezing<br />&bull; mouth problems including dry mouth, sore mouth, sensitive tongue,<br />bleeding gums, mouth<br />&bull; ulcers<br /><strong>The following side effects have been reported to be associated<br />with treatment with Elbag in combination with peginterferon<br />and ribavirin in patients with HCV:<br />Very common side effects</strong><br />These may affect <strong>more than 1 in 10 </strong>people:<br />&bull; headache<br />&bull; decreased appetite<br />&bull; cough<br />&bull; feeling sick )nausea(, diarrhoea<br />&bull; muscle pain, muscle weakness<br />&bull; itching<br />&bull; lack of energy<br />&bull; high temperature<br />&bull; unusual hair loss<br />&bull; feeling weak<br />&bull; flu-like illness<br />&bull; swelling in the hands or feet<br />&bull; chills<br /><strong>Very common side effects that may show up in blood tests:</strong><br />&bull; decreased number of red blood cells )anaemia(<br /><strong>Common side effects</strong><br />These may affect <strong>up to 1 in 10 </strong>people:<br />&bull; infection of the urinary system<br />&bull; inflammation of the nasal passages, throat and mouth, flu-like<br />symptoms, dry mouth, sore or inflamed mouth, toothache<br />&bull; weight loss<br />&bull; sleep disorders, abnormal drowsiness, depression, anxiety<br />&bull; dizziness, problems with attention and memory, change in mood<br />&bull; tingling or numbness of the hands or feet<br />&bull; fever, headache<br />&bull; eye problems, including cloudy lens in the eye )cataract(, dry eye,<br />small yellow deposits in the retina, yellowing of the whites of the eye<br />&bull; bleeding of the retina<br />&bull; spinning sensation )vertigo(<br />&bull; fast or irregular heartbeat )palpitations(, shortness of breath<br />&bull; cough bringing up phlegm, runny nose, flu, cold sore, sore throat and<br />discomfort when swallowing<br />&bull; digestive system problems, including being sick )vomiting(, stomach<br />pain, indigestion, constipation, swollen stomach, taste disturbances,<br />inflammation of the stomach, piles )haemorrhoids(, irritation of the<br />gut<br />&bull; toothache<br />&bull; liver problems, including blood clot, tumour in the liver )see &lsquo;Liver<br />problems&rsquo; earlier in section 4(<br />&bull; skin changes, including rash, dry skin, eczema, redness of the skin,<br />itching, excessive sweating, unusual skin growths<br />&bull; joint pain, back pain, bone pain, pain in the hands or feet, muscle<br />spasms<br />&bull; irritability, generally feeling unwell, chest pain and discomfort<br />&bull; infection in the nose, sinuses, throat and upper airways, common<br />cold )upper respiratory tract infection(<br />&bull; depression, anxiety, sleep problems, nervousness<br /><strong>Common side effects that may show up in blood tests:</strong><br />&bull; increased blood sugar )glucose(<br />&bull; decreased number of white blood cells<br />&bull; decreased level of blood proteins<br />&bull; increased levels of blood bilirubin )a substance produced by the<br />liver(<br />&bull; changes in the enzymes that control blood clotting<br /><strong>Uncommon side effects</strong><br />These may affect <strong>up to 1 in 100 </strong>people:<br />&bull; painful urination<br />&bull; disturbances of heart rhythm )QT prolongation(<br />&bull; stomach flu )gastroenteritis(<br />&bull; skin changes including change in colour, peeling, redness, itching<br />and sweating.<br />&bull; yellowing of the whites of the eyes or skin )jaundice(<br />&bull; swollen blood vessels and bleeding in the gullet )oesophagus(<br />&bull; rash, bruising at the injection site<br />&bull; decreased number of red blood cells )anaemia( caused by excessive<br />destruction of red blood cells )haemolytic anaemia(<br />&bull; confusion, agitation<br />&bull; liver injury due to medication<br /><strong>The following side effects have been reported to be associated<br />with treatment with Elbag in patients with severe aplastic<br />anaemia )SAA(:</strong><br />If these side effects become severe, please tell your doctor,<br />pharmacist or nurse.<br /><strong>Very common side effects</strong><br />These may affect <strong>more than 1 in 10 </strong>people.<br />&bull; cough<br />&bull; headache<br />&bull; pain in the nose and throat<br />&bull; diarrhoea<br />&bull; nausea<br />&bull; joint pain )arthralgia(<br />&bull; pain in extremities )arms, legs, hands and feet(<br />&bull; dizziness<br />&bull; feeling very tired )fatigue(<br />&bull; fever<br />&bull; chills<br />&bull; itchy eyes<br />&bull; blisters in the mouth<br />&bull; abdominal pain<br />&bull; muscle spasms<br /><strong>Very common side effects that may show up in the blood tests</strong><br />&bull; abnormal changes to the cells in your bone marrow<br /><strong>Common side effects</strong><br />These may affect up to <strong>1 in 10 </strong>people.<br />&bull; anxiety<br />&bull; depression<br />&bull; feeling cold<br />&bull; feeling unwell<br />&bull; eye problems including blurred vision, cloudy lens in the eye<br />)cataract(, spots or deposits in eye )vitreous floaters(, dry eye, itchy<br />eye, yellowing of the whites of the eyes or skin<br />&bull; nose bleed<br />&bull; bleeding of the gums<br />&bull; digestive system problems including being sick )vomiting(, change<br />in appetite )increased or<br />decreased(, stomach pain/discomfort, swollen stomach, passing wind,<br />change in stool colour<br />&bull; fainting<br />&bull; skin problems including small red or purple spots caused by bleeding<br />into the skin )petechiae( rash, itching, skin lesion<br />&bull; back pain<br />&bull; muscle pain<br />&bull; bone pain<br />&bull; weakness )asthenia(<br />&bull; swelling of the lower limbs due to the accumulation of fluids<br />&bull; abnormal colored urine<br />&bull; interruption in blood supply to spleen )splenic infarction(<br />&bull; runny nose<br /><strong>Common side effects that may show up in the blood tests</strong><br />&bull; increase in enzymes due to muscle breakdown )creatine<br />phosphokinase(<br />&bull; accumulation of iron in the body )iron overload(<br />&bull; decrease in blood sugar levels )hypoglycaemia(<br />&bull; increased levels of bilirubin )a substance produced by the liver(<br />&bull; increased levels of liver enzymes )aspartate aminotransferase<br />)AST((<br />&bull; decreased levels of white blood cells<br /><strong>Side effects with frequency not known</strong><br />Frequency cannot be estimated from the available data<br />&bull; skin discolouration<br />&bull; darkening of the skin<br />&bull; yellowing of the skin and eyes, tenderness around the liver<br /><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse.<br />This includes any possible side effects not listed in this leaflet. You<br />can also report side effects directly. By reporting side effects you can<br />help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children.<br />&bull; Do not use this medicine after the expiry date, which is stated on<br />the carton and the blister.<br />&bull; Do not throw away any medicines via wastewater or household<br />waste. Ask your pharmacist how to throw away medicines you no<br />longer use. These measures will help protect the environment.<br />&bull; Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Elbag is eltrombopag.<br /><strong>25 mg film-coated tablets: </strong>Each film-coated tablet contains<br />eltrombopag olamine equivalent to 25 mg eltrombopag.<br /><strong>50 mg film-coated tablets: </strong>Each film-coated tablet contains<br />eltrombopag olamine equivalent to 50 mg eltrombopag.<br />The other core ingredients are: magnesium stearate, mannitol,<br />microcrystalline cellulose, povidone, sodium starch glycolate,<br />Calcium silicate and Isomalt )E 953(.<br />Elbag 25 mg and 50 mg film-coated tablets also contain coating<br />ingredients which are: Hypromellose, titanium dioxide, Iron oxide<br />red )E 172(, Iron oxide yellow )E 172( and Triacetin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Elbag 25 mg film-coated tablets are dark pink, round, biconvex
film-coated tablet with ”II“ debossed on one side and with a
diameter of approximately 8 mm.
Elbag 50 mg film-coated tablets are pink, round, biconvex filmcoated tablet with ”III“ debossed on one side and with a diameter
of approximately 10 mm.
The tablets are supplied in oPA/Al/PVC/Al blister in carton packs,
containing 28 film-coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder:</strong><br />SAJA Pharmaceuticals<br />Saudi Arabian Japanese pharmaceutical company limited<br />Jeddah &ndash; Kingdom of Saudi Arabia<br /><strong>Manufacturer:</strong><br />Synthon Hispania S.L.<br />c/ Castell&oacute;, 1<br />08830 Sant Boi de Llobregat<br />Barcelona, Spain<br /><br /><strong>To report any side effect)s(:<br />&bull; Saudi Arabia:</strong><br />- The National Pharmacovigilance Centre )NPC(:<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa<br /><strong>&bull; United Arab Emirates</strong><br />Pharmacovigilance &amp; Medical Device section<br />Email : pv@ede.gov.ae<br />Emirates Drug Establishment<br />United Arab Emirates<br /><strong>&bull; Other GCC States / other countries:</strong><br />- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August / 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي إلباج على عقار إلترومبوباج، الذي ينتمي إلى مجموعة من الأدوية تسمى ناهضات مستقبلات الثرومبوبويتين. ويتم استخدامه للمساعدة في زيادة عدد الصفائح الدموية في دمك. الصفائح الدموية هي خلايا الدم التي تساعد على تقليل النزيف أو الوقاية منه.</p><p dir="RTL">&bull; يستخدم إلباج لعلاج اضطراب نزفي يسمى قلة الصفيحات المناعية (الأولية) (ITP) في المرضى الذين تتراوح أعمارهم بين سنة واحدة وما فوق ممن تناولوا بالفعل أدوية أخرى (الكورتيكوستيرويدات أو الغلوبولين المناعي)، ولم تنجح.</p><p dir="RTL">تحدث قلة الصفيحات المناعية بسبب انخفاض عدد الصفائح الدموية (قلة الصفيحات). ويتعرض الأشخاص المصابون بقلة الصفيحات المناعية لمخاطرة متزايدة للنزيف. تشمل الأعراض التي قد يلاحظها المرضى الذين يعانون من قلة الصفيحات المناعية نمشات (بقع حمراء مستديرة مسطحة دقيقة الحجم تحت الجلد)، وكدمات، ونزيف الأنف، ونزيف اللثة وعدم القدرة على السيطرة على النزيف إذا تعرضوا لجرح أو لإصابة.</p><p dir="RTL">&bull; يمكن أيضًا استخدام إلباج لعلاج انخفاض عدد الصفائح الدموية (قلة الصفيحات) عند البالغين المصابين بعدوى فيروس التهاب الكبد الوبائي ج(HCV)، إذا كانوا يعانون من مشكلات مع الآثار الجانبية أثناء العلاج بالإنترفيرون. يعاني الكثير من المصابين بالتهاب الكبد ج من انخفاض عدد الصفائح الدموية، ليس فقط نتيجةً للمرض، ولكن أيضًا بسبب بعض الأدوية المضادة للفيروسات المستخدمة لعلاجه. قد يسهل عليك تناول إلباج إكمال دورة كاملة من الأدوية المضادة للفيروسات (بيج-إنترفيرون وريبافيرين).</p><p dir="RTL">&bull; يمكن أيضًا استخدام إلباج لعلاج المرضى البالغين الذين يعانون من انخفاض تعدادات الدم الناجم عن فقر الدم اللاتنسجي الوخيم (SAA). فقر الدم اللاتنسجي الوخيم هو مرض يتلف فيه نخاع العظام، مما يتسبب في نقص خلايا الدم الحمراء (فقر الدم) وخلايا الدم البيضاء (قلة الكريات البيض) والصفائح الدموية (قلة الصفيحات).</p><p dir="RTL">مــن أجــل علاج الخــط الأول مــن فقــر الــدم غيــر التنســجي الحــاد المكتســب<br />&ldquo; &rdquo;SAAبالاشــتراك مــع الــعلاج القياســي المثبــط للمناعــة لــدى المرـــى البالغيــن<br />والأطفــال الذيــن تــتراوح أعمارهــم بيــن عاميــن واكثــر ممــن هــم غيــر مناسبيــن<br />لزراعــة الخلايــا الجذعيــة المكونــة للــدم فــي وقــت التشــخيص<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول إلباج</strong></p><p dir="RTL">&bull; إذا كنت تعاني من حساسية تجاه إلترومبوباج أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦ تحت عنوان &quot;محتويات إلباج&quot;)</p><p dir="RTL">&ccedil;&nbsp;<strong>استشر طبيبك</strong>&nbsp;إذا كنت تعتقد أن هذا ينطبق عليك.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك قبل تناول إلباج:</p><p dir="RTL">&bull; إذا كنت مصابًا&nbsp;<strong>بمشكلات الكبد</strong>. الأشخاص الذين يعانون من انخفاض تعدادات الصفائح الدموية بالإضافة إلى مرض الكبد المزمن (طويل الأمد) أكثر عرضة لخطر الآثار الجانبية، بما في ذلك تلف الكبد الذي يهدد الحياة والجلطات الدموية. إذا رأى طبيبك أن فوائد تناول إلباج تفوق المخاطر، فستتم مراقبتك عن كثب أثناء العلاج.</p><p dir="RTL">&bull; إذا كنت معرضًا لخطر الإصابة&nbsp;<strong>بجلطات دموية</strong>&nbsp;في الأوردة أو الشرايين، أو إذا كنت تعلم أن جلطات الدم شائعة في عائلتك.</p><p dir="RTL">قد تكون&nbsp;<strong>أكثر عرضة للإصابة بجلطات الدم</strong>:</p><p dir="RTL">- مع تقدم عمرك</p><p dir="RTL">- إذا اضطررت إلى ملازمة السرير لفترة طويلة</p><p dir="RTL">- إذا كنت مصابًا بالسرطان</p><p dir="RTL">- إذا كنت تتناولين حبوب منع الحمل أو العلاج الهرموني التعويضي</p><p dir="RTL">- إذا كنت قد خضعت لعملية جراحية أو تعرضت لإصابة جسدية مؤخرًا</p><p dir="RTL">- إذا كنت تعاني من زيادة الوزن (السمنة)</p><p dir="RTL">- إذا كنت مدخنا</p><p dir="RTL">- إذا كنت مصابًا بمرض كبدي مزمن متقدم</p><p dir="RTL">&ccedil;&nbsp;إذا كان أي من هذه ينطبق عليك،&nbsp;<strong>فأخبر طبيبك</strong>&nbsp;قبل بدء العلاج. لا يجب أن تتناول إلباج إلا إذا رأى طبيبك أن الفوائد المتوقعة تفوق خطر تجلط الدم.</p><p dir="RTL">&bull; إذا كنت مصابًا&nbsp;<strong>بالساد</strong>&nbsp;(إعتام عدسة العين)</p><p dir="RTL">&bull; إذا كنت تعاني من&nbsp;<strong>حالة دموية</strong>&nbsp;أخرى، مثل متلازمة خلل التنسج النقوي (MDS). فسيقوم طبيبك بإجراء فحوصات للتأكد من عدم وجود حالة الدم هذه قبل البدء في استخدام إلباج. إذا كنت مصابًا بمتلازمة خلل التنسج النقوي وتناولت إلباج، فقد تسوء متلازمة خلل التنسج النقوي لديك.</p><p dir="RTL">&ccedil;&nbsp;<strong>أخبر طبيبك إذا كان أي من ذلك ينطبق عليك.</strong></p><p dir="RTL"><strong>فحوصات العين</strong></p><p dir="RTL">سيوصيك طبيبك بفحص إعتام عدسة العين. وإذا لم يكن لديك فحوصات عين روتينية، يجب أن يقوم طبيبك بالترتيب لاختبارات منتظمة. قد يتم فحصك أيضًا للتحقق من حدوث أي نزيف في شبكية العين (طبقة الخلايا الحساسة للضوء في الجزء الخلفي من العين) أو حولها.</p><p dir="RTL"><strong>سوف تحتاج إلى اختبارات منتظمة</strong></p><p dir="RTL">قبل البدء في تناول إلباج، سيجري طبيبك فحوصات الدم لفحص خلايا الدم، بما في ذلك الصفائح الدموية. وستتكرر هذه الاختبارات على فترات أثناء تناوله.</p><p dir="RTL"><strong>اختبارات الدم لوظائف الكبد</strong></p><p dir="RTL">يمكن أن يسبب إلباج نتائج لفحص الدم قد تكون علامات على تلف الكبد - زيادة في بعض إنزيمات الكبد، وخاصة البيليروبين وناقلة أمين الألانين/الأسبارتات. إذا كنت تتناول علاجات تقوم على الإنترفيرون مع إلباج لعلاج انخفاض عدد الصفائح الدموية بسبب التهاب الكبد ج، فقد تتفاقم بعض مشكلات الكبد.</p><p dir="RTL">ستخضع لفحوصات دم للتحقق من وظائف الكبد قبل البدء في تناول إلباج وعلى فترات منتظمة أثناء تناوله. وقد تحتاج إلى التوقف عن تناول إلباج إذا زادت كمية هذه المواد بشكل كبير، أو إذا ظهرت عليك علامات أخرى لتلف الكبد.</p><p dir="RTL">&ccedil;&nbsp;<strong>اقرأ المعلومات عن &quot;مشكلات الكبد&quot; في القسم ٤ من هذه النشرة.</strong></p><p dir="RTL"><strong>اختبارات الدم لعدد الصفائح الدموية</strong></p><p dir="RTL">إذا توقفت عن تناول إلباج، فمن المحتمل أن ينخفض عدد الصفائح الدموية مرة أخرى في غضون عدة أيام. ستتم مراقبة عدد الصفائح الدموية، وسوف يناقش طبيبك معك الاحتياطات المناسبة.</p><p dir="RTL">قد يؤدي ارتفاع عدد الصفائح الدموية إلى زيادة خطر تجلط الدم. ومع ذلك، يمكن أن تتكون جلطات الدم أيضًا مع تعداد طبيعي أو منخفض للصفائح الدموية. سيقوم طبيبك بتعديل جرعتك من إلباج لضمان عدم ارتفاع عدد الصفائح الدموية لديك.</p><p dir="RTL">&ccedil;&nbsp;<strong>احصل على مساعدة طبية على الفور إذا كان لديك أي من هذه العلامات للجلطة الدموية</strong></p><p dir="RTL">&bull; تورم أو ألم أو إيلام في إحدى الساقين</p><p dir="RTL">&bull;&nbsp;<strong>ضيق مفاجئ في التنفس</strong>&nbsp;خاصة مع ألم حاد في الصدر أو سرعة في التنفس</p><p dir="RTL">&bull; ألم في البطن (المعدة)، وتضخم البطن، ووجود دم في البراز</p><p dir="RTL"><strong>اختبارات لفحص نخاعك العظمي</strong></p><p dir="RTL">في الأشخاص الذين يعانون من مشكلات في نخاع العظام، يمكن أن تؤدي الأدوية مثل إلباج إلى تفاقم المشكلات. قد تظهر علامات تغيرات نخاع العظم كنتائج غير طبيعية في اختبارات الدم. وقد يقوم طبيبك أيضًا بإجراء فحوصات لفحص نخاع العظم مباشرةً أثناء العلاج بإلباج.</p><p dir="RTL"><strong>فحوص للتحقق من نزيف الجهاز الهضمي</strong></p><p dir="RTL">إذا كنت تتناول علاجات تعتمد على الإنترفيرون مع إلباج، فستجري مراقبتك للتحقق عن أي علامات نزيف في معدتك أو أمعائك بعد التوقف عن تناول إلباج.</p><p dir="RTL"><strong>مراقبة القلب</strong></p><p dir="RTL">قد يرى طبيبك أنه من الضروري مراقبة قلبك أثناء العلاج بإلباج وإجراء اختبار مخطط كهربية القلب (ECG).</p><p dir="RTL"><strong>كبار السن (٦٥ سنة وما فوق)</strong></p><p dir="RTL">لا توجد سوى بيانات محدودة عن استخدام إلباج في المرضى الذين تتراوح أعمارهم بين ٦٥ سنة وما فوق. لذلك يجب توخي الحذر عند استخدام إلباج إذا كان عمرك ٦٥ عامًا أو أكثر.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا ينصح بإلباج للأطفال الذين تقل أعمارهم عن سنة ويعانون من قلة الصفيحات المناعية. ولا يُنصح به أيضًا للأشخاص الذين تقل أعمارهم عن ١٨ عامًا ممن يعانون من انخفاض عدد الصفائح الدموية بسبب التهاب الكبد ج أو فقر الدم اللاتنسجي الحاد.</p><p dir="RTL"><strong>الأدوية الأخرى وإلباج</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. ويشمل ذلك الأدوية التي يتم الحصول عليها بدون وصفة طبية والفيتامينات.</p><p dir="RTL"><strong>تتفاعل بعض الأدوية اليومية مع إلباج</strong>&nbsp;- يشمل ذلك الأدوية الموصوفة وغير الموصوفة والمعادن. ومن ذلك:</p><p dir="RTL">&bull; الأدوية المضادة للحموضة لعلاج&nbsp;<strong>عسر الهضم</strong>&nbsp;أو&nbsp;<strong>حرقة المعدة</strong>&nbsp;أو&nbsp;<strong>قرحة المعدة</strong>&nbsp;(انظر أيضًا &quot;<strong>متى يجب تناولها</strong>&quot; في القسم ٣)</p><p dir="RTL">&bull; أدوية تسمى الستاتينات&nbsp;<strong>لتخفيض الكولسترول</strong></p><p dir="RTL">&bull; بعض الأدوية لعلاج عدوى<strong>&nbsp;فيروس نقص المناعة البشرية</strong>، مثل لوبينافير و/أو ريتونافير</p><p dir="RTL">&bull; سيكلوسبورين المستخدم في سياق&nbsp;<strong>زرع الأعضاء أو أمراض المناعة</strong>.</p><p dir="RTL">&bull; المعادن مثل الحديد والكالسيوم والمغنيسيوم والألمنيوم والسيلينيوم والزنك التي يمكن العثور عليها في&nbsp;<strong>مكملات الفيتامينات والمعادن</strong>&nbsp;(انظر أيضًا &quot;<strong>متى يجب تناولها</strong>&quot; في القسم ٣)</p><p dir="RTL">&bull; الأدوية مثل الميثوتريكسات والتوبوتيكان، لعلاج&nbsp;<strong>السرطان</strong></p><p dir="RTL">&ccedil;&nbsp;<strong>تحدث إلى طبيبك</strong>&nbsp;إذا تناولت أيًا من هذه. لا يجب تناول بعضها مع إلباج، أو قد تحتاج الجرعة إلى تعديل، أو قد تحتاج إلى تغيير توقيت تناولها. وسيراجع طبيبك الأدوية التي تتناولها، ويقترح بدائل مناسبة إذا لزم الأمر.</p><p dir="RTL">إذا كنت تتناول أيضًا أدوية لمنع تجلط الدم، فهناك مخاطرة أكبر بحدوث نزيف. وسيناقش طبيبك هذا الأمر معك.</p><p dir="RTL">إذا كنت تتناول&nbsp;<strong>الكورتيكوستيرويدات و/أو دانازول و/أو الآزوثيوبرين،</strong>&nbsp;فقد تحتاج إلى تناول جرعة أقل أو التوقف عن تناولها أثناء تناول إلباج.</p><p dir="RTL"><strong>إلباج مع الطعام والشراب</strong></p><p dir="RTL">لا تتناول إلباج مع منتجات الألبان أو المشروبات لأن الكالسيوم الموجود في منتجات الألبان يؤثر على امتصاص الدواء. لمزيد من المعلومات، راجع &quot;<strong>موعد تناولها</strong>&quot; في القسم ٣.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><strong>لا تستخدمي إلباج إذا كنت حاملاً&nbsp;</strong>إلا إذا أوصى طبيبك بذلك على وجه التحديد. وتأثير إلباج أثناء الحمل غير معروف.</p><p dir="RTL">&bull;&nbsp;<strong>أخبري طبيبك إذا كنت حاملاً</strong>، أو تعتقدين أنك حامل، أو تخططين للإنجاب.</p><p dir="RTL">&bull;&nbsp;<strong>استخدمي وسيلة موثوقة لمنع الحمل</strong>&nbsp;أثناء تناول إلباج، لمنع الحمل</p><p dir="RTL">&bull;&nbsp;<strong>إذا أصبحت حاملاً أثناء العلاج بإلباج</strong>، فأخبري طبيبك.</p><p dir="RTL"><strong>لا ترضعي أثناء تناولك إلباج</strong>. فمن غير المعروف ما إذا كان إلباج يمر في حليب الثدي.</p><p dir="RTL">&ccedil;&nbsp;إذا كنت ترضعين رضاعة طبيعية أو تخططين للإرضاع، فأخبري طبيبك.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL"><strong>يمكن أن يصيبك إلباج بالدوار</strong>&nbsp;وله آثار جانبية أخرى تجعلك أقل يقظة.</p><p dir="RTL">&ccedil;&nbsp;لا تقُد أو تستخدم الآلات ما لم تكن متأكدًا من عدم تأثرك.</p><p dir="RTL"><strong>يحتوي إلباج على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ مليمول صوديوم (٢٣ ملج) لكل قرص، وهذا يعني أنه يكاد يكون &quot;خاليًا من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا. لا تقم بتغيير الجرعة أو الجدول الزمني لأخذ إلباج ما لم ينصحك طبيبك أو الصيدلي بذلك. وأثناء تناولك إلباج، ستكون تحت رعاية طبيب ذي خبرة متخصصة بعلاج حالتك.</p><p dir="RTL"><strong>الكمية التي ينبغي تناولها</strong></p><p dir="RTL"><strong>لقلة الصفيحات المناعية</strong></p><p dir="RTL"><strong>البالغون والأطفال</strong>&nbsp;(من ٦ إلى ١٧ عامًا) - الجرعة المبدئية المعتادة لقلة الصفيحات المناعية هي&nbsp;<strong>قرص واحد ٥٠ ملج</strong>&nbsp;من إلباج في اليوم. وإذا كنت من أصل شرق/جنوب شرق آسيوي، فقد تحتاج إلى البدء&nbsp;<strong>بجرعة أقل تبلغ ٢٥ ملج</strong>.</p><p dir="RTL">الأطفال (من ١ إلى ٥ سنوات): جرعة البدء المعتادة لقلة الصفيحات المناعية هي&nbsp;<strong>قرص واحد ٢٥ ملج</strong>&nbsp;من إلباج في اليوم.</p><p dir="RTL"><strong>لالتهاب الكبد ج</strong></p><p dir="RTL"><strong>البالغون</strong>: الجرعة المبدئية المعتادة لالتهاب الكبد ج هي&nbsp;<strong>قرص واحد ٢٥ ملج</strong>&nbsp;من إلباج في اليوم. إذا كنت من أصل شرق/جنوب شرق آسيوي، فستبدأ&nbsp;<strong>بنفس جرعة ٢٥ ملج</strong>.</p><p dir="RTL"><strong>لفقر الدم اللاتنسجي الوخيم</strong></p><p dir="RTL"><strong>البالغون</strong>: جرعة البدء المعتادة لفقر الدم اللاتنسجي الوخيم هي&nbsp;<strong>قرص واحد ٥٠ ملج</strong>&nbsp;من إلباج في اليوم. إذا كنت من أصل شرق/جنوب شرق آسيوي، فقد تحتاج إلى البدء&nbsp;<strong>بجرعة أقل تبلغ ٢٥ ملج</strong>.</p><p dir="RTL">قد يستغرق إلباج من أسبوع إلى أسبوعين حتى يعمل. وبناءً على استجابتك لإلباج، فقد يوصي طبيبك بتغيير جرعتك اليومية.</p><p dir="RTL"><strong>كيف تتناول الأقراص</strong></p><p dir="RTL">ابتلع القرص كاملاً مع القليل من الماء.</p><p dir="RTL"><strong>متى تتناولها</strong></p><p dir="RTL">تأكد من أن -</p><p dir="RTL">&bull;&nbsp;<strong>قبل ٤ ساعات</strong>&nbsp;من تناول إلباج</p><p dir="RTL">&bull;&nbsp;<strong>بعد ساعتين</strong>&nbsp;من تناول إلباج</p><p dir="RTL"><strong>لا&nbsp;</strong>تتناول أيًا مما يلي:</p><p dir="RTL">&bull;&nbsp;<strong>منتجات الألبان</strong>&nbsp;مثل الجبن أو الزبد أو الزبادي أو ألآيس كريم</p><p dir="RTL">&bull;&nbsp;<strong>الحليب أو الحليب المخفوق</strong>&nbsp;والمشروبات التي تحتوي على الحليب أو الزبادي أو القشدة</p><p dir="RTL">&bull;&nbsp;<strong>مضادات الحموضة</strong>&nbsp;وهي نوع من أدوية&nbsp;<strong>عسر الهضم</strong>&nbsp;وحرقة المعدة</p><p dir="RTL">&bull; بعض&nbsp;<strong>مكملات المعادن والفيتامينات</strong>&nbsp;بما في ذلك الحديد والكالسيوم والمغنيسيوم والألمونيوم والسيلينيوم والزنك.</p><p dir="RTL">إذا قمت بذلك، فلن يمتص جسمك الدواء بشكل صحيح.</p><p dir="RTL"><img alt="" width="315" height="172" src="data:image/png;base64,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" /></p><p dir="RTL"><strong>لمزيد من النصائح حول الأطعمة والمشروبات المناسبة، تحدث إلى طبيبك.</strong></p><p dir="RTL"><strong>إذا تناولت كمية أكبر مما ينبغي من إلباج</strong></p><p dir="RTL"><strong>اتصل بالطبيب أو الصيدلي</strong>&nbsp;على الفور. اعرض عليهم العلبة، أو هذه النشرة، إن أمكن.</p><p dir="RTL">ستجري مراقبتك للتحقق من أي علامات أو أعراض للآثار الجانبية وستتلقى العلاج المناسب على الفور.</p><p dir="RTL"><strong>إذا نسيت تناول إلباج</strong></p><p dir="RTL">تناول الجرعة التالية في الوقت المعتاد. لا تتناول أكثر من جرعة واحدة من إلباج في اليوم.</p><p dir="RTL"><strong>إذا أوقفت تناول إلباج</strong></p><p dir="RTL">لا تتوقف عن تناول إلباج دون التحدث مع طبيبك. وإذا نصحك طبيبك بالتوقف عن العلاج، فسيتم فحص عدد الصفائح الدموية كل أسبوع لمدة أربعة أسابيع. انظر أيضًا &quot;<strong>النزيف أو الكدمات بعد التوقف عن العلاج</strong>&quot; في القسم ٤.</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها للجميع.</p><p dir="RTL"><strong>الأعراض التي تحتاج إلى عناية: راجع الطبيب</strong></p><p dir="RTL">يمكن للأشخاص الذين يتناولون إلباج، إما من أجل قلة الصفيحات المناعية أو انخفاض عدد الصفائح الدموية بسبب التهاب الكبد ج، أن يصابوا بعلامات على الآثار الجانبية الخطيرة المحتملة.&nbsp;<strong>ومن المهم إخبار الطبيب إذا ظهرت عليك هذه الأعراض</strong>.</p><p dir="RTL"><strong>ارتفاع خطر الإصابة بجلطات الدم</strong></p><p dir="RTL">قد يكون لدى بعض الأشخاص مخاطر أعلى للإصابة بجلطات الدم، وقد تؤدي الأدوية مثل إلباج إلى تفاقم هذه المشكلة. ويعد الانسداد المفاجئ للأوعية الدموية عن طريق الجلطة الدموية من الآثار الجانبية غير الشائعة وقد يؤثر على ما يصل إلى ١ من كل ١٠٠ شخص.</p><p dir="RTL">&bull;&nbsp;<strong>تورم أو ألم أو حرارة أو احمرار أو إيلام في إحدى الساقين</strong></p><p dir="RTL">&bull;&nbsp;<strong>ضيق مفاجئ في التنفس</strong>&nbsp;وخاصة مع ألم حاد في الصدر أو سرعة في التنفس</p><p dir="RTL">&bull;&nbsp;<strong>ألم في البطن</strong>&nbsp;(المعدة)، وتضخم البطن، ووجود دم في البراز</p><p dir="RTL"><strong>مشكلات الكبد</strong></p><p dir="RTL">يمكن أن يسبب إلباج تغيرات تظهر في اختبارات الدم، وقد تكون علامات لتلف الكبد. مشكلات الكبد (زيادة الإنزيمات التي تظهر في اختبارات الدم) شائعة وقد تؤثر على ما يصل إلى ١ من كل ١٠ أشخاص. مشكلات الكبد الأخرى غير شائعة وقد تؤثر على ما يصل إلى ١ من كل ١٠٠ شخص.</p><p dir="RTL">إذا كان لديك أي من هذه العلامات لمشكلات الكبد:</p><p dir="RTL">&bull;&nbsp;<strong>اصفرار الجلد</strong>&nbsp;أو بياض العينين (اليرقان)</p><p dir="RTL">&bull;&nbsp;<strong>البول داكن اللون</strong>&nbsp;بشكل غير عادي</p><p dir="RTL">&ccedil;&nbsp;<strong>فأخبر طبيبك على الفور.</strong></p><p dir="RTL"><strong>نزيف أو كدمات بعد التوقف عن العلاج</strong></p><p dir="RTL">في غضون أسبوعين من إيقاف إلباج، عادةً ما ينخفض عدد الصفائح الدموية إلى ما كان عليه قبل بدء إلباج. قد يؤدي انخفاض عدد الصفائح الدموية إلى زيادة خطر حدوث نزيف أو كدمات. سيقوم طبيبك بفحص عدد الصفائح الدموية لمدة ٤ أسابيع على الأقل بعد توقفك عن تناول إلباج.</p><p dir="RTL">&ccedil;&nbsp;<strong>أخبر طبيبك&nbsp;إذا أصابك أي نزيف أو كدمات بعد التوقف عن تناول إلباج.</strong></p><p dir="RTL">يعاني بعض الأشخاص من&nbsp;<strong>نزيف في الجهاز الهضمي</strong>&nbsp;بعد توقفهم عن تناول بيج إنتيرفيرون وريبافيرين وإيلباج. وتشمل الأعراض ما يلي:</p><p dir="RTL">&bull; براز أسود قطراني (تغير لون البراز من الآثار الجانبية غير الشائعة التي قد تؤثر على ما يصل إلى ١ من كل ١٠٠ شخص)</p><p dir="RTL">&bull; دم في برازك</p><p dir="RTL">&bull; تقيؤ الدم أو شيء يشبه ثفل القهوة</p><p dir="RTL">&ccedil;&nbsp;<strong>أخبر طبيبك على الفور إذا أصابك أي من هذه الأعراض</strong>.</p><p dir="RTL"><strong>تم الإبلاغ عن الآثار الجانبية التالية المرتبطة بالعلاج بإلباج في المرضى البالغين المصابين بقلة الصفيحات المناعية:</strong></p><p dir="RTL"><strong>آثار جانبية شائعة جدا</strong></p><p dir="RTL"><strong>قد تؤثر على ما يصل ١ من كل ١٠ أشخاص:</strong></p><p dir="RTL">&bull; نزلة برد</p><p dir="RTL">&bull; الشعور بالتوعك (الغثيان)</p><p dir="RTL">&bull; إسهال</p><p dir="RTL">&bull; سعال</p><p dir="RTL">&bull; عدوى في الأنف والجيوب الأنفية والحنجرة والمسالك الهوائية العلوية (عدوى الجهاز التنفسي العلوي)</p><p dir="RTL">&bull; ألم الظهر</p><p dir="RTL"><strong>آثار جانبية شائعة جدًا قد تظهر في اختبارات الدم:</strong></p><p dir="RTL">&bull; زيادة إنزيمات الكبد (ناقلة أمين الألانين (ALT))</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong></p><p dir="RTL"><strong>قد تؤثر على ما يصل ١ من كل ١٠ أشخاص:</strong></p><p dir="RTL">&bull; ألم عضلي، تشنج عضلي، ضعف عضلي</p><p dir="RTL">&bull; ألم العظام</p><p dir="RTL">&bull; غزارة الدورة الشهرية</p><p dir="RTL">&bull; التهاب الحلق والانزعاج عند البلع</p><p dir="RTL">&bull; مشكلات في العين بما في ذلك اختبار العين غير الطبيعي وجفاف العين وألم العين وعدم وضوح الرؤية</p><p dir="RTL">&bull; القيء</p><p dir="RTL">&bull; الزكام (الإنفلونزا)</p><p dir="RTL">&bull; قرحة باردة</p><p dir="RTL">&bull; التهاب رئوي</p><p dir="RTL">&bull; تهيج والتهاب (تورم) الجيوب الأنفية</p><p dir="RTL">&bull; التهاب (تورم) وعدوى اللوزتين.</p><p dir="RTL">&bull; التهاب الرئتين والجيوب الأنفية والأنف والحلق</p><p dir="RTL">&bull; التهاب أنسجة اللثة</p><p dir="RTL">&bull; فقدان الشهية</p><p dir="RTL">&bull; الشعور بخدر أو وخز أو تنميل، وهو ما يُعرف باسم &quot;وخز الإبر والمسامير&quot;</p><p dir="RTL">&bull; قلة الإحساس بالجلد</p><p dir="RTL">&bull; الشعور بالنعاس</p><p dir="RTL">&bull; ألم الأذن</p><p dir="RTL">&bull; ألم وتورم وألم في إحدى ساقيك (عادة ربلة الساق) مع دفء الجلد في المنطقة المصابة (علامات لجلطة دموية في وريد عميق)</p><p dir="RTL">&bull; تورم موضعي مليء بالدم من قطع في وعاء دموي (ورم دموي)</p><p dir="RTL">&bull; الهبات الساخنة</p><p dir="RTL">&bull; مشكلات الفم، بما في ذلك جفاف الفم، والتهاب الفم، وحساسية اللسان، ونزيف اللثة، وتقرحات الفم</p><p dir="RTL">&bull; سيلان الأنف</p><p dir="RTL">&bull; وجع الأسنان</p><p dir="RTL">&bull; وجع البطن</p><p dir="RTL">&bull; خلل في وظيفة الكبد</p><p dir="RTL">&bull; تغيرات في الجلد بما في ذلك التعرق المفرط، والحكة، والطفح الجلدي المصحوب بهرش، والبقع الحمراء، والتغيرات في مظهر الجلد</p><p dir="RTL">&bull; تساقط الشعر</p><p dir="RTL">&bull; البول الرغوي أو الغروي أو الفقاعي (علامات تدل على وجود بروتين في البول)</p><p dir="RTL">&bull; ارتفاع درجة الحرارة والشعور بالحرارة</p><p dir="RTL">&bull; ألم الصدر</p><p dir="RTL">&bull; الشعور بالضعف</p><p dir="RTL">&bull; مشكلات النوم والاكتئاب</p><p dir="RTL">&bull; صداع نصفي</p><p dir="RTL">&bull; ضعف الرؤية</p><p dir="RTL">&bull; الإحساس بالدوران (الدوار)</p><p dir="RTL">&bull; الريح/الغازات الهضمية</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة التي قد تظهر في اختبار الدم:</strong></p><p dir="RTL">&bull; انخفاض عدد خلايا الدم الحمراء (فقر الدم)</p><p dir="RTL">&bull; انخفاض عدد الصفائح الدموية (قلة الصفيحات الدموية)</p><p dir="RTL">&bull; انخفاض عدد خلايا الدم البيضاء</p><p dir="RTL">&bull; انخفاض مستوى الهيموجلوبين</p><p dir="RTL">&bull; زيادة عدد الخلايا الحمضية (اليوزينية)</p><p dir="RTL">&bull; زيادة عدد خلايا الدم البيضاء (زيادة عدد الكريات البيضاء)</p><p dir="RTL">&bull; زيادة مستويات حمض اليوريك</p><p dir="RTL">&bull; انخفاض مستويات البوتاسيوم</p><p dir="RTL">&bull; زيادة مستويات الكرياتينين</p><p dir="RTL">&bull; زيادة مستويات الفوسفاتيز القلوي</p><p dir="RTL">&bull; زيادة إنزيمات الكبد (ناقلة أمين الألانين (ALT))</p><p dir="RTL">&bull; زيادة في نسبة البيليروبين في الدم (مادة ينتجها الكبد)</p><p dir="RTL">&bull; زيادة مستويات بعض البروتينات</p><p dir="RTL"><strong>آثار جانبية غير شائعة</strong></p><p dir="RTL"><strong>قد تؤثر على ما يصل ١ من كل ١٠٠ شخص:</strong></p><p dir="RTL">&bull; رد فعل تحسسي</p><p dir="RTL">&bull; انقطاع إمداد الدم لجزء من القلب</p><p dir="RTL">&bull; ضيق مفاجئ في التنفس، خاصة عندما يكون مصحوبًا بألم حاد في الصدر و/أو سرعة في التنفس، وهو ما يمكن أن يكون علامات لجلطة دموية في الرئتين (انظر &quot;<strong>زيادة خطر حدوث جلطات دموية</strong>&quot; سابقًا في القسم ٤)</p><p dir="RTL">&bull; فقدان وظيفة جزء من الرئة بسبب انسداد في الشريان الرئوي</p><p dir="RTL">&bull; احتمال وجود ألم و/أو تورم و/أو احمرار حول الوريد وهو ما يمكن أن يكون علامات على جلطة دموية في الوريد</p><p dir="RTL">&bull; اصفرار الجلد و/أو ألم البطن وهو ما يمكن أن يكون علامات على انسداد في القنوات الصفراوية، وآفة في الكبد، وتلف الكبد بسبب الالتهاب (انظر &quot;<strong>مشكلات الكبد</strong>&quot; سابقًا في القسم ٤)</p><p dir="RTL">&bull; إصابة الكبد بسبب الأدوية</p><p dir="RTL">&bull; تسارع ضربات القلب، وعدم انتظام ضربات القلب، وتغير لون الجلد إلى الزرقة، واضطرابات في إيقاع نبض القلب (إطالة كيو تي) وهو ما يمكن أن يكون علامات لاضطراب متعلق بالقلب والأوعية الدموية</p><p dir="RTL">&bull; جلطة دموية</p><p dir="RTL">&bull; تورد</p><p dir="RTL">&bull; تورم المفاصل المؤلم الناجم عن حمض أليوريك (النقرس)</p><p dir="RTL">&bull; قلة الاهتمام، أو تغيرات المزاج، أو البكاء الذي يصعب إيقافه، أو الذي يحدث في أوقات غير متوقعة</p><p dir="RTL">&bull; مشكلات في التوازن والكلام ووظيفة الأعصاب والارتعاش</p><p dir="RTL">&bull; أحاسيس جلدية مؤلمة أو غير طبيعية</p><p dir="RTL">&bull; شلل في جانب واحد من الجسم</p><p dir="RTL">&bull; صداع نصفي مع هالة</p><p dir="RTL">&bull; تلف الأعصاب</p><p dir="RTL">&bull; توسع أو انتفاخ الأوعية الدموية مما يسبب الصداع</p><p dir="RTL">&bull; مشكلات في العين بما في ذلك زيادة إنتاج الدموع، والساد (إعتام عدسة العين)، ونزيف في الشبكية، وجفاف العين</p><p dir="RTL">&bull; مشكلات الأنف والحنجرة والجيوب الأنفية ومشكلات التنفس عند النوم</p><p dir="RTL">&bull; تقرحات/تقرحات بالفم والحلق</p><p dir="RTL">&bull; فقدان الشهية</p><p dir="RTL">&bull; مشكلات الجهاز الهضمي بما في ذلك التبرز المتكرر، والتسمم الغذائي، والدم في البراز، والقيء الدموي</p><p dir="RTL">&bull; نزيف المستقيم، وتغير لون البراز، وانتفاخ البطن، وإمساك</p><p dir="RTL">&bull; مشكلات الفم، بما في ذلك جفاف الفم أو التهابه، وألم اللسان، ونزيف اللثة، والانزعاج في الفم</p><p dir="RTL">&bull; حرق الشمس</p><p dir="RTL">&bull; الشعور بالحرارة والقلق</p><p dir="RTL">&bull; احمرار أو تورم حول جرح</p><p dir="RTL">&bull; نزيف حول القسطرة (إن وُجدت) في الجلد</p><p dir="RTL">&bull; الإحساس بجسم غريب</p><p dir="RTL">&bull; مشكلات الكلى بما في ذلك التهاب الكلى، والتبول المفرط ليلاً، والفشل الكلوي، ووجود خلايا الدم البيضاء في البول</p><p dir="RTL">&bull; عرق بارد</p><p dir="RTL">&bull; الشعور بتوعك عام</p><p dir="RTL">&bull; عدوى الجلد</p><p dir="RTL">&bull; تغيرات الجلد بما في ذلك تغير لون الجلد، والتقشر، والاحمرار، والحكة، والتعرق</p><p dir="RTL">&bull; ضعف العضلات</p><p dir="RTL">&bull; سرطان المستقيم والقولون</p><p dir="RTL"><strong>آثار جانبية غير شائعة قد تظهر في الاختبارات المعملية:</strong></p><p dir="RTL">&bull; تغيرات في شكل خلايا الدم الحمراء</p><p dir="RTL">&bull; وجود خلايا الدم البيضاء النامية والتي قد تدل على أمراض معينة</p><p dir="RTL">&bull; زيادة عدد الصفائح الدموية</p><p dir="RTL">&bull; انخفاض مستويات الكالسيوم</p><p dir="RTL">&bull; انخفاض عدد خلايا الدم الحمراء (فقر الدم) الناجم عن التدمير المفرط لخلايا الدم الحمراء (فقر الدم الانحلالي)</p><p dir="RTL">&bull; زيادة عدد الخلايا النخاعية</p><p dir="RTL">&bull; زيادة عدد العدلات الشريطية</p><p dir="RTL">&bull; زيادة اليوريا في الدم</p><p dir="RTL">&bull; زيادة مستويات البروتين في البول</p><p dir="RTL">&bull; زيادة مستويات الزلال في الدم</p><p dir="RTL">&bull; زيادة مستويات البروتين الكلي</p><p dir="RTL">&bull; انخفاض مستويات الزلال في الدم</p><p dir="RTL">&bull; زيادة الرقم الهيدروجيني للبول</p><p dir="RTL">&bull; زيادة مستوى الهيموجلوبين</p><p dir="RTL"><strong>تم الإبلاغ عن الآثار الجانبية الإضافية التالية المرتبطة بالعلاج بإلباج في المرضى الأطفال (من سنة واحدة إلى ١٧ سنة) المصابين بقلة الصفيحات المناعية:</strong></p><p dir="RTL">إذا تفاقمت هذه الآثار الجانبية، فيرجى إخبار طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL"><strong>أعراض جانبية شائعة جدا</strong></p><p dir="RTL">قد تؤثر هذه على&nbsp;<strong>أكثر من ١ من كل ١٠</strong>&nbsp;أطفال:</p><p dir="RTL">&bull; عدوى في الأنف والجيوب الأنفية والحنجرة والمسالك الهوائية العلوية ونزلات البرد (عدوى الجهاز التنفسي العلوي)</p><p dir="RTL">&bull; إسهال</p><p dir="RTL">&bull; وجع البطن</p><p dir="RTL">&bull; سعال</p><p dir="RTL">&bull; درجة حرارة عالية</p><p dir="RTL">&bull; الشعور بالتوعك (الغثيان)</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong></p><p dir="RTL">قد تؤثر على&nbsp;<strong>ما يصل ١ من كل ١٠</strong>&nbsp;أطفال:</p><p dir="RTL">&bull; صعوبة النوم (الأرق)</p><p dir="RTL">&bull; وجع الأسنان</p><p dir="RTL">&bull; ألم في الأنف والحلق</p><p dir="RTL">&bull; حكة أو سيلان أو انسداد بالأنف</p><p dir="RTL">&bull; التهاب الحلق وسيلان الأنف واحتقان الأنف والعطس</p><p dir="RTL">&bull; مشكلات الفم، بما في ذلك جفاف الفم، والتهاب الفم، وحساسية اللسان، ونزيف اللثة، وتقرحات الفم</p><p dir="RTL"><strong>تم الإبلاغ عن الآثار الجانبية التالية المرتبطة بالعلاج بإلباج في المرضى الذين يتلقون كذلك البيج-إنترفيرون وريبافيرين من المصابين بالتهاب الكبد الوبائي ج:</strong></p><p dir="RTL"><strong>آثار جانبية شائعة جدا</strong></p><p dir="RTL">قد تؤثر على&nbsp;<strong>أكثر من ١ من كل ١٠</strong>&nbsp;أشخاص:</p><p dir="RTL">&bull; صداع</p><p dir="RTL">&bull; فقدان الشهية</p><p dir="RTL">&bull; سعال</p><p dir="RTL">&bull; الشعور بالتوعك (الغثيان)، والإسهال</p><p dir="RTL">&bull; ألم العضلات وضعف العضلات</p><p dir="RTL">&bull; الهرش</p><p dir="RTL">&bull; الشعور بالتعب</p><p dir="RTL">&bull; حمى</p><p dir="RTL">&bull; تساقط شعر غير عادي</p><p dir="RTL">&bull; الشعور بالضعف</p><p dir="RTL">&bull; مرض شبيه بالإنفلونزا</p><p dir="RTL">&bull; تورم في اليدين أو القدمين</p><p dir="RTL">&bull; قشعريرة</p><p dir="RTL"><strong>آثار جانبية شائعة جدًا قد تظهر في اختبارات الدم:</strong></p><p dir="RTL">&bull; انخفاض عدد خلايا الدم الحمراء (فقر الدم)</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong></p><p dir="RTL"><strong>قد تؤثر على ما يصل ١ من كل ١٠ أشخاص</strong>:</p><p dir="RTL">&bull; عدوى الجهاز البولي</p><p dir="RTL">&bull; التهاب المسالك الأنفية والحلق والفم وأعراض تشبه أعراض الأنفلونزا وجفاف الفم وتقرح الفم أو التهابه وألم الأسنان</p><p dir="RTL">&bull; فقدان الوزن</p><p dir="RTL">&bull; اضطرابات النوم، والنعاس غير الطبيعي، والاكتئاب، والقلق</p><p dir="RTL">&bull; دوار، ومشكلات في الانتباه والذاكرة، وتغير في المزاج</p><p dir="RTL">&bull; تناقص وظيفة المخ بشكل إضافي بالإضافة إلى إصابة الكبد</p><p dir="RTL">&bull; وخز أو تنميل في اليدين أو القدمين</p><p dir="RTL">&bull; الحمى والصداع</p><p dir="RTL">&bull; مشكلات في العين، بما في ذلك الساد (إعتام عدسة العين)، وجفاف العين، ورواسب صفراء صغيرة في شبكية العين، واصفرار بياض العين</p><p dir="RTL">&bull; نزيف في الشبكية</p><p dir="RTL">&bull; الإحساس بالدوران (الدوار)</p><p dir="RTL">&bull; سرعة ضربات القلب أو عدم انتظامها (خفقان)، وضيق في التنفس</p><p dir="RTL">&bull; السعال مع خروج البلغم وسيلان الأنف والإنفلونزا والقرحة الباردة والتهاب الحلق والانزعاج عند البلع</p><p dir="RTL">&bull; مشكلات في الجهاز الهضمي، بما في ذلك القيء، وآلام المعدة، وعسر الهضم، والإمساك، وتورم المعدة، واضطرابات التذوق، والبواسير، وألم/انزعاج في المعدة، وتورم الأوعية الدموية ونزيف في المريء</p><p dir="RTL">&bull; وجع الأسنان</p><p dir="RTL">&bull; مشكلات الكبد، بما في ذلك ورم في الكبد، واصفرار بياض العين أو الجلد (اليرقان)، وإصابة الكبد بسبب الأدوية (انظر &quot;<strong>مشكلات الكبد</strong>&quot; سابقًا في القسم ٤)</p><p dir="RTL">&bull; تغيرات في الجلد، بما في ذلك الطفح الجلدي وجفاف الجلد والأكزيما واحمرار الجلد والحكة والتعرق الزائد والزوائد الجلدية غير المعتادة وتساقط الشعر</p><p dir="RTL">&bull; آلام المفاصل وآلام الظهر وآلام العظام وآلام الأطراف (الذراعين والساقين واليدين أو القدمين) وتشنجات عضلية</p><p dir="RTL">&bull; التهيج، والشعور بالإعياء بشكل عام، ورد فعل الجلد مثل الاحمرار أو التورم والألم في موقع الحقن، وألم الصدر والانزعاج، وتراكم السوائل في الجسم أو الأطراف مما يسبب التورم</p><p dir="RTL">&bull; عدوى في الأنف والجيوب الأنفية والحنجرة والمسالك الهوائية العلوية ونزلات البرد (عدوى الجهاز التنفسي العلوي) والتهاب الأغشية المخاطية المبطنة للقصبات الهوائية</p><p dir="RTL">&bull; الاكتئاب والقلق ومشكلات النوم والعصبية</p><p dir="RTL"><strong>الآثار الجانبية الشائعة التي قد تظهر في اختبارات الدم:</strong></p><p dir="RTL">&bull; ارتفاع نسبة السكر (الجلوكوز) في الدم</p><p dir="RTL">&bull; انخفاض عدد خلايا الدم البيضاء</p><p dir="RTL">&bull; انخفاض عدد العدلات</p><p dir="RTL">&bull; انخفاض مستوى الزلال في الدم</p><p dir="RTL">&bull; انخفاض مستوى الهيموجلوبين</p><p dir="RTL">&bull; زيادة مستويات البيليروبين في الدم (مادة ينتجها الكبد)</p><p dir="RTL">&bull; تغيرات في الإنزيمات التي تتحكم في تجلط الدم</p><p dir="RTL"><strong>آثار جانبية غير شائعة</strong></p><p dir="RTL"><strong>قد تؤثر على ما يصل ١ من كل ١٠٠ شخص:</strong></p><p dir="RTL">&bull; تبول مؤلم</p><p dir="RTL">&bull; اضطرابات إيقاع ضربات القلب (إطالة كيو تي)</p><p dir="RTL">&bull; إنفلونزا المعدة (التهاب المعدة والأمعاء) والتهاب الحلق</p><p dir="RTL">&bull; تقرحات/قروح الفم والتهاب المعدة</p><p dir="RTL">&bull; تغيرات الجلد بما في ذلك تغير اللون، والتقشير، والاحمرار، والحكة، والآفات، والتعرق الليلي</p><p dir="RTL">&bull; جلطات دموية في وريد كبدي (ضرر محتمل في الكبد و/أو الجهاز الهضمي)</p><p dir="RTL">&bull; تجلط دم غير طبيعي في الأوعية الدموية الصغيرة مع فشل كلوي</p><p dir="RTL">&bull; طفح جلدي، وكدمات في مكان الحقن، وانزعاج في الصدر</p><p dir="RTL">&bull; انخفاض عدد خلايا الدم الحمراء (فقر الدم) الناجم عن التدمير المفرط لخلايا الدم الحمراء (فقر الدم الانحلالي)</p><p dir="RTL">&bull; ارتباك وتهيّج</p><p dir="RTL">&bull; فشل كبدي</p><p dir="RTL"><strong>تم الإبلاغ عن الآثار الجانبية التالية المرتبطة بالعلاج بإلباج في المرضى البالغين المصابين بفقر الدم اللاتنسجي الوخيم (</strong><strong>SAA</strong><strong>):</strong></p><p dir="RTL">إذا تفاقمت هذه الآثار الجانبية، فيرجى إخبار طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL"><strong>أعراض جانبية شائعة جدا</strong></p><p dir="RTL"><strong>قد تؤثر على ما يصل ١ من كل ١٠ أشخاص</strong>.</p><p dir="RTL">&bull; سعال</p><p dir="RTL">&bull; صداع</p><p dir="RTL">&bull; ألم الفم والحلق</p><p dir="RTL">&bull; إسهال</p><p dir="RTL">&bull; الشعور بالتوعك (الغثيان)</p><p dir="RTL">&bull; ألم (وجع) المفاصل</p><p dir="RTL">&bull; ألم في الأطراف (الذراعين والساقين واليدين والقدمين)</p><p dir="RTL">&bull; دوار</p><p dir="RTL">&bull; الشعور بالتعب الشديد</p><p dir="RTL">&bull; حمى</p><p dir="RTL">&bull; قشعريرة</p><p dir="RTL">&bull; حكة في العينين</p><p dir="RTL">&bull; بثور في الفم</p><p dir="RTL">&bull; نزيف اللثة</p><p dir="RTL">&bull; وجع البطن</p><p dir="RTL">&bull; تشنجات عضلية</p><p dir="RTL"><strong>آثار جانبية شائعة جدًا قد تظهر في اختبارات الدم.</strong></p><p dir="RTL">&bull; تغيرات غير طبيعية في خلايا نخاع العظام</p><p dir="RTL">&bull; زيادة مستويات إنزيمات الكبد (الأسبارتات أمينوترانسفيراز (AST))</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong></p><p dir="RTL"><strong>قد تؤثر على ما يصل ١ من كل ١٠ أشخاص:</strong></p><p dir="RTL">&bull; القلق</p><p dir="RTL">&bull; الاكتئاب</p><p dir="RTL">&bull; الشعور بالبرد</p><p dir="RTL">&bull; الشعور بتوعك عام</p><p dir="RTL">&bull; مشكلات في العين بما في ذلك مشكلات في الرؤية، وعدم وضوح الرؤية، والساد (إعتام عدسة العين)، وبقع أو ترسبات في العين (عوامات بالجسم الزجاجي)، وجفاف العين، وحكة في العين، واصفرار بياض العين أو الجلد</p><p dir="RTL">&bull; نزيف الأنف</p><p dir="RTL">&bull; مشكلات في الجهاز الهضمي بما في ذلك صعوبة البلع وألم الفم وتورم اللسان والقيء وفقدان الشهية وآلام المعدة/عدم الراحة وتورم المعدة والريح/الغازات الهضمية والإمساك واضطراب حركية الأمعاء، مما يمكن أن يسبب التهابًا وانتفاخًا وإسهالًا و/أو الأعراض المذكورة أعلاه، وتغير لون البراز</p><p dir="RTL">&bull; الإغماء</p><p dir="RTL">&bull; مشكلات الجلد بما في ذلك طفح جلدي في صورة بقع حمراء أو أرجوانية صغيرة ناجمة عن نزيف في الجلد (نمشات)، والحكة، والشري، والآفات الجلدية</p><p dir="RTL">&bull; ألم الظهر</p><p dir="RTL">&bull; ألم العضلات</p><p dir="RTL">&bull; ألم العظام</p><p dir="RTL">&bull; ضعف (وهن)</p><p dir="RTL">&bull; تورم الطرفين السفليين نتيجة تراكم السوائل</p><p dir="RTL">&bull; لون البول غير الطبيعي</p><p dir="RTL">&bull; انقطاع تدفق الدم إلى الطحال (احتشاء الطحال)</p><p dir="RTL">&bull; سيلان الأنف</p><p dir="RTL"><strong>آثار جانبية شائعة قد تظهر في اختبارات الدم</strong></p><p dir="RTL">&bull; زيادة في الإنزيمات بسبب انهيار العضلات (كرياتين فسفوكيناز)</p><p dir="RTL">&bull; تراكم الحديد في الجسم (الحديد الزائد)</p><p dir="RTL">&bull; انخفاض في مستويات السكر في الدم (نقص سكر الدم)</p><p dir="RTL">&bull; زيادة مستويات البيليروبين في الدم (مادة ينتجها الكبد)</p><p dir="RTL">&bull; انخفاض مستويات خلايا الدم البيضاء</p><p dir="RTL"><strong>آثار جانبية معدلها غير معروف</strong></p><p dir="RTL">لا يمكن تقدير المعدل من البيانات المتاحة</p><p dir="RTL">&bull; تغير لون الجلد</p><p dir="RTL">&bull; اسوداد الجلد</p><p dir="RTL">&bull; إصابة الكبد بسبب الأدوية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن أنظار ومتناول أيدي الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية والشريط.</p><p dir="RTL">يحفظ في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p>لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة في إلباج هي إلترومبوباج.</p><p dir="RTL"><strong>أقراص مغلفة ٢٥ ملج</strong></p><p dir="RTL">كل قرص مغلف يحتوي على كمية إلترومبوباج أولامين تعادل ٢٥ ملج من إلترومبوباج.</p><p dir="RTL"><strong>أقراص مغلفة ٥٠ ملج</strong></p><p dir="RTL">كل قرص مغلف يحتوي على كمية إلترومبوباج أولامين تعادل ٥٠ ملج من إلترومبوباج.</p><p dir="RTL">المكونات الأساسية الأخرى هي: ستيرات المغنيسيوم، مانيتول، سليلوز دقيق التبلور، بوفيدون، نشا الصوديوم جلايكولات، سيليكات الكالسيوم وأيزومالت (إي ٩٥٣).</p><p dir="RTL">تحتوي أقراص إلباج ٢٥ ملج و٥٠ ملج المغلفة أيضًا على مكونات غلاف هي: هيبروميلوز وثاني أكسيد التيتانيوم وأكسيد الحديد الأحمر (E 172) وأكسيد الحديد الأصفر (E 172) وترياسيتين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أقراص إلباج ٢٥ ملج</strong>&nbsp;المغلفة هي أقراص مغلفة وردية غامقة، مستديرة، محدبة من الجانبين و مميزة من جانب واحد ب &quot;II&quot; يبلغ قطرها حوالي ٨ مليمتر.</p><p dir="RTL"><strong>أقراص إلباج ٥٠ ملج</strong>&nbsp;المغلفة هي أقراص مغلفة وردية، مستديرة، محدبة من الجانبين و مميزة من جانب واحد ب &quot;III&quot;، قطرها ١٠ مليمتر تقريبًا.</p><p>تتوفر الأقراص في عبوات كرتونية تحتوي على ٢٨ قرصًا و التي تتوفر بشرائط مكونة من بولي أميد/ الألومونيوم/ كلوريد متعدد الفاينيل/ الألومونيوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق</strong></p><p dir="RTL">ساجا الصيدلانية</p><p dir="RTL">الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة</p><p dir="RTL">جدة &ndash; المملكة العربية السعودية</p><p dir="RTL"><strong>جهة التصنيع:</strong></p><p dir="RTL">سينثون هيسبانيا اس ال</p><p dir="RTL">ج / كاستيلو ، ١</p><p dir="RTL">٠٨٨٣٠ سانت بوي دي يوبريغات</p><p>برشلونة, إسبانيا</p><p>&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>&bull;&nbsp;المملكة العربية السعودية</strong></p><p dir="RTL">- المركز الوطني للتيقظ والسلامة الدوائية</p><p dir="RTL">- مركز اتصالات الهيئة العامة للغذاء والدواء السعودية : ١٩٩٩٩</p><p dir="RTL">- البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">- الموقع الإلكتروني:&nbsp;https://ade.sfda.gov.sa</p><p dir="RTL"><strong>&bull; الإمارًات العربية المتحدة</strong><br />قسم اليقظة الدوائية والأجهزة الطبية<br />pv@ede.gov.ae :أيميل<br />مؤسسة الإمارات للدواء<br />الإمارات العربية المتحدة<br /><br />&bull;&nbsp;<strong>دول الخليج الأخرى/ الدول الأخرى</strong></p><p dir="RTL">- الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس /2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ELBAG® 25 mg film-coated tablets
ELBAG® 50 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ELBAG 25 mg film-coated tablets
Each film-coated tablet contains eltrombopag olamine equivalent to 25 mg eltrombopag.
ELBAG 50 mg film-coated tablets
Each film-coated tablet contains eltrombopag olamine equivalent to 50 mg eltrombopag.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
ELBAG 25 mg film-coated tablets
Dark pink, round, biconvex, film-coated tablet with “II” debossed on one side
and with a diameter of approximately 8 mm. ELBAG 50 mg film-coated tablets
Pink, round, biconvex filmcoated tablet with “III” debossed on one side and
with a diameter of approximately 10 mm.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ELBAG is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).</p><p>ELBAG is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).</p><p>ELBAG is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of</p><p>&nbsp;</p><p>thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4.4 and 5.1).</p><p>ELBAG is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Eltrombopag treatment should be initiated by and remain under the supervision of a physician who is experienced in the treatment of haematological diseases or the management of chronic hepatitis C and its complications.</p><p><u>Posology</u></p><p>Eltrombopag dosing requirements must be individualised based on the patient&#39;s platelet counts. The objective of treatment with eltrombopag should not be to normalise platelet counts.</p><p>The powder for oral suspension may lead to higher eltrombopag exposure than the tablet formulation (see section 5.2). When switching between the tablet and the powder for oral suspension formulations, platelet counts should be monitored weekly for 2 weeks.</p><p><em><u>Immune (primary) thrombocytopenia</u></em></p><p>The lowest dose of eltrombopag to achieve and maintain a platelet count &ge;50 000/&micro;l should be used. Dose adjustments are based upon the platelet count response. Eltrombopag must not be used to normalise platelet counts. In clinical studies, platelet counts generally increased within 1 to 2 weeks after starting eltrombopag and decreased within 1 to 2 weeks after discontinuation.</p><p><em>Adults and paediatric population aged 6 to 17 years</em></p><p>The recommended starting dose of eltrombopag is 50 mg once daily. For patients of East-/Southeast-Asian ancestry, eltrombopag should be initiated at a reduced dose of 25 mg once daily (see section 5.2).</p><p><em>Paediatric population aged 1 to 5 years</em></p><p>The recommended starting dose of eltrombopag is 25 mg once daily.</p><p><em>Monitoring and dose adjustment</em></p><p>After initiating eltrombopag, the dose must be adjusted to achieve and maintain a platelet count &ge;50 000/&micro;l as necessary to reduce the risk for bleeding. A daily dose of 75 mg must not be exceeded.</p><p>&nbsp;</p><p>Clinical haematology and liver tests should be monitored regularly throughout therapy with eltrombopag and the dose regimen of eltrombopag modified based on platelet counts as outlined in Table 1. During therapy with eltrombopag full blood counts (FBCs), including platelet count and peripheral blood smears, should be assessed weekly until a stable platelet count (&ge;50 000/&micro;l for at least 4 weeks) has been achieved. FBCs including platelet counts and peripheral blood smears should be obtained monthly thereafter.</p><p>Table 1 Dose adjustments of eltrombopag in ITP patients</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Platelet count</p></td><td style="vertical-align:top"><p>Dose adjustment or response</p></td></tr><tr><td style="vertical-align:top"><p>&lt;50 000/&micro;l following at least 2 weeks of therapy</p></td><td style="vertical-align:top"><p>Increase daily dose by 25 mg to a maximum of 75 mg/day*.</p></td></tr><tr><td style="vertical-align:top"><p>&ge;50 000/&micro;l to &le;150 000/&micro;l</p></td><td style="vertical-align:top"><p>Use lowest dose of eltrombopag and/or concomitant ITP treatment to maintain platelet counts that avoid or reduce bleeding.</p></td></tr><tr><td style="vertical-align:top"><p>&gt;150 000/&micro;l to &le;250 000/&micro;l</p></td><td style="vertical-align:top"><p>Decrease the daily dose by 25 mg. Wait 2 weeks to assess the effects of this and any subsequent dose adjustments .</p></td></tr><tr><td style="vertical-align:top"><p>&gt;250 000/&micro;l</p></td><td style="vertical-align:top"><p>Stop eltrombopag; increase the frequency of platelet monitoring to twice weekly.</p><p>Once the platelet count is &le; 100 000/&micro;l, reinitiate therapy at a daily dose reduced by 25 mg.</p></td></tr></tbody></table><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image1.png" o:spid="_x0000_s1029" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:444.85pt;
 margin-top:-61.25pt;width:4.85pt;height:6.9pt;z-index:-17029120;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="9" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />* For patients taking 25 mg eltrombopag once every other day, increase dose to 25 mg once daily.</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1028" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:1in;margin-top:11.35pt;width:4.85pt;height:6.9pt;
 z-index:-17028608;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="9" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />For patients taking 25 mg eltrombopag once daily, consideration should be given to dosing at 12.5 mg once daily or alternatively a dose of 25 mg once every other day.</p><p>Eltrombopag can be administered in addition to other ITP medicinal products. The dose regimen of concomitant ITP medicinal products should be modified, as medically appropriate, to avoid excessive increases in platelet counts during therapy with eltrombopag.</p><p>It is necessary to wait for at least 2 weeks to see the effect of any dose adjustment on the patient&#39;s platelet response prior to considering another dose adjustment.</p><p>The standard eltrombopag dose adjustment, either decrease or increase, would be 25 mg once daily.</p><p><em>Discontinuation</em></p><p>Treatment with eltrombopag should be discontinued if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks of eltrombopag therapy at 75 mg once daily.</p><p>Patients should be clinically evaluated periodically and continuation of treatment should be decided on an individual basis by the treating physician. In non-splenectomised patients this should include evaluation relative to</p><p>&nbsp;</p><p>splenectomy. The reoccurrence of thrombocytopenia is possible upon discontinuation of treatment (see section 4.4).</p><p><em><u>Chronic hepatitis C (HCV) associated thrombocytopenia</u></em></p><p>When eltrombopag is given in combination with antivirals reference should be made to the full summary of product characteristics of the respective coadministered medicinal products for comprehensive details of relevant safety information or contraindications.</p><p>In clinical studies, platelet counts generally began to increase within 1 week of starting eltrombopag. The aim of treatment with eltrombopag should be to achieve the minimum level of platelet counts needed to initiate antiviral therapy, in adherence to clinical practice recommendations. During antiviral therapy, the aim of treatment should be to keep platelet counts at a level that prevents the risk of bleeding complications, normally around 50 000-75 000/&micro;l. Platelet counts &gt;75 000/&micro;l should be avoided. The lowest dose of eltrombopag needed to achieve the targets should be used. Dose adjustments are based upon the platelet count response.</p><p><em>Initial dose regimen</em></p><p>Eltrombopag should be initiated at a dose of 25 mg once daily. No dosage adjustment is necessary for HCV patients of East-/Southeast-Asian ancestry or patients with mild hepatic impairment (see section 5.2).</p><p><em>Monitoring and dose adjustment</em></p><p>The dose of eltrombopag should be adjusted in 25 mg increments every 2 weeks as necessary to achieve the target platelet count required to initiate antiviral therapy. Platelet counts should be monitored every week prior to starting antiviral therapy. On initiation of antiviral therapy the platelet count may fall, so immediate eltrombopag dose adjustments should be avoided (see Table 2).</p><p>During antiviral therapy, the dose of eltrombopag should be adjusted as necessary to avoid dose reductions of peginterferon due to decreasing platelet counts that may put patients at risk of bleeding (see Table 2). Platelet counts should be monitored weekly during antiviral therapy until a stable platelet count is achieved, normally around 50 000-75 000/&micro;l. FBCs including platelet counts and peripheral blood smears should be obtained monthly thereafter. Dose reductions on the daily dose by 25 mg should be considered if platelet counts exceed the required target. It is recommended to wait for 2 weeks to assess the effects of this and any subsequent dose adjustments.</p><p>A dose of 100 mg eltrombopag once daily must not be exceeded.</p><p>Table 2 Dose adjustments of eltrombopag in HCV patients during antiviral therapy</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Platelet count</p></td><td style="vertical-align:top"><p>Dose adjustment or response</p></td></tr><tr><td style="vertical-align:top"><p>&lt;50 000/&micro;l following at least 2 weeks of therapy</p></td><td style="vertical-align:top"><p>Increase daily dose by 25 mg to a maximum of 100 mg/day.</p></td></tr><tr><td style="vertical-align:top"><p>&ge;50 000/&micro;l to &le;100 000/&micro;l</p></td><td style="vertical-align:top"><p>Use lowest dose of eltrombopag as necessary to avoid dose reductions of peginterferon.</p></td></tr><tr><td style="vertical-align:top"><p>&gt;100 000/&micro;l to &le;150 000/&micro;l</p></td><td style="vertical-align:top"><p>Decrease the daily dose by 25 mg. Wait 2 weeks to assess the effects of this and any subsequent dose adjustments .</p></td></tr><tr><td style="vertical-align:top"><p>&gt;150 000/&micro;l</p></td><td style="vertical-align:top"><p>Stop eltrombopag; increase the frequency of platelet monitoring to twice weekly.</p><p>Once the platelet count is &le;100 000/&micro;l, reinitiate therapy at a daily dose reduced by 25 mg*.</p></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1027" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:411pt;margin-top:-61.15pt;width:4.85pt;height:6.9pt;
 z-index:-17028096;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="9" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />* For patients taking 25 mg eltrombopag once daily, consideration should be given to reinitiating dosing at 25 mg every other day.</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1026" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:1in;margin-top:11.35pt;width:4.85pt;height:6.9pt;
 z-index:-17027584;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="9" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />On initiation of antiviral therapy the platelet count may fall, so immediate eltrombopag dose reductions should be avoided.</p><p><em>Discontinuation</em></p><p>If after 2 weeks of eltrombopag therapy at 100 mg the required platelet level to initiate antiviral therapy is not achieved, eltrombopag should be discontinued.</p><p>Eltrombopag treatment should be terminated when antiviral therapy is discontinued unless otherwise justified. Excessive platelet count responses or important liver test abnormalities also necessitate discontinuation.</p><p><em><u>Severe aplastic anaemia</u></em><em> </em><em>Initial dose regimen</em></p><p>Eltrombopag should be initiated at a dose of 50 mg once daily. For patients of East-/Southeast-Asian ancestry, eltrombopag should be initiated at a reduced dose of 25 mg once daily (see section 5.2). The treatment should not be initiated when the patient has existing cytogenetic abnormalities of chromosome 7.</p><p><em>Monitoring and dose adjustment</em></p><p>Haematological response requires dose titration, generally up to 150 mg, and may take up to 16 weeks after starting eltrombopag (see section 5.1). The dose of eltrombopag should be adjusted in 50 mg increments every 2 weeks as necessary to achieve the target platelet count &ge;50 000/&micro;l. For patients taking 25 mg once daily, the dose should be increased to 50 mg daily before increasing the dose amount by 50 mg. A dose of 150 mg daily must not be exceeded. Clinical haematology and liver tests should be monitored regularly throughout therapy with eltrombopag and the dosage regimen of eltrombopag modified based on platelet counts as outlined in Table 3.</p><p>&nbsp;</p><p>Table 3 Dose adjustments of eltrombopag in patients with severe aplastic anaemia</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Platelet count</p></td><td style="vertical-align:top"><p>Dose adjustment or response</p></td></tr><tr><td style="vertical-align:top"><p>&lt;50 000/&micro;l following at least 2 weeks of therapy</p></td><td style="vertical-align:top"><p>Increase daily dose by 50 mg to a maximum of 150 mg/day.</p><p>For patients taking 25 mg once daily, increase the dose to 50 mg daily before increasing the dose amount by 50 mg.</p></td></tr><tr><td style="vertical-align:top"><p>&ge;50 000/&micro;l to &le;150 000/&micro;l</p></td><td style="vertical-align:top"><p>Use lowest dose of eltrombopag to maintain platelet counts.</p></td></tr><tr><td style="vertical-align:top"><p>&gt;150 000/&micro;l to &le;250 000/&micro;l</p></td><td style="vertical-align:top"><p>Decrease the daily dose by 50 mg. Wait 2 weeks to assess the effects of this and any subsequent dose adjustments.</p></td></tr><tr><td style="vertical-align:top"><p>&gt;250 000/&micro;l</p></td><td style="vertical-align:top"><p>Stop eltrombopag; for at least one week.</p><p>Once the platelet count is &le;100 000/&micro;l, reinitiate therapy at a daily dose reduced by 50 mg.</p></td></tr></tbody></table><p><em>Tapering for tri-lineage (white blood cells, red blood cells, and platelets) responders</em></p><p>For patients who achieve tri-lineage response, including transfusion independence, lasting at least 8 weeks: the dose of eltrombopag may be reduced by 50%.</p><p>If counts remain stable after 8 weeks at the reduced dose, then eltrombopag must be discontinued and blood counts monitored. If platelet counts drop to</p><p>&lt;30 000/&micro;l, haemoglobin drops to &lt; 9 g/dl or absolute neutrophil count (ANC)</p><p>&lt;0.5 x 109/l, eltrombopag may be reinitiated at the previous effective dose.</p><p><em>Discontinuation</em></p><p>If no haematological response has occurred after 16 weeks of therapy with eltrombopag, therapy should be discontinued. If new cytogenetic abnormalities are detected, it must be evaluated whether continuation of eltrombopag is appropriate <em>(</em>see sections 4.4 and 4.8). Excessive platelet count responses (as outlined in Table 3) or important liver test abnormalities also necessitate discontinuation of eltrombopag (see section 4.8).</p><p><em><u>Special populations</u></em><em> </em><em>Renal impairment</em></p><p>No dose adjustment is necessary in patients with renal impairment. Patients with impaired renal function should use eltrombopag with caution and close monitoring, for example by testing serum creatinine and/or performing urine analysis (see section 5.2).</p><p><em>Hepatic impairment</em></p><p>Eltrombopag should not be used in ITP patients with hepatic impairment (Child-Pugh score &ge;5) unless the expected benefit outweighs the identified risk of portal venous thrombosis (see section 4.4).</p><p>&nbsp;</p><p>If the use of eltrombopag is deemed necessary for ITP patients with hepatic impairment the starting dose must be 25 mg once daily. After initiating the dose of eltrombopag in patients with hepatic impairment an interval of 3 weeks should be observed before increasing the dose.</p><p>No dose adjustment is required for thrombocytopenic patients with chronic HCV and mild hepatic impairment (Child-Pugh score &le;6). Chronic HCV patients and severe aplastic anaemia patients with hepatic impairment should initiate eltrombopag at a dose of 25 mg once daily (see section 5.2).</p><p>After initiating the dose of eltrombopag in patients with hepatic impairment an interval of 2 weeks should be observed before increasing the dose.</p><p>There is an increased risk for adverse events, including hepatic decompensation and thromboembolic events (TEEs), in thrombocytopenic patients with advanced chronic liver disease treated with eltrombopag, either in preparation for invasive procedure or in HCV patients undergoing antiviral therapy (see sections 4.4 and 4.8).</p><p><em>Elderly</em></p><p>There are limited data on the use of eltrombopag in ITP patients aged 65 years and older and no clinical experience in ITP patients aged over 85 years. In the clinical studies of eltrombopag, overall no clinically significant differences in safety of eltrombopag were observed between patients aged at least 65 years and younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out (see section 5.2).</p><p>There are limited data on the use of eltrombopag in HCV and SAA patients aged over 75 years. Caution should be exercised in these patients (see section 4.4).</p><p><em>East-/Southeast-Asian patients</em></p><p>For adult and paediatric patients of East-/Southeast-Asian ancestry, including those with hepatic impairment, eltrombopag should be initiated at a dose of 25 mg once daily (see section 5.2).</p><p>Patient platelet count should continue to be monitored and the standard criteria for further dose modification followed.</p><p><em>Paediatric population</em></p><p>ELBAG is not recommended for use in children under the age of one year with ITP due to insufficient data on safety and efficacy. The safety and efficacy of eltrombopag has not been established in children and adolescents (&lt;18 years) with chronic HCV related thrombocytopenia or SAA. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u> Oral use.</p><p>The tablets should be taken at least two hours before or four hours after any products such as antacids, dairy products (or other calcium containing food products), or mineral supplements containing polyvalent cations (e.g. iron, calcium, magnesium, aluminium, selenium and zinc) (see sections 4.5 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to eltrombopag or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is an increased risk for adverse reactions, including potentially fatal hepatic decompensation and thromboembolic events, in thrombocytopenic HCV patients with advanced chronic liver disease, as defined by low albumin levels &le;35 g/l or model for end stage liver disease (MELD) score &ge;10, when treated with eltrombopag in combination with interferon-based therapy. In addition, the benefits of treatment in terms of the proportion achieving sustained virological response (SVR) compared with placebo were modest in these patients (especially for those with baseline albumin &le;35g/l) compared with the group overall. Treatment with eltrombopag in these patients should be initiated only by physicians experienced in the management of advanced HCV, and only when the risks of thrombocytopenia or withholding antiviral therapy necessitate intervention. If treatment is considered clinically indicated, close monitoring of these patients is required.</p><p><u>Combination with direct-acting antiviral agents</u></p><p>Safety and efficacy have not been established in combination with direct- acting antiviral agents approved for treatment of chronic hepatitis C infection.</p><p><u>Risk of hepatotoxicity</u></p><p>Eltrombopag administration can cause abnormal liver function and severe hepatotoxicity, which might be life-threatening (see section 4.8).</p><p>Serum alanine aminotransferase (ALT), aspartate aminotrasferase (AST) and bilirubin should be measured prior to initiation of eltrombopag, every 2 weeks during the dose adjustment phase and monthly following establishment of a stable dose. Eltrombopag inhibits UGT1A1 and OATP1B1, which may lead to indirect hyperbilirubinaemia. If bilirubin is elevated fractionation should be performed. Abnormal serum liver tests should be evaluated with repeat testing within 3 to 5 days. If the abnormalities are confirmed, serum liver tests should be monitored until the abnormalities resolve, stabilise, or return to</p><p>&nbsp;</p><p>baseline levels. Eltrombopag should be discontinued if ALT levels increase (&ge;3 times the upper limit of normal [x ULN] in patients with normal liver function, or &ge;3 x baseline or &gt;5 x ULN, whichever is the lower, in patients with pre- treatment elevations in transaminases) and are:</p><p>&bull;&nbsp;&nbsp;&nbsp; progressive, or</p><p>&bull;&nbsp;&nbsp;&nbsp; persistent for &ge;4 weeks, or</p><p>&bull;&nbsp;&nbsp;&nbsp; accompanied by increased direct bilirubin, or</p><p>&bull;&nbsp;&nbsp;&nbsp; accompanied by clinical symptoms of liver injury or evidence for hepatic</p><p>decompensation.</p><p>Caution is required when administering eltrombopag to patients with hepatic disease. In ITP and SAA patients a lower starting dose of eltrombopag should be used. Close monitoring is required when administering to patients with hepatic impairment (see section 4.2).</p><p><u>Hepatic decompensation (use with interferon)</u></p><p>Hepatic decompensation in patients with chronic hepatitis C: Monitoring is required in patients with low albumin levels (&le;35 g/l) or with MELD score &ge;10 at baseline.</p><p>Chronic HCV patients with liver cirrhosis may be at risk of hepatic decompensation when receiving alfa interferon therapy. In two controlled clinical studies in thrombocytopenic patients with HCV, hepatic decompensation (ascites, hepatic encephalopathy, variceal haemorrhage, spontaneous bacterial peritonitis) occurred more frequently in the eltrombopag arm (11%) than in the placebo arm (6%). In patients with low albumin levels (&le; 35 g/l) or with a MELD score &ge;10 at baseline, there was a 3- fold greater risk of hepatic decompensation and an increase in the risk of a fatal adverse event compared to those with less advanced liver disease. In addition, the benefits of treatment in terms of the proportion achieving SVR compared with placebo were modest in these patients (especially for those with baseline albumin &le;35 g/l) compared with the group overall. Eltrombopag should only be administered to such patients after careful consideration of the expected benefits in comparison with the risks. Patients with these characteristics should be closely monitored for signs and symptoms of hepatic decompensation. The respective interferon summary of product characteristics should be referenced for discontinuation criteria. Eltrombopag should be terminated if antiviral therapy is discontinued for hepatic decompensation.</p><p><u>Thrombotic/thromboembolic complications</u></p><p>In controlled studies in thrombocytopenic patients with HCV receiving interferon-based therapy (n=1 439), 38 out of 955 patients (4%) treated with</p><p>&nbsp;</p><p>eltrombopag and 6 out of 484 patients (1%) in the placebo group experienced TEEs. Reported thrombotic/thromboembolic complications included both venous and arterial events. The majority of TEEs were non-serious and resolved by the end of the study. Portal vein thrombosis was the most common TEE in both treatment groups (2% in patients treated with eltrombopag versus &lt;1% for placebo). No specific temporal relationship between start of treatment and event of TEE were observed. Patients with low albumin levels (&le;35 g/l) or MELD &ge;10 had a 2-fold greater risk of TEEs than those with higher albumin levels; those aged &ge;60 years had a 2-fold greater risk of TEEs compared to younger patients. Eltrombopag should only be administered to such patients after careful consideration of the expected benefits in comparison with the risks. Patients should be closely monitored for signs and symptoms of TEE.</p><p>The risk of TEEs has been found to be increased in patients with chronic liver disease (CLD) treated with 75 mg eltrombopag once daily for 2 weeks in preparation for invasive procedures. Six of 143 (4%) adult patients with CLD receiving eltrombopag experienced TEEs (all of the portal venous system) and two of 145 (1%) patients in the placebo group experienced TEEs (one in the portal venous system and one myocardial infarction). Five of the 6 patients treated with eltrombopag experienced the thrombotic complication at a platelet count &gt;200 000/&micro;l and within 30 days of the last dose of eltrombopag. Eltrombopag is not indicated for the treatment of thrombocytopenia in patients with chronic liver disease in preparation for invasive procedures.</p><p>In eltrombopag clinical studies in ITP thromboembolic events were observed at low and normal platelet counts. Caution should be used when administering eltrombopag to patients with known risk factors for thromboembolism including but not limited to inherited (e.g. Factor V Leiden) or acquired risk factors (e.g. ATIII deficiency, antiphospholipid syndrome), advanced age, patients with prolonged periods of immobilisation, malignancies, contraceptives and hormone replacement therapy, surgery/trauma, obesity and smoking. Platelet counts should be closely monitored and consideration given to reducing the dose or discontinuing eltrombopag treatment if the platelet count exceeds the target levels (see section 4.2). The risk-benefit balance should be considered in patients at risk of TEEs of any aetiology.</p><p>No case of TEE was identified from a clinical study in refractory SAA, however the risk of these events cannot be excluded in this patient population due to the limited number of exposed patients. As the highest authorised dose is indicated for patients with SAA (150 mg/day) and due to the nature of the reaction, TEEs might be expected in this patient population.</p><p>&nbsp;</p><p>Eltrombopag should not be used in ITP patients with hepatic impairment (Child-Pugh score &ge;5) unless the expected benefit outweighs the identified risk of portal venous thrombosis. When treatment is considered appropriate, caution is required when administering eltrombopag to patients with hepatic impairment (see sections 4.2 and 4.8).</p><p><u>Bleeding following discontinuation of eltrombopag</u></p><p>Thrombocytopenia is likely to reoccur in ITP patients upon discontinuation of treatment with eltrombopag. Following discontinuation of eltrombopag, platelet counts return to baseline levels within 2 weeks in the majority of patients, which increases the bleeding risk and in some cases may lead to bleeding. This risk is increased if eltrombopag treatment is discontinued in the presence of anticoagulants or anti-platelet agents. It is recommended that, if treatment with eltrombopag is discontinued, ITP treatment be restarted according to current treatment guidelines. Additional medical management may include cessation of anticoagulant and/or anti-platelet therapy, reversal of anticoagulation, or platelet support. Platelet counts must be monitored weekly for 4 weeks following discontinuation of eltrombopag.</p><p>In HCV clinical studies, a higher incidence of gastrointestinal bleeding, including serious and fatal cases, was reported following discontinuation of peginterferon, ribavirin, and eltrombopag. Following discontinuation of therapy, patients should be monitored for any signs or symptoms of gastrointestinal bleeding.</p><p><u>Bone marrow reticulin formation and risk of bone marrow fibrosis</u></p><p>Eltrombopag may increase the risk for development or progression of reticulin fibres within the bone marrow. The relevance of this finding, as with other thrombopoietin-receptor (TPO-R) agonists, has not been established yet.</p><p>Prior to initiation of eltrombopag, the peripheral blood smear should be examined closely to establish a baseline level of cellular morphologic abnormalities. Following identification of a stable dose of eltrombopag, full blood count (FBC) with white blood cell count (WBC) differential should be performed monthly. If immature or dysplastic cells are observed, peripheral blood smears should be examined for new or worsening morphological abnormalities (e.g. teardrop and nucleated red blood cells, immature white blood cells) or cytopenia(s). If the patient develops new or worsening morphological abnormalities or cytopenia(s), treatment with eltrombopag should be discontinued and a bone marrow biopsy considered, including staining for fibrosis.</p><p><u>Progression of existing myelodysplastic syndrome (MDS)</u></p><p>&nbsp;</p><p>There is a theoretical concern that TPO-R agonists may stimulate the progression of existing haematological malignancies such as MDS. TPO-R agonists are growth factors that lead to thrombopoietic progenitor cell expansion, differentiation and platelet production. The TPO-R is predominantly expressed on the surface of cells of the myeloid lineage.</p><p>In clinical studies with a TPO-R agonist in patients with MDS, cases of transient increases in blast cell counts were observed and cases of MDS disease progression to acute myeloid leukaemia (AML) were reported.</p><p>The diagnosis of ITP or SAA in adults and elderly patients should be confirmed by the exclusion of other clinical entities presenting with thrombocytopenia, in particular the diagnosis of MDS must be excluded. Consideration should be given to performing a bone marrow aspirate and biopsy over the course of the disease and treatment, particularly in patients over 60 years of age, those with systemic symptoms, or abnormal signs such as increased peripheral blast cells.</p><p>The effectiveness and safety of ELBAG have not been established for the treatment of thrombocytopenia due to MDS. ELBAG should not be used outside of clinical studies for the treatment of thrombocytopenia due to MDS.</p><p><u>Cytogenetic abnormalities and progression to MDS/AML in patients with SAA</u></p><p>Cytogenetic abnormalities are known to occur in SAA patients. It is not known whether eltrombopag increases the risk of cytogenetic abnormalities in patients with SAA. In the phase II refractory SAA clinical study with eltrombopag with a starting dose of 50 mg/day (escalated every 2 weeks to a maximum of 150 mg/day) (ELT112523), the incidence of new cytogenetic abnormalities was observed in 17.1% of adult patients [7/41 (where 4 of them had changes in chromosome 7)]. The median time on study to a cytogenetic abnormality was 2.9 months.</p><p>In the phase II refractory SAA clinical study with eltrombopag at a dose of 150 mg/day (with ethnic or age related modifications as indicated) (ELT116826), the incidence of new cytogenetic abnormalities was observed in 22.6% of adult patients [7/31 (where 3 of them had changes in chromosome 7)]. All 7 patients had normal cytogenetics at baseline. Six patients had cytogenetic abnormality at Month 3 of eltrombopag therapy and one patient had cytogenetic abnormality at Month 6.</p><p>In clinical studies with eltrombopag in SAA, 4% of patients (5/133) were diagnosed with MDS. The median time to diagnosis was 3 months from the start of eltrombopag treatment.</p><p>For SAA patients refractory to or heavily pretreated with prior immunosuppressive therapy, bone marrow examination with aspirations for cytogenetics is recommended prior to initiation of eltrombopag, at 3 months</p><p>&nbsp;</p><p>of treatment and 6 months thereafter. If new cytogenetic abnormalities are detected, it must be evaluated whether continuation of eltrombopag is appropriate.</p><p><u>Ocular changes</u></p><p>Cataracts were observed in toxicology studies of eltrombopag in rodents (see section 5.3). In controlled studies in thrombocytopenic patients with HCV receiving interferon therapy (n=1 439), progression of pre-existing baseline cataract(s) or incident cataracts was reported in 8% of the eltrombopag group and 5% of the placebo group. Retinal haemorrhages, mostly Grade 1 or 2, have been reported in HCV patients receiving interferon, ribavirin and eltrombopag (2% of the eltrombopag group and 2% of the placebo group.</p><p>Haemorrhages occurred on the surface of the retina (preretinal), under the retina (subretinal), or within the retinal tissue. Routine ophthalmologic monitoring of patients is recommended.</p><p><u>QT/QTc prolongation</u></p><p>A QTc study in healthy volunteers dosed 150 mg eltrombopag per day did not show a clinically significant effect on cardiac repolarisation. QTc interval prolongation has been reported in clinical studies of patients with ITP and thrombocytopenic patients with HCV. The clinical significance of these QTc prolongation events is unknown.</p><p><u>Loss of response to eltrombopag</u></p><p>A loss of response or failure to maintain a platelet response with eltrombopag treatment within the recommended dosing range should prompt a search for causative factors, including an increased bone marrow reticulin.</p><p><u>Paediatric population</u></p><p>The above warnings and precautions for ITP also apply to the paediatric population.</p><p><u>Interference with laboratory tests</u></p><p>Eltrombopag is highly coloured and so has the potential to interfere with some laboratory tests. Serum discolouration and interference with total bilirubin and creatinine testing have been reported in patients taking ELBAG. If the laboratory results and clinical observations are inconsistent, re-testing using another method may help in determining the validity of the result.</p><p><u>Sodium content</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per film- coated tablet, that is to say essentially &#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of eltrombopag on other medicinal products</u></p><p><em><u>HMG CoA reductase inhibitors</u></em></p><p>Administration of eltrombopag 75 mg once daily for 5 days with a single 10 mg dose of the OATP1B1 and BCRP substrate rosuvastatin to 39 healthy adult subjects&nbsp;increased plasma rosuvastatin Cmax &nbsp;103%&nbsp;(90%&nbsp;confidence&nbsp;interval&nbsp;[CI]: 82%,&nbsp;126%)&nbsp;and&nbsp;AUC0-&infin; &nbsp;55%&nbsp;(90%&nbsp;CI:&nbsp;42%,&nbsp;69%).&nbsp;Interactions&nbsp;are also expected with other HMG-CoA reductase inhibitors, including atorvastatin, fluvastatin, lovastatin, pravastatin and simvastatin. When co-administered with eltrombopag, a reduced dose of statins should be considered and careful monitoring for statin adverse reactions should be undertaken (see section 5.2).</p><p><em><u>OA</u></em><em><u>T</u></em><em><u>P1B</u></em><em><u>1</u></em><em><u> </u></em><em><u>an</u></em><em><u>d</u></em><em><u> </u></em><em><u>B</u></em><em><u>CR</u></em><em><u>P</u></em><em><u> </u></em><em><u>subst</u></em><em><u>rat</u></em><em><u>e</u></em><em><u>s</u></em></p><p>Concomitant administration of eltrombopag and OATP1B1 (e.g. methotrexate) and BCRP (e.g. topotecan and methotrexate) substrates should be undertaken with caution (see section 5.2).</p><p><em><u>Cytochrome P450 substrates</u></em></p><p>In studies utilising human liver microsomes, eltrombopag (up to 100 &mu;M) showed no <em>in vitro </em>inhibition of the CYP450 enzymes 1A2, 2A6, 2C19, 2D6, 2E1, 3A4/5, and 4A9/11 and was an inhibitor of CYP2C8 and CYP2C9 as measured using paclitaxel and diclofenac as the probe substrates. Administration of eltrombopag 75 mg once daily for 7 days to 24 healthy male subjects did not inhibit or induce the metabolism of probe substrates for 1A2 (caffeine), 2C19 (omeprazole), 2C9 (flurbiprofen), or 3A4 (midazolam) in humans. No clinically significant interactions are expected when eltrombopag and CYP450 substrates are co-administered (see section 5.2).</p><p><em><u>HCV protease inhibitors</u></em></p><p>Dose adjustment is not required when eltrombopag is co-administered with either telaprevir or boceprevir. Co-administration of a single dose of eltrombopag 200 mg with telaprevir 750 mg every 8 hours did not alter plasma telaprevir exposure.</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image2.png" o:spid="_x0000_s1026" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:431.7pt;
 margin-top:27.7pt;width:4.7pt;height:5.3pt;z-index:-17027072;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="7" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />Co-administration of a single dose of eltrombopag 200 mg with boceprevir 800&nbsp;mg&nbsp;every&nbsp;8&nbsp;hours&nbsp;did&nbsp;not&nbsp;alter&nbsp;plasma boceprevir AUC(0-&nbsp;&nbsp;&nbsp; &nbsp;),&nbsp;but&nbsp;increased Cmax &nbsp;by 20%, and decreased Cmin &nbsp;by 32%. The clinical relevance of the decrease in Cmin has not been established, increased clinical and laboratory monitoring for HCV suppression is recommended.</p><p><u>Effects of other medicinal products on eltrombopag</u></p><p><em><u>Ciclosporin</u></em></p><p>&nbsp;</p><p>A decrease in eltrombopag exposure was observed with co-administration of 200 mg and 600 mg ciclosporin (a BCRP inhibitor). The co-administration of 200&nbsp;mg&nbsp;ciclosporin&nbsp;decreased&nbsp;the&nbsp;Cmax &nbsp;and&nbsp;the&nbsp;AUC0-&infin; &nbsp;of&nbsp;eltrombopag&nbsp;by 25% and 18%, respectively. The co-administration of 600 mg ciclosporin decreased the&nbsp;Cmax &nbsp;and&nbsp;the&nbsp;AUC0-&infin; &nbsp;of&nbsp;eltrombopag&nbsp;by&nbsp;39%&nbsp;and&nbsp;24%,&nbsp;respectively.</p><p>Eltrombopag dose adjustment is permitted during the course of the treatment based on the patient&#39;s platelet count (see section 4.2). Platelet count should be monitored at least weekly for 2 to 3 weeks when eltrombopag is co-administered with ciclosporin. Eltrombopag dose may need to be increased based on these platelet counts.</p><p><em><u>Polyvalent cations (chelation)</u></em></p><p>Eltrombopag chelates with polyvalent cations such as iron, calcium, magnesium, aluminium, selenium and zinc. Administration of a single dose of eltrombopag 75 mg with a polyvalent cation-containing antacid (1 524 mg aluminium hydroxide and 1 425 mg magnesium carbonate) decreased plasma&nbsp;eltrombopag&nbsp;AUC0-&infin; &nbsp;by 70% (90% CI: 64%, 76%) and Cmax by 70% (90% CI: 62%, 76%). Eltrombopag should be taken at least two hours before or four hours after any products such as antacids, dairy products or mineral supplements containing polyvalent cations to avoid significant reduction in eltrombopag absorption due to chelation (see sections 4.2 and 5.2).</p><p><em><u>Lopinavir/ritonavir</u></em></p><p>Co-administration of eltrombopag with lopinavir/ritonavir may cause a decrease in the concentration of eltrombopag. A study in 40 healthy volunteers showed that the co-administration of a single 100 mg dose of eltrombopag with repeat dose lopinavir/ritonavir 400/100 mg twice daily resulted&nbsp;in&nbsp;a&nbsp;reduction&nbsp;in&nbsp;eltrombopag&nbsp;plasma&nbsp;AUC0-&infin; &nbsp;by 17% (90% CI: 6.6%, 26.6%). Therefore, caution should be used when co-administration of eltrombopag with lopinavir/ritonavir takes place. Platelet count should be closely monitored in order to ensure appropriate medical management of the dose of eltrombopag when lopinavir/ritonavir therapy is initiated or discontinued.</p><p><em><u>CYP1A2 and CYP2C8 inhibitors and inducers</u></em></p><p>Eltrombopag is metabolised through multiple pathways including CYP1A2, CYP2C8, UGT1A1, and UGT1A3 (see section 5.2). Medicinal products that inhibit or induce a single enzyme are unlikely to significantly affect plasma eltrombopag concentrations, whereas medicinal products that inhibit or induce multiple enzymes have the potential to increase (e.g. fluvoxamine) or decrease (e.g. rifampicin) eltrombopag concentrations.</p><p><em><u>HCV protease inhibitors</u></em></p><p>&nbsp;</p><p>Results of a drug-drug pharmacokinetic (PK) interaction study show that co- administration of repeat doses of boceprevir 800 mg every 8 hours or telaprevir 750 mg every 8 hours with a single dose of eltrombopag 200 mg did not alter plasma eltrombopag exposure to a clinically significant extent.</p><p><u>Medicinal products for treatment of ITP</u></p><p>Medicinal products used in the treatment of ITP in combination with eltrombopag in clinical studies included corticosteroids, danazol, and/or azathioprine, intravenous immunoglobulin (IVIG), and anti-D immunoglobulin. Platelet counts should be monitored when combining eltrombopag with other medicinal products for the treatment of ITP in order to avoid platelet counts outside of the recommended range (see section 4.2).</p><p><u>Food interaction</u></p><p>The administration of eltrombopag tablet or powder for oral suspension formulations with a high-calcium meal (e.g. a meal that included dairy products)&nbsp;significantly&nbsp;reduced&nbsp;plasma&nbsp;eltrombopag&nbsp;AUC0-&infin; &nbsp;and&nbsp;Cmax.&nbsp;In contrast, the administration of eltrombopag 2 hours before or 4 hours after a high-calcium meal or with low-calcium food [&lt;50 mg calcium] did not alter plasma eltrombopag exposure to a clinically significant extent (see section 4.2).</p><p>Administration of a single 50 mg dose of eltrombopag in tablet form with a standard high-calorie, high-fat breakfast that included dairy products reduced&nbsp;plasma&nbsp;eltrombopag&nbsp;mean&nbsp;AUC0-&infin; &nbsp;by 59% and mean Cmax &nbsp;by 65%.</p><p>Administration of a single 25 mg dose of eltrombopag as powder for oral suspension with a high-calcium, moderate-fat and moderate-calorie meal reduced&nbsp;plasma&nbsp;eltrombopag&nbsp;mean&nbsp;AUC0-&infin; &nbsp;by 75% and mean Cmax &nbsp;by 79%. This decrease of exposure was attenuated when a single 25 mg dose of eltrombopag powder for oral suspension was administered 2 hours before a high-calcium&nbsp;meal&nbsp;(mean&nbsp;AUC0-&infin; &nbsp;was&nbsp;decreased&nbsp;by 20% and mean Cmax &nbsp;by 14%).</p><p>Food low in calcium (&lt;50 mg calcium), including fruit, lean ham, beef and unfortified (no added calcium, magnesium or iron) fruit juice, unfortified soya milk and unfortified grain, did not significantly impact plasma eltrombopag exposure, regardless of calorie and fat content (see sections 4.2 and 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><u>Pregnancy Category C</u></p><p><u>Pregnancy</u></p><p>There are no or limited amount of data from the use of eltrombopag in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>&nbsp;</p><p>ELBAG is not recommended during pregnancy.</p><p><u>Women of childbearing potential / Contraception in males and females</u></p><p>ELBAG is not recommended in women of childbearing potential not using contraception.</p><p><u>Breast-feeding</u></p><p>It is not known whether eltrombopag/metabolites are excreted in human milk. Studies in animals have shown that eltrombopag is likely secreted into milk (see section 5.3); therefore a risk to the suckling child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to continue/abstain from ELBAG therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p><u>Fertility</u></p><p>Fertility was not affected in male or female rats at exposures that were comparable to those in humans. However a risk for humans cannot be ruled out (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Eltrombopag has negligible influence on the ability to drive and use machines. The clinical status of the patient and the adverse reaction profile of eltrombopag, including dizziness and lack of alertness, should be borne in mind when considering the patient&#39;s ability to perform tasks that require judgement, motor and cognitive skills.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A.&nbsp;&nbsp;&nbsp; <u>Summary of the safety profile</u></p><p><em><u>Immune thrombocytopenia in adult and paediatric patients</u></em></p><p>The safety of ELBAG was assessed in adult patients (N=763) using the pooled double-blind, placebo-controlled studies TRA100773A and B, TRA102537 (RAISE) and TRA113765, in which 403 patients were exposed to ELBAG and 179 to placebo, in addition to data from the completed open-label studies (N=360) TRA108057 (REPEAT), TRA105325 (EXTEND) and TRA112940 (see</p><p>section 5.1). Patients received study medication for up to 8 years (in EXTEND). The most important serious adverse reactions were hepatotoxicity and thrombotic/thromboembolic events. The most common adverse reactions occurring in at least 10% of patients included nausea, diarrhoea, increased alanine aminotransferase and back pain.</p><p>The safety of ELBAG in paediatric patients (aged 1 to 17 years) with previously treated ITP has been demonstrated in two studies (N=171) (see section 5.1).</p><p>PETIT2 (TRA115450) was a two-part, double-blind and open-label, randomised, placebo-controlled study. Patients were randomised 2:1 and received ELBAG</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image1.png" o:spid="_x0000_s1036" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:363.8pt;
 margin-top:81.25pt;width:4.85pt;height:6.9pt;z-index:-17026560;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="9" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />(n=63) or placebo (n=29) for up to 13 weeks in the randomised period of the study. PETIT (TRA108062) was a three-part, staggered-cohort, open-label and double-blind, randomised, placebo-controlled study. Patients were randomised 2:1 and received ELBAG (n=44) or placebo (n=21), for up to 7 weeks. The profile of adverse reactions was comparable to that seen in adults with some additional adverse reactions, marked&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the table below. The most common adverse reactions in paediatric ITP patients 1 year and older (&ge;3% and greater than placebo) were upper respiratory tract infection, nasopharyngitis, cough, pyrexia, abdominal pain, oropharyngeal pain, toothache and rhinorrhoea.</p><p><em><u>Thrombocytopenia with HCV infection</u></em><em> </em><em><u>in adult patients</u></em></p><p>ENABLE 1 (TPL103922 n=716, 715 treated with eltrombopag) and ENABLE 2 (TPL108390 n=805) were randomised, double-blind, placebo-controlled, multicentre studies to assess the efficacy and safety of ELBAG in thrombocytopenic patients with HCV infection who were otherwise eligible to initiate antiviral therapy. In the HCV studies the safety population consisted of all randomised patients who received double-blind study medicinal product during Part 2 of ENABLE 1 (ELBAG treatment n=450, placebo treatment n=232) and ENABLE 2 (ELBAG treatment n=506, placebo treatment n=252). Patients are analysed according to the treatment received (total safety double-blind population, ELBAG n=955 and placebo n=484). The most important serious adverse reactions identified were hepatotoxicity and thrombotic/thromboembolic events. The most common adverse reactions occurring in at least 10% of patients included headache, anaemia, decreased appetite, cough, nausea, diarrhoea, hyperbilirubinaemia, alopecia, pruritus, myalgia, pyrexia, fatigue, influenza-like illness, asthenia, chills and oedema.</p><p><em><u>Severe aplastic anaemia in adult patients</u></em></p><p>The safety of ELBAG in severe aplastic anaemia was assessed in a single-arm, open-label study (N=43) in which 11 patients (26%) were treated for &gt;6 months and 7 patients (16%) were treated for &gt;1 year (see section 5.1). The most common adverse reactions occurring in at least 10% of patients included headache, dizziness, cough, oropharyngeal pain, rhinorrhoea, nausea, diarrhoea, abdominal pain, transaminases increased, arthralgia, pain in extremity, muscle spasms, fatigue and pyrexia.</p><p>B.&nbsp;&nbsp;&nbsp;&nbsp; <u>Tabulated</u><u> </u><u>list of adverse reactions</u></p><p>The adverse reactions in the adult ITP studies (N=763), paediatric ITP studies (N=171), the HCV studies (N=1 520), the SAA studies (N=43) and post-marketing reports are listed below by MedDRA system organ class and by frequency.</p><p>Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. The corresponding frequency category for each adverse drug reaction is based on the following</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1035"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:336.55pt;margin-top:604.1pt;width:4.85pt;height:6.9pt;z-index:-17025024;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:page'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page" anchory="page"/>
</v:shape><![endif]--><img width="6" height="9" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1034"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:394.95pt;margin-top:619.35pt;width:4.85pt;height:6.9pt;z-index:-17024512;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:page'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page" anchory="page"/>
</v:shape><![endif]--><img width="6" height="9" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1033"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:456.5pt;margin-top:619.35pt;width:4.85pt;height:6.9pt;z-index:-17024000;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:page'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page" anchory="page"/>
</v:shape><![endif]--><img width="6" height="9" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1032"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:430.5pt;margin-top:688.1pt;width:4.85pt;height:6.9pt;z-index:-17023488;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:page'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page" anchory="page"/>
</v:shape><![endif]--><img width="6" height="9" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />convention (CIOMS III): very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1 000 to &lt;1/100); rare (&ge;1/10 000 to &lt;1/1 000); not known (cannot be estimated from the available data).</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1031"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:378.8pt;margin-top:49.2pt;width:4.85pt;height:6.9pt;z-index:-17026048;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="9" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1030"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:527.05pt;margin-top:49.2pt;width:4.85pt;height:6.9pt;z-index:-17025536;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="9" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />ITP study population</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nasopharyngitis , upper respiratory tract infection</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pharyngitis, influenza, oral herpes, pneumonia, sinusitis, tonsillitis, respiratory tract infection, gingivitis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Skin infection</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rectosigmoid cancer</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anaemia, eosinophilia, leukocytosis, thrombocytopenia, haemoglobin decreased, white blood cell count decreased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anisocytosis, haemolytic anaemia, myelocytosis, band neutrophil count increased, myelocyte present, platelet count increased, haemoglobin increased</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypokalaemia, decreased appetite, blood uric acid increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anorexia, gout, hypocalcaemia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sleep disorder, depression</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Apathy, mood altered, tearfulness</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Paraesthesia, hypoaesthesia, somnolence, migraine</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tremor, balance disorder, dysaesthesia, hemiparesis, migraine with aura, neuropathy peripheral, peripheral sensory neuropathy, speech disorder, toxic neuropathy, vascular headache</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dry eye, vision blurred, eye pain, visual acuity reduced</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Lenticular opacities, astigmatism, cataract cortical, lacrimation increased, retinal haemorrhage, retinal pigment epitheliopathy, visual impairment, visual acuity tests abnormal, blepharitis, keratoconjunctivitis sicca</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Ear pain, vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tachycardia, acute myocardial infarction, cardiovascular disorder, cyanosis, sinus tachycardia, electrocardiogram QT prolonged</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Deep vein thrombosis, haematoma, hot flush</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Embolism, thrombophlebitis superficial, flushing</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Oropharyngeal pain , rhinorrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pulmonary embolism, pulmonary infarction, nasal discomfort, oropharyngeal blistering, sinus disorder, sleep apnoea syndrome</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea, diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Mouth ulceration, toothache , vomiting, abdominal pain*, mouth haemorrhage, flatulence</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>* Very common in paediatric ITP</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dry mouth, glossodynia, abdominal tenderness, faeces discoloured, food poisoning, frequent bowel movements, haematemesis, oral discomfort</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased&dagger;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Aspartate aminotransferase increased&dagger;, hyperbilirubinaemia, hepatic function abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cholestasis, hepatic lesion, hepatitis, drug-induced liver injury</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash, alopecia, hyperhidrosis, pruritus generalised, petechiae</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urticaria, dermatosis, cold sweat, erythema, melanosis, pigmentation disorder, skin discolouration, skin exfoliation</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Back pain</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Myalgia, muscle spasm, musculoskeletal pain, bone pain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Muscular weakness</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Proteinuria, blood creatinine increased, thrombotic microangiopathy with renal failure&Dagger;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Renal failure, leukocyturia, lupus nephritis, nocturia, blood urea increased, urine protein/creatinine ratio increased</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Menorrhagia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pyrexia*, chest pain, asthenia</p><p>*Very common in paediatric ITP</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Feeling hot, vessel puncture site haemorrhage, feeling jittery, inflammation of wound, malaise, sensation of foreign body</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood alkaline phosphatase increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Blood albumin increased, protein total increased, blood albumin decreased, pH urine increased</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Sunburn</p></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1029" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:1in;margin-top:4.45pt;width:4.85pt;height:6.9pt;
 z-index:-17022976;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="9" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />Additional adverse reactions observed in paediatric studies (aged 1 to 17 years).</p><p>&dagger; Increase of alanine aminotransferase and aspartate aminotransferase may occur simultaneously, although at a lower frequency.</p><p>&Dagger; Grouped term with preferred terms acute kidney injury and renal failure</p><p>HCV study population (in combination with anti-viral interferon and ribavirin therapy)</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Urinary tract infection, upper respiratory tract infection, bronchitis, nasopharyngitis, influenza, oral herpes</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Gastroenteritis, pharyngitis</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hepatic neoplasm malignant</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Lymphopenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Haemolytic anaemia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperglycaemia, abnormal loss of weight</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Depression, anxiety, sleep disorder</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Confusional state, agitation</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness, disturbance in attention, dysgeusia, hepatic encephalopathy, lethargy, memory impairment, paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Cataract, retinal exudates, dry eye, ocular icterus, retinal haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Palpitations</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dyspnoea, oropharyngeal pain, dyspnoea exertional, productive cough</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea, diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting, ascites, abdominal pain, abdominal pain upper, dyspepsia, dry mouth, constipation, abdominal distension, toothache, stomatitis, gastrooesophagal reflux disease, haemorrhoids, abdominal discomfort, varices oesophageal</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Oesophageal varices haemorrhage, gastritis, aphthous stomatitis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperbilirubinaemia, jaundice, drug-induced liver injury</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Portal vein thrombosis, hepatic failure</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash, dry skin, eczema, rash pruritic, erythema, hyperhidrosis, pruritus generalised, alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Skin lesion, skin discolouration, skin hyperpigmentation, night sweats</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorder</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Arthralgia, muscle spasms, back pain, pain in extremity, musculoskeletal pain, bone pain</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Thrombotic microangiopathy with acute renal failure&dagger;, dysuria</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pyrexia, fatigue, influenza-like illness, asthenia, chills</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Irritability, pain, malaise, injection site reaction, non-cardiac chest pain, oedema, oedema peripheral</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Injection site pruritus, injection site rash, chest discomfort</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood bilirubin increased, weight decreased, white blood cell count decreased, haemoglobin decreased, neutrophil count decreased, international normalised ratio increased, activated partial thromboplastin time prolonged, blood glucose increased, blood albumin decreased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Electrocardiogram QT prolonged</p></td></tr></tbody></table><p>&dagger; Grouped term with preferred terms oliguria, renal failure and renal</p><p>impairment</p><p>&nbsp;</p><p>SAA study population</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Neutropenia, splenic infarction</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Iron overload, decreased appetite, hypoglycaemia, increased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anxiety, depression</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache, dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Syncope</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dry eye, cataract, ocular icterus, vision blurred, visual impairment, vitreous floaters</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Cough, oropharyngeal pain, rhinorrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Epistaxis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea, nausea, gingival bleeding, abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Oral mucosal blistering, oral pain, vomiting, abdominal discomfort, constipation, abdominal distension, dysphagia, faeces discoloured, swollen tongue, gastrointestinal motility disorder, flatulence</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Transaminases increased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood bilirubin increased (hyperbilirubinemia), jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Drug-induced liver injury*</p><p>* Cases of drug-induced liver injury have been reported in patients with ITP and HCV</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Petechiae, rash, pruritus, urticaria, skin lesion, rash macular</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Skin discolouration, skin hyperpigmentation</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Musculosketal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Arthralgia, pain in extremity, muscle spasms</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Back pain, myalgia, bone pain</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Chromaturia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fatigue, pyrexia, chills</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Asthenia, oedema peripheral, malaise</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood creatine phosphokinase increased</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>C.&nbsp;&nbsp; <u>Description of selected adverse reactions</u></p><p><em><u>Thrombotic/thromboembolic events (TEEs)</u></em></p><p>In 3 controlled and 2 uncontrolled clinical studies among adult ITP patients receiving eltrombopag (n=446), 17 patients experienced a total of 19 TEEs, which included (in descending order of occurrence) deep vein thrombosis (n=6), pulmonary embolism (n=6), acute myocardial infarction (n=2), cerebral infarction (n=2), embolism (n=1) (see section 4.4).</p><p>In a placebo-controlled study (n=288, Safety population), following 2 weeks&#39; treatment in preparation for invasive procedures, 6 of 143 (4%) adult patients with chronic liver disease receiving eltrombopag experienced 7 TEEs of the</p><p>&nbsp;</p><p>portal venous system and 2 of 145 (1%) patients in the placebo group experienced 3 TEEs. Five of the 6 patients treated with eltrombopag experienced the TEE at a platelet count &gt;200 000/&micro;l</p><p>No specific risk factors were identified in those patients who experienced a</p><p>TEE with the exception of platelet counts &ge;200 000/&micro;l (see section 4.4).</p><p>In controlled studies in thrombocytopenic patients with HCV (n=1 439), 38 out of 955 patients (4%) treated with eltrombopag experienced a TEE and 6 out of 484 patients (1%) in the placebo group experienced TEEs. Portal vein thrombosis was the most common TEE in both treatment groups (2% in patients treated with eltrombopag versus &lt; 1% for placebo) (see section 4.4).</p><p>Patients with low albumin levels (&le; 35 g/l) or MELD &ge;10 had a 2-fold greater risk of TEEs than those with higher albumin levels; those aged &ge;60 years had a 2-fold greater risk of TEEs compared to younger patients.</p><p><em><u>Hepatic decompensation (use with interferon)</u></em></p><p>Chronic HCV patients with cirrhosis may be at risk of hepatic decompensation when receiving alfa interferon therapy. In 2 controlled clinical studies in thrombocytopenic patients with HCV, hepatic decompensation (ascites, hepatic encephalopathy, variceal haemorrhage, spontaneous bacterial peritonitis) was reported more frequently in the eltrombopag arm (11%) than in the placebo arm (6%). In patients with low albumin levels (&le;35 g/l) or MELD score &ge;10 at baseline, there was a 3-fold greater risk of hepatic decompensation and an increase in the risk of a fatal adverse event compared to those with less advanced liver disease.</p><p>Eltrombopag should only be administered to such patients after careful consideration of the expected benefits in comparison with the risks. Patients with these characteristics should be closely monitored for signs and symptoms of hepatic decompensation (see section 4.4).</p><p><em><u>Hepatotoxicity</u></em></p><p>In the controlled clinical studies in chronic ITP with eltrombopag, increases in serum ALT, AST and bilirubin were observed (see section 4.4).</p><p>These findings were mostly mild (Grade 1-2), reversible and not accompanied by clinically significant symptoms that would indicate an impaired liver function. Across the 3 placebo-controlled studies in adults with chronic ITP, 1 patient in the placebo group and 1 patient in the eltrombopag group experienced a Grade 4 liver test abnormality. In two placebo-controlled studies in paediatric patients (aged 1 to 17 years) with chronic ITP, ALT &ge;3 x ULN was reported in 4.7% and 0% of the eltrombopag and placebo groups, respectively.</p><p>In 2 controlled clinical studies in patients with HCV, ALT or AST &ge;3 x ULN was</p><p>reported in 34% and 38% of the eltrombopag and placebo groups,</p><p>&nbsp;</p><p>respectively. Most patients receiving eltrombopag in combination with peginterferon / ribavirin therapy will experience indirect hyperbilirubinaemia. Overall, total bilirubin &ge;1.5 x ULN was reported in 76% and 50% of the eltrombopag and placebo groups, respectively.</p><p>In the single-arm phase II monotherapy refractory SAA study, concurrent ALT or AST &gt;3 x ULN with total (indirect) bilirubin &gt;1.5 x ULN were reported in 5% of patients. Total bilirubin &gt;1.5 x ULN occurred in 14% of patients.</p><p><em><u>Thrombocytopenia following discontinuation of treatment</u></em></p><p>In the 3 controlled clinical ITP studies, transient decreases in platelet counts to levels lower than baseline were observed following discontinuation of treatment in 8% and 8% of the eltrombopag and placebo groups, respectively (see section 4.4).</p><p><em><u>Increased bone marrow reticulin</u></em></p><p>Across the programme, no patients had evidence of clinically relevant bone marrow abnormalities or clinical findings that would indicate bone marrow dysfunction. In a small number of ITP patients, eltrombopag treatment was discontinued due to bone marrow reticulin (see section 4.4).</p><p><em><u>Cytogenetic abnormalities</u></em></p><p>In the phase II refractory SAA clinical study with eltrombopag with a starting dose of 50 mg/day (escalated every 2 weeks to a maximum of 150 mg/day) (ELT112523), the incidence of new cytogenetic abnormalities was observed in 17.1% of adult patients [7/41 (where 4 of them had changes in chromosome 7)]. The median time on study to a cytogenetic abnormality was 2.9 months.</p><p>In the phase II refractory SAA clinical study with eltrombopag at a dose of 150 mg/day (with ethnic or age related modifications as indicated) (ELT116826), the incidence of new cytogenetic abnormalities was observed in 22.6% of adult patients [7/31 (where 3 of them had changes in chromosome 7)]. All 7 patients had normal cytogenetics at baseline. Six patients had cytogenetic abnormality at Month 3 of eltrombopag therapy and one patient had cytogenetic abnormality at Month 6.</p><p><em><u>Haematologic malignancies</u></em></p><p>In the single-arm, open-label study in SAA, three (7%) patients were diagnosed with MDS following treatment with eltrombopag, in the two ongoing studies (ELT116826 and ELT116643), 1/28 (4%) and 1/62 (2%) patient has been diagnosed with MDS or AML in each study.</p><p>D.&nbsp;&nbsp;&nbsp;&nbsp; Special populations</p><p>Renal impairment</p><p>&nbsp;</p><p>No dose adjustment is necessary in patients with renal impairment. Patients with impaired renal function should use eltrombopag with caution and close monitoring, for example by testing serum creatinine and/or performing urine analysis (see section 5.2).</p><p>Hepatic impairment</p><p>Eltrombopag should not be used in ITP patients with hepatic impairment (Child-Pugh score &ge;5) unless the expected benefit outweighs the identified risk of portal venous thrombosis</p><p>If the use of eltrombopag is deemed necessary for ITP patients with hepatic impairment the starting dose must be 25 mg once daily. After initiating the dose of eltrombopag in patients with hepatic impairment an interval of 3 weeks should be observed before increasing the dose.</p><p>No dose adjustment is required for thrombocytopenic patients with chronic HCV and mild hepatic impairment (Child-Pugh score &le;6). Chronic HCV patients and severe aplastic anaemia patients with hepatic impairment should initiate eltrombopag at a dose of 25 mg once daily (see section 5.2).</p><p>After initiating the dose of eltrombopag in patients with hepatic impairment an interval of 2 weeks should be observed before increasing the dose.</p><p>There is an increased risk for adverse events, including hepatic decompensation and thromboembolic events (TEEs), in thrombocytopenic patients with advanced chronic liver disease treated with eltrombopag, either in preparation for invasive procedure or in HCV patients undergoing antiviral therapy</p><p>Elderly</p><p>There are limited data on the use of eltrombopag in ITP patients aged 65 years and older and no clinical experience in ITP patients aged over 85 years. In the clinical studies of eltrombopag, overall no clinically significant differences in safety of eltrombopag were observed between patients aged at least 65 years and younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out</p><p>There are limited data on the use of eltrombopag in HCV and SAA patients aged over 75 years. Caution should be exercised in these patients</p><p>East-/Southeast-Asian patients</p><p>For adult and paediatric patients of East-/Southeast-Asian ancestry, including those with hepatic impairment, eltrombopag should be initiated at a dose of 25 mg once daily</p><p>&nbsp;</p><p>Patient platelet count should continue to be monitored and the standard criteria for further dose modification followed.</p><p>E.&nbsp;&nbsp;&nbsp;&nbsp; Paediatric population</p><p>ELBAG is not recommended for use in children under the age of one year with ITP due to insufficient data on safety and efficacy. The safety and efficacy of eltrombopag has not been established in children and adolescents (&lt;18 years) with chronic HCV related thrombocytopenia or SAA. No data are available.</p><p><strong><u>To report any side effect (s):</u></strong><strong> </strong></p><p><strong>Saudi Arabia:</strong></p><p>The national pharmacovigilance center (NPC):<br />-SFDA call center: 19999<br />-E-mail: npc.drug@sfda.gov.sa<br />-Website: http://ade.sfda.gov.sa</p><p><br /><strong>United Arab Emirates</strong><br />Pharmacovigilance &amp; Medical Device section<br />P.O.Box: 1853<br />Tel: 80011111<br />Email: pv@mohap.gov.ae<br />Drug Department Ministry of Health &amp; Prevention Dubai &ndash; UAE<br />&nbsp;</p><p><strong>Other GCC states and other countries:</strong><br />-Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdose, platelet counts may increase excessively and result in thrombotic/thromboembolic complications. In case of an overdose, consideration should be given to oral administration of a metal cation- containing preparation, such as calcium, aluminium, or magnesium preparations to chelate eltrombopag and thus limit absorption. Platelet counts should be closely monitored. Treatment with eltrombopag should be reinitiated in accordance with dosing and administration recommendations (see section 4.2).</p><p>In the clinical studies there was one report of overdose where the patient ingested 5 000 mg of eltrombopag. Reported adverse reactions included mild rash, transient bradycardia, ALT and AST elevation, and fatigue. Liver enzymes measured between Days 2 and 18 after ingestion peaked at a 1.6- fold ULN in AST, a 3.9-fold ULN in ALT, and a 2.4-fold ULN in total bilirubin. The platelet counts were 672 000/&micro;l on Day 18 after ingestion and the maximum</p><p>&nbsp;</p><p>platelet count was 929 000/&micro;l. All events were resolved without sequelae following treatment.</p><p>Because eltrombopag is not significantly renally excreted and is highly bound to plasma proteins, haemodialysis would not be expected to be an effective method to enhance the elimination of eltrombopag.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antihemorrhagics, other systemic hemostatics. ATC code: B02BX 05.</p><p><u>Mechanism of action</u></p><p>TPO is the main cytokine involved in regulation of megakaryopoiesis and platelet production, and is the endogenous ligand for the TPO-R. Eltrombopag interacts with the transmembrane domain of the human TPO- R and initiates signalling cascades similar but not identical to that of endogenous thrombopoietin (TPO), inducing proliferation and differentiation from bone marrow progenitor cells.</p><p><u>Clinical efficacy and safety</u></p><p><em><u>Immune (primary) thrombocytopenia (ITP) studies</u></em></p><p>Two phase III, randomised, double-blind, placebo-controlled studies RAISE (TRA102537) and TRA100773B and two open-label studies REPEAT (TRA108057) and EXTEND (TRA105325) evaluated the safety and efficacy of eltrombopag in adult patients with previously treated ITP. Overall, eltrombopag was administered to 277 ITP patients for at least 6 months and 202 patients for at least 1 year. The single-arm phase II study TAPER (CETB115J2411) evaluated the safety and efficacy of eltrombopag and its ability to induce sustained response after treatment discontinuation in 105 adult ITP patients who relapsed or failed to respond to first-line corticosteroid treatment.</p><p><em>Double-blind placebo-controlled studies</em></p><p>RAISE:</p><p>197 ITP patients were randomised 2:1, eltrombopag (n=135) to placebo (n=62), and randomisation was stratified based upon splenectomy status, use of ITP medicinal products at baseline and baseline platelet count. The dose of eltrombopag was adjusted during the 6-month treatment period based on individual platelet counts. All patients initiated treatment with eltrombopag 50 mg. From Day 29 to the end of treatment, 15 to 28% of eltrombopag- treated patients were maintained on &le;25 mg and 29 to 53% received 75 mg.</p><p>&nbsp;</p><p>In addition, patients could taper off concomitant ITP medicinal products and receive rescue treatments as dictated by local standard of care. More than half of all patients in each treatment group had &ge;3 prior ITP therapies and 36% had a prior splenectomy.</p><p>Median platelet counts at baseline were 16 000/&mu;l for both treatment groups and in the eltrombopag group were maintained above 50 000/&micro;l at all on- therapy visits starting at Day 15; in contrast, median platelet counts in the placebo group remained &lt;30 000/&micro;l throughout the study.</p><p>Platelet count response between 50 000-400 000/&mu;l in the absence of rescue treatment was achieved by significantly more patients in the eltrombopag treated group during the 6-month treatment period, p &lt;0.001. Fifty-four percent of the eltrombopag-treated patients and 13% of placebo-treated patients achieved this level of response after 6 weeks of treatment. A similar platelet response was maintained throughout the study, with 52% and 16% of patients responding at the end of the 6-month treatment period.</p><p>Table 4 Secondary efficacy results from RAISE</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Eltrombopag N=135</p></td><td style="vertical-align:top"><p>Placebo N=62</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Key secondary endpoints</p></td></tr><tr><td style="vertical-align:top"><p>Number of cumulative weeks with platelet counts &ge;50 000-400 000/&micro;l, Mean (SD)</p></td><td style="vertical-align:top"><p>11.3 (9.46)</p></td><td style="vertical-align:top"><p>2.4 (5.95)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Patients with &ge;75% of assessments in the target range (50 000 to 400 000/&mu;l), n (%)</p><p><em>p-</em>value a</p></td><td style="vertical-align:top"><p>51 (38)</p></td><td style="vertical-align:top"><p>4 (7)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Patients with bleeding (WHO Grades 1-4) at any time during 6 months, n (%)</p><p><em>p-</em>value a</p></td><td style="vertical-align:top"><p>106 (79)</p></td><td style="vertical-align:top"><p>56 (93)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>0.012</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Patients with bleeding (WHO Grades 2-4) at any time during 6 months, n (%)</p><p><em>p-</em>value a</p></td><td style="vertical-align:top"><p>44 (33)</p></td><td style="vertical-align:top"><p>32 (53)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>0.002</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Requiring rescue therapy, n (%)</p><p><em>p-</em>value a</p></td><td style="vertical-align:top"><p>24 (18)</p></td><td style="vertical-align:top"><p>25 (40)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>0.001</p></td></tr><tr><td style="vertical-align:top"><p>Patients receiving ITP therapy at baseline (n)</p></td><td style="vertical-align:top"><p>63</p></td><td style="vertical-align:top"><p>31</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Patients who attempted to reduce or discontinue baseline therapy, n (%)b</p><p><em>p-</em>value a</p></td><td style="vertical-align:top"><p>37 (59)</p></td><td style="vertical-align:top"><p>10 (32)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>0.016</p></td></tr></tbody></table><p>a Logistic regression model adjusted for randomisation stratification variables</p><p>b 21 out of 63 (33%) patients treated with eltrombopag who were taking an ITP medicinal product at baseline permanently discontinued all baseline ITP medicinal products.</p><p>At baseline, more than 70% of ITP patients in each treatment group reported any bleeding (WHO Grades 1-4) and more than 20% reported clinically significant bleeding (WHO Grades 2-4), respectively. The proportion of eltrombopag-treated patients with any bleeding (Grades 1-4) and clinically</p><p>&nbsp;</p><p>significant bleeding (Grades 2-4) was reduced from baseline by approximately 50% from Day 15 to the end of treatment throughout the 6- month treatment period.</p><p>TRA100773B:</p><p>The primary efficacy endpoint was the proportion of responders, defined as ITP patients who had an increase in platelet counts to &ge;50 000/&mu;l at Day 43 from a baseline of &lt;30 000/&mu;l; patients who withdrew prematurely due to a platelet count &gt;200 000/&mu;l were considered responders, those that discontinued for any other reason were considered non-responders irrespective of platelet count. A total of 114 patients with previously treated ITP were randomised 2:1 eltrombopag (n=76) to placebo (n=38).</p><p>Table 5 Efficacy results from TRA100773B</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Eltrombopag N=74</p></td><td style="vertical-align:top"><p>Placebo N=38</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Key primary endpoints</p></td></tr><tr><td style="vertical-align:top"><p>Eligible for efficacy analysis, n</p></td><td style="vertical-align:top"><p>73</p></td><td style="vertical-align:top"><p>37</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Patients with platelet count &ge;50 000/&mu;l after up to 42 days of dosing (compared to a baseline count of &lt;30 000/&mu;l), n (%)</p><p><em>p-</em>valuea</p></td><td style="vertical-align:top"><p>43 (59)</p></td><td style="vertical-align:top"><p>6 (16)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Key secondary endpoints</p></td></tr><tr><td style="vertical-align:top"><p>Patients with a Day 43 bleeding assessment, n</p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>30</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Bleeding (WHO Grades 1-4) n (%)</p><p><em>p-</em>valuea</p></td><td style="vertical-align:top"><p>20 (39)</p></td><td style="vertical-align:top"><p>18 (60)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>0.029</p></td></tr></tbody></table><p>a Logistic regression model adjusted for randomisation stratification variables</p><p>In both RAISE and TRA100773B the response to eltrombopag relative to placebo was similar irrespective of ITP medicinal product use, splenectomy status and baseline platelet count (&le;15 000/&micro;l, &gt;15 000/&micro;l) at randomisation.</p><p>In RAISE and TRA100773B studies, in the subgroup of ITP patients with baseline platelet count &le;15 000/&mu;l the median platelet counts did not reach the target level (&gt;50 000/&mu;l), although in both studies 43% of these patients treated with eltrombopag responded after 6 weeks of treatment. In addition, in the RAISE study, 42% of patients with baseline platelet count &le;15 000/&mu;l treated with eltrombopag responded at the end of the 6-month treatment period. Forty-two to 60% of the eltrombopag-treated patients in the RAISE study were receiving 75 mg from Day 29 to the end of treatment.</p><p><em>Open-label non-controlled studies</em></p><p>REPEAT (TRA108057):</p><p>&nbsp;</p><p>This open-label, repeat-dose study (3 cycles of 6 weeks of treatment, followed by 4 weeks off treatment) showed that episodic use with multiple courses of eltrombopag has demonstrated no loss of response.</p><p>EXTEND (TRA105325):</p><p>Eltrombopag was administered to 302 ITP patients in this open-label extension study, 218 patients completed 1 year, 180 completed 2 years, 107</p><p>completed 3 years, 75 completed 4 years, 34 completed 5 years and 18 completed 6 years. The median baseline platelet count was 19 000/&mu;l prior to eltrombopag administration. Median platelet counts at 1, 2, 3, 4, 5, 6 and 7</p><p>years on study were 85 000/&mu;l, 85 000/&mu;l, 105 000/&mu;l, 64 000/&mu;l, 75 000/&mu;l, 119 000/&mu;l and 76 000/&mu;l, respectively.</p><p>TAPER (CETB115J2411):</p><p>This was a single-arm phase II study including ITP patients treated with eltrombopag after first-line corticosteroid failure irrespective of time since diagnosis. A total of 105 patients were enrolled on the study and started eltrombopag treatment on 50 mg once daily (25 mg once daily for patients of East-/Southeast-Asian ancestry). The dose of eltrombopag was adjusted during the treatment period based on individual platelet counts with the goal to achieve a platelet count &ge;100 000/&mu;l.</p><p>Of the 105 patients who were enrolled in the study and who received at least one dose of eltrombopag, 69 patients (65.7%) completed treatment and 36 patients (34.3%) discontinued treatment early.</p><p>Analysis of sustained response off treatment</p><p>The primary endpoint was the proportion of patients with sustained response off treatment until Month 12. Patients who reached a platelet count of &ge;100 000/&micro;l and maintained platelet counts around 100 000/&micro;l for 2 months (no counts below 70 000/&micro;l) were eligible for tapering off eltrombopag and treatment discontinuation. To be considered as having achieved a sustained response off treatment, a patient had to maintain platelet counts &ge;30 000/&micro;l, in the absence of bleeding events or the use of rescue therapy, both during the treatment tapering period and following discontinuation of treatment until Month 12.</p><p>The duration of tapering was individualised depending on the starting dose and the response of the patient. The tapering schedule recommended dose reductions of 25 mg every 2 weeks if the platelet counts were stable. After the daily dose was reduced to 25 mg for 2 weeks, the dose of 25 mg was then only administered on alternate days for 2 weeks until treatment discontinuation.</p><p>The tapering was done in smaller decrements of 12.5 mg every second week for patients of East-/Southeast-Asian ancestry. If a relapse (defined as platelet</p><p>&nbsp;</p><p>count &lt;30 000/&micro;l) occurred, patients were offered a new course of eltrombopag at the appropriate starting dose.</p><p>Eighty-nine patients (84.8%) achieved a complete response (platelet count</p><p>&ge;100 000/&micro;l) (Step 1, Table 6) and 65 patients (61.9%) maintained the complete response for at least 2 months with no platelet counts below 70 000/&micro;l (Step 2, Table 6). Forty-four patients (41.9%) were able to be tapered off eltrombopag until treatment discontinuation while maintaining platelet counts &ge;30 000/&micro;l in the absence of bleeding events or the use of rescue therapy (Step 3, Table 6).</p><p>The study met the primary objective by demonstrating that eltrombopag was able to induce sustained response off treatment, in the absence of bleeding events or the use of rescue therapy, by Month 12 in 32 of the 105 enrolled patients (30.5%; p&lt;0.0001; 95% CI: 21.9, 40.2) (Step 4, Table 6). By Month 24, 20</p><p>of the 105 enrolled patients (19.0%; 95% CI: 12.0, 27.9) maintained sustained response off treatment in the absence of bleeding events or the use of rescue therapy (Step 5, Table 6).</p><p>The median duration of sustained response after treatment discontinuation to Month 12 was 33.3 weeks (min-max: 4-51), and the median duration of sustained response after treatment discontinuation to Month 24 was 88.6 weeks (min-max: 57-107).</p><p>After tapering off and discontinuation of eltrombopag treatment, 12 patients had a loss of response, 8 of them re-started eltrombopag and 7 had a recovery response.</p><p>During the 2-year follow-up, 6 out of 105 patients (5.7%) experienced thromboembolic events, of which 3 patients (2.9%) experienced deep vein thrombosis, 1 patient (1.0%) experienced superficial vein thrombosis, 1 patient (1.0%) experienced cavernous sinus thrombosis, 1 patient (1.0%) experienced cerebrovascular accident and 1 patient (1.0%) experienced pulmonary embolism. Of the 6 patients, 4 patients experienced thromboembolic events that were reported at or greater than Grade 3, and 4 patients experienced thromboembolic event that were reported as serious. No fatal cases were reported.</p><p>Twenty out of 105 patients (19.0%) experienced mild to severe haemorrhage events on treatment before tapering started. Five out of 65 patients (7.7%) who started tapering experienced mild to moderate haemorrhage events during tapering. No severe haemorrhage event occurred during tapering.</p><p>Two out of 44 patients (4.5%) who tapered off and discontinued eltrombopag treatment experienced mild to moderate haemorrhage events after treatment discontinuation until Month 12. No severe haemorrhage event occurred during this period. None of the patients who discontinued eltrombopag and entered the second year follow-up experienced</p><p>&nbsp;</p><p>haemorrhage event during the second year. Two fatal intracranial haemorrhage events were reported during the 2-year follow-up. Both events occurred on treatment, not in the context of tapering. The events were not considered to be related to study treatment.</p><p>The overall safety analysis is consistent with previously reported data and the risk-benefit assessment remained unchanged for the use of eltrombopag in patients with ITP.</p><p>Table 6 Proportion of patients with sustained response off treatment at Month 12 and at Month 24 (full analysis set) in TAPER</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>All </strong><strong>patients N=105</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Hypothesis </strong><strong>testing</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>n (%)</strong></p></td><td style="vertical-align:top"><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p><strong>p-value</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Reject H0</strong></p></td></tr><tr><td style="vertical-align:top"><p>Step 1: Patients who reached platelet count &ge;100 000/&micro;l at least once</p></td><td style="vertical-align:top"><p>89 (84.8)</p></td><td style="vertical-align:top"><p>(76.4, 91.0)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Step 2: Patients who maintained stable platelet count for 2 months after reaching 100 000/&micro;l (no counts &lt;70 000/&micro;l)</p></td><td style="vertical-align:top"><p>65 (61.9)</p></td><td style="vertical-align:top"><p>(51.9, 71.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Step 3: Patients who were able to be tapered off eltrombopag until treatment discontinuation, maintaining platelet count &ge;30 000/&micro;L in the absence of bleeding events or use of any rescue therapy</p></td><td style="vertical-align:top"><p>44 (41.9)</p></td><td style="vertical-align:top"><p>(32.3, 51.9)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Step 4: Patients with sustained response off treatment until Month 12, with platelet count maintained &ge;30 000/&micro;l in the absence of bleeding events or use of any rescue therapy</p></td><td style="vertical-align:top"><p>32 (30.5)</p></td><td style="vertical-align:top"><p>(21.9, 40.2)</p></td><td style="vertical-align:top"><p>&lt;0.0001*</p></td><td colspan="2" style="vertical-align:top"><p>Yes</p></td></tr><tr><td style="vertical-align:top"><p>Step 5: Patients with sustained response off treatment from Month 12 to Month 24, maintaining platelet count &ge;30 000/&micro;l in the absence of bleeding events or use of any rescue therapy</p></td><td style="vertical-align:top"><p>20 (19.0)</p></td><td style="vertical-align:top"><p>(12.0, 27.9)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>N: The total number of patients in the treatment group. This is the denominator for percentage (%) calculation. n: Number of patients in the corresponding category.</p><p>The 95% CI for the frequency distribution was computed using Clopper-Pearson exact method. Clopper-Pearson test was used for testing whether the proportion of responders was &gt;15%. CI and p-values are reported.</p><p>* Indicates statistical significance (one-sided) at the 0.05 level.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Results of response on treatment analysis by time since ITP diagnosis</p><p>An ad-hoc analysis was conducted on the n=105 patients by time since ITP diagnosis to assess the response to eltrombopag across four different ITP categories by time since diagnosis (newly diagnosed ITP &lt;3 months, persistent ITP 3 to &lt;6 months, persistent ITP 6 to &le;12 months, and chronic ITP</p><p>&gt;12 months). 49% of patients (n=51) had an ITP diagnosis of &lt;3 months, 20% (n=21) of 3 to &lt;6 months, 17% (n=18) of 6 to &le;12 months and 14% (n=15) of &gt;12 months.</p><p>Until the cut-off date (22-Oct-2021), patients were exposed to eltrombopag for a median (Q1-Q3) duration of 6.2 months (2.3-12.0 months). The median (Q1- Q3) platelet count at baseline was 16 000/&mu;l (7 800-28 000/&mu;l).</p><p>&nbsp;</p><p>Platelet count response, defined as a platelet count &ge;50 000/&mu;l at least once</p><p>by Week 9 without rescue therapy, was achieved in 84% (95% CI: 71% to 93%)</p><p>of newly diagnosed ITP patients, 91% (95% CI: 70% to 99%) and 94% (95% CI: 73% to 100%) of persistent ITP patients (i.e. with ITP diagnosis 3 to &lt;6 months and 6 to &le;12 months, respectively), and in 87% (95% CI: 60% to 98%) of chronic ITP patients.</p><p>The rate of complete response, defined as platelet count &ge;100 000/&mu;l at least</p><p>once by Week 9 without rescue therapy, was 75% (95% CI: 60% to 86%) in</p><p>newly diagnosed ITP patients, 76% (95% CI: 53% to 92%) and 72% (95% CI: 47% to 90%) in persistent ITP patients (ITP diagnosis 3 to &lt;6 months and 6 to &le;12 months, respectively), and 87% (95% CI: 60% to 98%) in chronic ITP patients.</p><p>The rate of durable response, defined as a platelet count &ge;50 000/&mu;l for at least 6 out of 8 consecutive assessments without rescue therapy during the first 6 months on study, was 71% (95% CI: 56% to 83%) in newly diagnosed ITP</p><p>patients, 81% (95% CI: 58% to 95%) and 72% (95% CI: 47% to 90.3%) in persistent ITP patients (ITP diagnosis 3 to &lt;6 months and 6 to &le;12 months, respectively), and 80% (95% CI: 52% to 96%) in chronic ITP patients.</p><p>When assessed with the WHO Bleeding Scale, the proportion of newly diagnosed and persistent ITP patients without bleeding at Week 4 ranged from 88% to 95% compared to 37% to 57% at baseline. For chronic ITP patients it was 93% compared to 73% at baseline.</p><p>The safety of eltrombopag was consistent across all ITP categories and in line with its known safety profile.</p><p>Clinical studies comparing eltrombopag to other treatment options (e.g. splenectomy) have not been conducted. The long-term safety of eltrombopag should be considered prior to starting therapy.</p><p><em>Paediatric population (aged 1 to 17 years)</em></p><p>The safety and efficacy of eltrombopag in paediatric patients have been investigated in two studies.</p><p>TRA115450 (PETIT2):</p><p>The primary endpoint was a sustained response, defined as the proportion of patients receiving eltrombopag, compared to placebo, achieving platelet counts &ge;50 000/&micro;l for at least 6 out of 8 weeks (in the absence of rescue therapy), between weeks 5 to 12 during the double-blind randomised period. Patients were diagnosed with chronic ITP for at least 1 year and were refractory or relapsed to at least one prior ITP therapy or unable to continue other ITP treatments for a medical reason and had platelet count &lt;30 000/&micro;l. Ninety-two patients were randomised by three age cohort strata (2:1) to</p><p>&nbsp;</p><p>eltrombopag (n=63) or placebo (n=29). The dose of eltrombopag could be adjusted based on individual platelet counts.</p><p>Overall, a significantly greater proportion of eltrombopag patients (40%) compared with placebo patients (3%) achieved the primary endpoint (Odds Ratio: 18.0 [95% CI: 2.3, 140.9] p &lt;0.001) which was similar across the three age</p><p>cohorts (Table 7).</p><p>Table 7 Sustained platelet response rates by age cohort in paediatric patients with chronic ITP</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Eltrombopag n/N (%) [95% CI]</p></td><td style="vertical-align:top"><p>Placebo n/N (%) [95% CI]</p></td></tr><tr><td style="vertical-align:top"><p>Cohort 1 (12 to 17 years)</p></td><td style="vertical-align:top"><p>9/23 (39%)</p></td><td style="vertical-align:top"><p>1/10 (10%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>[20%, 61%]</p></td><td style="vertical-align:top"><p>[0%, 45%]</p></td></tr><tr><td style="vertical-align:top"><p>Cohort 2 (6 to 11 years)</p></td><td style="vertical-align:top"><p>11/26 (42%)</p></td><td style="vertical-align:top"><p>0/13 (0%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>[23%, 63%]</p></td><td style="vertical-align:top"><p>[N/A]</p></td></tr><tr><td style="vertical-align:top"><p>Cohort 3 (1 to 5 years)</p></td><td style="vertical-align:top"><p>5/14 (36%)</p></td><td style="vertical-align:top"><p>0/6 (0%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>[13%, 65%]</p></td><td style="vertical-align:top"><p>[N/A]</p></td></tr></tbody></table><p>Statistically fewer eltrombopag patients required rescue treatment during the randomised period compared to placebo patients (19% [12/63] vs. 24% [7/29], p=0.032).</p><p>At baseline, 71% of patients in the eltrombopag group and 69% in the placebo group reported any bleeding (WHO Grades 1-4). At Week 12, the proportion of eltrombopag patients reporting any bleeding was decreased to half of baseline (36%). In comparison, at Week 12, 55% of placebo patients reported any bleeding.</p><p>Patients were permitted to reduce or discontinue baseline ITP therapy only during the open-label phase of the study and 53% (8/15) of patients were able to reduce (n=1) or discontinue (n=7) baseline ITP therapy, mainly corticosteroids, without needing rescue therapy.</p><p>TRA108062 (PETIT):</p><p>The primary endpoint was the proportion of patients achieving platelet counts &ge;50 000/&micro;l at least once between weeks 1 and 6 of the randomised period. Patients were diagnosed with ITP for at least 6 months and were refractory or relapsed to at least one prior ITP therapy with a platelet count</p><p>&lt;30 000/&micro;l (n=67). During the randomised period of the study, patients were randomised by three age cohort strata (2:1) to eltrombopag (n=45) or placebo (n=22). The dose of eltrombopag could be adjusted based on individual platelet counts.</p><p>Overall, a significantly greater proportion of eltrombopag patients (62%) compared with placebo patients (32%) met the primary endpoint (Odds Ratio: 4.3 [95% CI: 1.4, 13.3] p=0.011).</p><p>&nbsp;</p><p>Sustained response was seen in 50% of the initial responders during 20 out of 24 weeks in the PETIT 2 study and 15 out of 24 weeks in the PETIT study.</p><p><em><u>Chronic hepatitis C associated thrombocytopenia studies</u></em></p><p>The efficacy and safety of eltrombopag for the treatment of thrombocytopenia in patients with HCV infection were evaluated in two randomised, double-blind, placebo-controlled studies. ENABLE 1 utilised peginterferon alfa-2a plus ribavirin for antiviral treatment and ENABLE 2 utilised peginterferon alfa-2b plus ribavirin. Patients did not receive direct acting antiviral agents. In both studies, patients with a platelet count of &lt;75 000/&micro;l were enrolled and stratified by platelet count (&lt;50 000/&micro;l and &ge;50 000/&micro;l to &lt;75 000/&micro;l), screening HCV RNA (&lt;800 000 IU/ml and &ge;800 000 IU/ml), and HCV genotype (genotype 2/3, and genotype 1/4/6).</p><p>Baseline disease characteristics were similar in both studies and were consistent with compensated cirrhotic HCV patient population. The majority of patients were HCV genotype 1 (64%) and had bridging fibrosis/cirrhosis.</p><p>Thirty-one percent of patients had been treated with prior HCV therapies, primarily pegylated interferon plus ribavirin. The median baseline platelet count was 59 500/&micro;l in both treatment groups: 0.8%, 28% and 72% of the patients recruited had platelet counts &lt;20 000/&micro;l, &lt;50 000/&micro;l and &ge;50 000/&micro;l respectively.</p><p>The studies consisted of two phases &ndash; a pre-antiviral treatment phase and an antiviral treatment phase. In the pre-antiviral treatment phase, patients received open-label eltrombopag to increase the platelet count to &ge;90 000/&micro;l for ENABLE 1 and &ge;100 000/&micro;l for ENABLE 2. The median time to achieve the target platelet count &ge;90 000/&micro;l (ENABLE 1) or &ge;100 000/&micro;l (ENABLE 2) was 2 weeks.</p><p>The primary efficacy endpoint for both studies was sustained virologic response (SVR), defined as the percentage of patients with no detectable HCV-RNA at 24 weeks after completion of the planned treatment period.</p><p>In both HCV studies, a significantly greater proportion of patients treated with eltrombopag (n=201, 21%) achieved SVR compared to those treated with placebo (n=65, 13%) (see Table 8). The improvement in the proportion of patients who achieved SVR was consistent across all subgroups in the randomisation strata (baseline platelet counts (&lt;50 000 vs. &gt;50 000), viral load (&lt;800 000 IU/ml vs. &ge;800 000 IU/ml) and genotype (2/3 vs. 1/4/6)).</p><p>Table 8 Virologic response in HCV patients in ENABLE 1 and ENABLE 2</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Pooled data</strong></p></td><td style="vertical-align:top"><p><strong>ENABLE 1</strong><strong>a</strong></p></td><td style="vertical-align:top"><p><strong>ENABLE 2</strong><strong>b</strong></p></td></tr><tr><td style="vertical-align:top"><p>Patients achieving target platelet counts and initiating antiviral therapy <strong>c</strong></p></td><td style="vertical-align:top"><p>1 439/1 520 (95%)</p></td><td style="vertical-align:top"><p>680/715 (95%)</p></td><td style="vertical-align:top"><p>759/805 (94%)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Eltrombopag</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Eltrombopag</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Eltrombopag</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Total number of patients entering antiviral treatment phase</strong></p></td><td style="vertical-align:top"><p><strong>n=956</strong></p></td><td style="vertical-align:top"><p><strong>n=485</strong></p></td><td style="vertical-align:top"><p><strong>n=450</strong></p></td><td style="vertical-align:top"><p><strong>n=232</strong></p></td><td style="vertical-align:top"><p><strong>n=506</strong></p></td><td style="vertical-align:top"><p><strong>n=253</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="6" style="vertical-align:top"><p><strong>% patients achieving virologic response</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall SVR </strong>d</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>13</p></td></tr><tr><td style="vertical-align:top"><p><em>HCV RNA Genotype</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 2/3</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>25</p></td></tr><tr><td style="vertical-align:top"><p>Genotype 1/4/6e</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p><em>Albumin levels </em><em>f</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&le; 35g/l</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 35g/l</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p><em>MELD score</em><em>f</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 10</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 10</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>17</p></td></tr></tbody></table><p>a Eltrombopag given in combination with peginterferon alfa-2a (180 &mu;g once weekly for 48 weeks for genotypes 1/4/6; 24 weeks for genotype 2/3) plus ribavirin (800 to 1 200 mg daily in 2 divided doses orally)</p><p>b Eltrombopag given in combination with peginterferon alfa-2b (1.5 &mu;g/kg once weekly for 48 weeks for genotype 1/4/6; 24 weeks for genotype 2/3) plus ribavirin (800 to 1 400 mg orally in 2 divided doses)</p><p>c Target platelet count was &ge;90 000/&micro;l for ENABLE 1 and &ge;100 000/&micro;l for ENABLE 2. For ENABLE 1, 682 patients were randomised to the antiviral treatment phase; however 2 patients then withdrew consent prior to receiving antiviral therapy</p><p>d <em>p-</em>value &lt;0.05 for eltrombopag versus placebo</p><p>e 64% patients participating in ENABLE 1 and ENABLE 2 were genotype 1 f Post-hoc analyses</p><p>Other secondary findings of the studies included the following: significantly fewer patients treated with eltrombopag prematurely discontinued antiviral therapy compared to placebo (45% vs. 60%, p=&lt;0.0001). A greater proportion of patients on eltrombopag did not require any antiviral dose reduction as compared to placebo (45% vs. 27%). Eltrombopag treatment delayed and reduced the number of peginterferon dose reductions.</p><p><em><u>Severe aplastic anaemia</u></em></p><p>Eltrombopag was studied in a single-arm, single-centre open-label study in 43 patients with severe aplastic anaemia with refractory thrombocytopenia following at least one prior immunosuppressive therapy (IST) and who had a platelet count &le;30 000/&micro;l.</p><p>&nbsp;</p><p>The majority of patients, 33 (77%), were considered to have &#39;primary refractory disease&#39;, defined as having no prior adequate response to IST in any lineage. The remaining 10 patients had insufficient platelet response to prior therapies. All 10 had received at least 2 prior IST regimens and 50% had received at least 3 prior IST regimens. Patients with diagnosis of Fanconi anaemia, infection not responding to appropriate therapy, PNH clone size in neutrophils of &ge;50%, where excluded from participation.</p><p>At baseline the median platelet count was 20 000/&micro;l, haemoglobin was 8.4 g/dl, ANC was 0.58 x 109/l and absolute reticulocyte count was 24.3 x 109/l.</p><p>Eighty-six percent of patients were RBC transfusion dependent, and 91% were platelet transfusion dependent. The majority of patients (84%) had received at least 2 prior immunosuppressive therapies. Three patients had cytogenetic abnormalities at baseline.</p><p>The primary endpoint was haematological response assessed after 12 weeks of eltrombopag treatment. Haematological response was defined as meeting one or more of the following criteria: 1) platelet count increases to 20 000/&micro;l above baseline or stable platelet counts with transfusion independence for a minimum of 8 weeks; 2) haemoglobin increase by &gt;1.5g/dl, or a reduction in</p><p>&ge;4 units of red blood cell (RBC) transfusions for 8 consecutive weeks; 3) absolute neutrophil count (ANC) increase of 100% or an ANC increase &gt;0.5 x 109/l.</p><p>The haematological response rate was 40% (17/43 patients; 95% CI 25, 56), the majority were unilineage responses (13/17, 76%) whilst there were 3 bilineage and 1 trilineage responses at week 12. Eltrombopag was discontinued after 16 weeks if no haematological response or transfusion independence was observed. Patients who responded continued therapy in an extension phase of the study. A total of 14 patients entered the extension phase of the trial.</p><p>Nine of these patients achieved a multi-lineage response, 4 of the 9 remain on treatment and 5 tapered off treatment with eltrombopag and maintained the response (median follow up: 20.6 months, range: 5.7 to 22.5 months). The remaining 5 patients discontinued treatment, three due to relapse at the month 3 extension visit.</p><p>During treatment with eltrombopag 59% (23/39) became platelet transfusion independent (28 days without platelet transfusion) and 27% (10/37) became RBC transfusion independent (56 days without RBC transfusion). The longest platelet transfusion-free period for non-responders was 27 days (median). The longest platelet transfusion-free period for responders was 287 days (median). The longest RBC transfusion-free period for non-responders was 29 days (median). The longest RBC transfusion-free period for responders was 266 days (median).</p><p>&nbsp;</p><p>Over 50% of responders who were transfusion-dependent at baseline, had</p><p>&gt;80% reduction in both platelet and RBC transfusion requirements compared to baseline.</p><p>Preliminary results from a supportive study (Study ELT116826), an ongoing non-randomised, phase II, single-arm, open-label study in refractory SAA patients, showed consistent results. Data are limited to 21 out of the planned 60 patients with haematological responses reported by 52% of patients at 6 months. Multilineage responses were reported by 45% of patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp;&nbsp;&nbsp;&nbsp; </strong><u>Pharmacokinetics</u></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image2.png" o:spid="_x0000_s1042" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:188.25pt;
 margin-top:57.2pt;width:4.7pt;height:5.3pt;z-index:-17020928;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="7" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />The plasma eltrombopag concentration-time data collected in 88 patients with ITP in studies TRA100773A and TRA100773B were combined with data from 111 healthy adult subjects in a population PK analysis. Plasma eltrombopag&nbsp;AUC(0-&nbsp;&nbsp; &nbsp;) &nbsp;and&nbsp;Cmax &nbsp;estimates&nbsp;for&nbsp;ITP&nbsp;patients&nbsp;are&nbsp;presented&nbsp;(Table 9).</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1041"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:330.6pt;margin-top:49.8pt;width:4.65pt;height:5.3pt;z-index:-17020416;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="7" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />Table 9 Geometric mean (95% confidence intervals) of steady-state plasma eltrombopag pharmacokinetic parameters in adults with ITP</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Eltrombopag dose, once daily</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>AUC</strong><strong>(0- )a, </strong><strong>&mu;g.h/ml</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong>max </strong><strong>, &mu;g/ml</strong></p><p><strong>a</strong></p></td></tr><tr><td style="vertical-align:top"><p>30 mg</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>47 (39, 58)</p></td><td style="vertical-align:top"><p>3.78 (3.18, 4.49)</p></td></tr><tr><td style="vertical-align:top"><p>50 mg</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>108 (88, 134)</p></td><td style="vertical-align:top"><p>8.01 (6.73, 9.53)</p></td></tr><tr><td style="vertical-align:top"><p>75 mg</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>168 (143, 198)</p></td><td style="vertical-align:top"><p>12.7 (11.0, 14.5)</p></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="_x0000_s1040"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:115.8pt;margin-top:5.95pt;width:4.7pt;height:5.3pt;z-index:-17019904;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="7" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />a&nbsp;AUC(0-&nbsp;&nbsp; &nbsp;) &nbsp;and&nbsp;Cmax &nbsp;based on population PK post-hoc estimates.</p><p><!--[if gte vml 1]><v:shape id="image3.png"
 o:spid="_x0000_s1039" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:427.2pt;margin-top:69.85pt;width:6.25pt;height:7.6pt;
 z-index:-17019392;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="8" height="10" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" />Plasma eltrombopag concentration-time data collected in 590 patients with HCV enrolled in phase III studies TPL103922/ENABLE 1 and TPL108390/ENABLE 2 were combined with data from patients with HCV enrolled in the phase II study TPL102357 and healthy adult subjects in a population&nbsp;PK&nbsp;analysis.&nbsp;Plasma&nbsp;eltrombopag&nbsp;Cmax &nbsp;and&nbsp;AUC(0-&nbsp;&nbsp; &nbsp;) &nbsp;estimates&nbsp;for patients with HCV enrolled in the phase III studies are presented for each dose studied in Table 10.</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1038"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:369.95pt;margin-top:49.7pt;width:4.65pt;height:5.3pt;z-index:-17018880;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="7" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />Table 10 Geometric mean (95% CI) steady-state plasma eltrombopag pharmacokinetic parameters in patients with chronic HCV</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Eltrombopag </strong><strong>dose (once daily)</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>AUC</strong><strong>(0- )</strong></p><p><strong>(&mu;g.h/ml)</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong>max </strong><strong>(&mu;g/ml)</strong></p></td></tr><tr><td style="vertical-align:top"><p>25 mg</p></td><td style="vertical-align:top"><p>330</p></td><td style="vertical-align:top"><p>118</p><p>(109, 128)</p></td><td style="vertical-align:top"><p>6.40</p><p>(5.97, 6.86)</p></td></tr><tr><td style="vertical-align:top"><p>50 mg</p></td><td style="vertical-align:top"><p>119</p></td><td style="vertical-align:top"><p>166</p><p>(143, 192)</p></td><td style="vertical-align:top"><p>9.08</p><p>(7.96, 10.35)</p></td></tr><tr><td style="vertical-align:top"><p>75 mg</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>301</p><p>(250, 363)</p></td><td style="vertical-align:top"><p>16.71</p><p>(14.26, 19.58)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>100 mg</p></td><td style="vertical-align:top"><p>96</p></td><td style="vertical-align:top"><p>354</p></td><td style="vertical-align:top"><p>19.19</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(304, 411)</p></td><td style="vertical-align:top"><p>(16.81, 21.91)</p></td></tr></tbody></table><p>Data presented as geometric mean (95% CI).</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1037"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:108.75pt;margin-top:13.4pt;width:4.7pt;height:5.3pt;z-index:-17018368;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="7" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />AUC (0-&nbsp;&nbsp; &nbsp;) &nbsp;and&nbsp;Cmax &nbsp;based on population PK post-hoc estimates at the highest dose in the data for each patient.</p><p><u>Absorption and bioavailability</u></p><p>Eltrombopag is absorbed with a peak concentration occurring 2 to 6 hours after oral administration. Administration of eltrombopag concomitantly with antacids and other products containing polyvalent cations such as dairy products and mineral supplements significantly reduces eltrombopag exposure (see section 4.2)<em>. </em>In a relative bioavailability study in adults, the eltrombopag&nbsp;powder&nbsp;for&nbsp;oral&nbsp;suspension&nbsp;delivered&nbsp;22%&nbsp;higher&nbsp;plasma&nbsp;AUC(0-</p><p>&infin;) than the film-coated tablet formulation. The absolute oral bioavailability of eltrombopag after administration to humans has not been established.</p><p>Based on urinary excretion and metabolites eliminated in faeces, the oral absorption of drug-related material following administration of a single 75 mg eltrombopag solution dose was estimated to be at least 52%.</p><p><u>Distribution</u></p><p>Eltrombopag is highly bound to human plasma proteins (&gt;99.9%), predominantly to albumin. Eltrombopag is a substrate for BCRP, but is not a substrate for P-glycoprotein or OATP1B1.</p><p><u>Biotransformation</u></p><p>Eltrombopag is primarily metabolised through cleavage, oxidation and conjugation with glucuronic acid, glutathione, or cysteine. In a human radiolabel study, eltrombopag accounted for approximately 64% of plasma radiocarbon&nbsp;AUC0-&infin;.&nbsp;Minor&nbsp;metabolites&nbsp;due&nbsp;to&nbsp;glucuronidation&nbsp;and&nbsp;oxidation were also detected. <em>In vitro </em>studies suggest that CYP1A2 and CYP2C8 are responsible for oxidative metabolism of eltrombopag. Uridine diphosphoglucuronyl transferase UGT1A1 and UGT1A3 are responsible for glucuronidation, and bacteria in the lower gastrointestinal tract may be responsible for the cleavage pathway.</p><p><u>Elimination</u></p><p>Absorbed eltrombopag is extensively metabolised. The predominant route of eltrombopag excretion is via faeces (59%) with 31% of the dose found in the urine as metabolites. Unchanged parent compound (eltrombopag) is not detected in urine. Unchanged eltrombopag excreted in faeces accounts for approximately 20% of the dose. The plasma elimination half-life of eltrombopag is approximately 21-32 hours.</p><p><u>Pharmacokinetic interactions</u></p><p>&nbsp;</p><p>Based on a human study with radiolabelled eltrombopag, glucuronidation plays a minor role in the metabolism of eltrombopag. Human liver microsome studies identified UGT1A1 and UGT1A3 as the enzymes responsible for eltrombopag glucuronidation. Eltrombopag was an inhibitor of a number of UGT enzymes <em>in vitro</em>. Clinically significant drug interactions involving glucuronidation are not anticipated due to limited contribution of individual UGT enzymes in the glucuronidation of eltrombopag.</p><p>Approximately 21% of an eltrombopag dose could undergo oxidative metabolism. Human liver microsome studies identified CYP1A2 and CYP2C8 as the enzymes responsible for eltrombopag oxidation. Eltrombopag does not inhibit or induce CYP enzymes based on <em>in vitro </em>and <em>in vivo </em>data (see section 4.5).</p><p><em>In vitro </em>studies demonstrate that eltrombopag is an inhibitor of the OATP1B1 transporter and an inhibitor of the BCRP transporter and eltrombopag increased exposure of the OATP1B1 and BCRP substrate rosuvastatin in a clinical drug interaction study (see section 4.5). In clinical studies with eltrombopag, a dose reduction of statins by 50% was recommended.</p><p>Eltrombopag chelates with polyvalent cations such as iron, calcium, magnesium, aluminium, selenium and zinc (see sections 4.2 and 4.5).</p><p><em>In vitro </em>studies demonstrated that eltrombopag is not a substrate for the organic anion transporter polypeptide, OATP1B1, but is an inhibitor of this transporter&nbsp;(IC50 &nbsp;value&nbsp;of&nbsp;2.7&nbsp;&mu;M&nbsp;[1.2&nbsp;&mu;g/ml]).&nbsp;<em>In&nbsp;vitro&nbsp;</em>studies&nbsp;also&nbsp;demonstrated that eltrombopag is a breast cancer resistance protein (BCRP) substrate and inhibitor&nbsp;(IC50 &nbsp;value&nbsp;of&nbsp;2.7&nbsp;&mu;M&nbsp;[1.2&nbsp;&mu;g/ml])<em>.</em></p><p><u>Special patient populations</u></p><p><em><u>Renal</u></em><em><u> </u></em><em><u>impairment</u></em></p><p>The pharmacokinetics of eltrombopag have been studied after administration of eltrombopag to adult patients with renal impairment. Following&nbsp;administration&nbsp;of&nbsp;a&nbsp;single&nbsp;50&nbsp;mg&nbsp;dose,&nbsp;the&nbsp;AUC0-&infin; &nbsp;of&nbsp;eltrombopag was 32% to 36% lower in patients with mild to moderate renal impairment, and 60% lower in patients with severe renal impairment compared with healthy volunteers. There was substantial variability and significant overlap in exposures between patients with renal impairment and healthy volunteers.</p><p>Unbound eltrombopag (active) concentrations for this highly protein-bound medicinal product were not measured. Patients with impaired renal function should use eltrombopag with caution and close monitoring, for example by testing serum creatinine and/or urine analysis (see section 4.2). The efficacy and safety of eltrombopag have not been established in patients with both moderate to severe renal impairment and hepatic impairment.</p><p><em><u>Hepatic impairment</u></em></p><p>&nbsp;</p><p>The pharmacokinetics of eltrombopag have been studied after administration of eltrombopag to adult patients with hepatic impairment. Following&nbsp;the&nbsp;administration&nbsp;of&nbsp;a&nbsp;single&nbsp;50&nbsp;mg&nbsp;dose,&nbsp;the&nbsp;AUC0-&infin; &nbsp;of eltrombopag was 41% higher in patients with mild hepatic impairment and 80% to 93% higher in patients with moderate to severe hepatic impairment compared with healthy volunteers. There was substantial variability and significant overlap in exposures between patients with hepatic impairment and healthy volunteers. Unbound eltrombopag (active) concentrations for this highly protein-bound medicinal product were not measured.</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1036"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:235.55pt;margin-top:129.4pt;width:6.25pt;height:7.6pt;z-index:-17017856;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="8" height="10" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /><!--[if gte vml 1]><v:shape id="_x0000_s1035"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:188.25pt;margin-top:160.15pt;width:4.7pt;height:5.3pt;z-index:-17017344;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="7" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />The influence of hepatic impairment on the pharmacokinetics of eltrombopag following repeat administration was evaluated using a population pharmacokinetic analysis in 28 healthy adults and 714 patients with hepatic impairment (673 patients with HCV and 41 patients with chronic liver disease of other aetiology). Of the 714 patients, 642 were with mild hepatic impairment, 67 with moderate hepatic impairment, and 2 with severe hepatic impairment. Compared to healthy volunteers, patients with mild hepatic impairment had approximately 111% (95% CI: 45% to 283%) higher plasma&nbsp;eltrombopag&nbsp;AUC(0-&nbsp;&nbsp; &nbsp;) &nbsp;values&nbsp;and&nbsp;patients&nbsp;with&nbsp;moderate&nbsp;hepatic impairment had approximately 183% (95% CI: 90% to 459%) higher plasma eltrombopag&nbsp;AUC(0-&nbsp;&nbsp; &nbsp;) &nbsp;values.</p><p>Therefore, eltrombopag should not be used in ITP patients with hepatic impairment (Child-Pugh score &ge;5) unless the expected benefit outweighs the identified risk of portal venous thrombosis (see sections 4.2 and 4.4). For patients with HCV initiate eltrombopag at a dose of 25 mg once daily (see section 4.2).</p><p><em><u>Race</u></em></p><p>The influence of East-Asian ethnicity on the pharmacokinetics of eltrombopag was evaluated using a population pharmacokinetic analysis in 111 healthy adults (31 East-Asians) and 88 patients with ITP (18 East-Asians).</p><p>Based on estimates from the population pharmacokinetic analysis, East- Asian&nbsp;ITP&nbsp;patients&nbsp;had&nbsp;approximately&nbsp;49%&nbsp;higher&nbsp;plasma&nbsp;eltrombopag&nbsp;AUC(0-</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1034" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:1in;margin-top:5.85pt;width:4.7pt;height:5.3pt;
 z-index:-17016832;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="7" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />) values as compared to non-East-Asian patients who were predominantly Caucasian (see section 4.2).</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1033"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:510.35pt;margin-top:70.15pt;width:6.25pt;height:7.6pt;z-index:-17016320;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="8" height="10" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" />The influence of East-/Southeast-Asian ethnicity on the pharmacokinetics of eltrombopag was evaluated using a population pharmacokinetic analysis in 635 patients with HCV (145 East-Asians and 69 Southeast-Asians). Based on estimates from the population pharmacokinetic analysis, East-/Southeast- Asian&nbsp;patients&nbsp;had&nbsp;approximately&nbsp;55%&nbsp;higher&nbsp;plasma&nbsp;eltrombopag&nbsp;AUC(0-</p><p>) values as compared to patients of other races who were predominantly Caucasian (see section 4.2).</p><p><em><u>Gender</u></em></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1032" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:395.25pt;margin-top:68.05pt;width:4.7pt;height:5.3pt;
 z-index:-17015808;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="7" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />The influence of gender on the pharmacokinetics of eltrombopag was evaluated using a population pharmacokinetic analysis in 111 healthy adults (14 females) and 88 patients with ITP (57 females). Based on estimates from the population pharmacokinetic analysis, female ITP patients had approximately&nbsp;23%&nbsp;higher&nbsp;plasma&nbsp;eltrombopag&nbsp;AUC(0-&nbsp;&nbsp; &nbsp;) &nbsp;as compared to male patients, without adjustment for body weight differences.</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1031"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:303.8pt;margin-top:56.05pt;width:6.25pt;height:7.6pt;z-index:-17015296;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="8" height="10" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" />The influence of gender on eltrombopag pharmacokinetics was evaluated using population pharmacokinetics analysis in 635 patients with HCV (260 females). Based on model estimate, female HCV patient had approximately 41%&nbsp;higher&nbsp;plasma&nbsp;eltrombopag&nbsp;AUC(0-&nbsp;&nbsp; &nbsp;) &nbsp;as&nbsp;compared&nbsp;to&nbsp;male&nbsp;patients.</p><p><em><u>Age</u></em></p><p><!--[if gte vml 1]><v:shape id="_x0000_s1030"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:511.6pt;margin-top:86.45pt;width:4.7pt;height:5.3pt;z-index:-17014784;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="7" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />The influence of age on eltrombopag pharmacokinetics was evaluated using population pharmacokinetics analysis in 28 healthy subjects, 673 patients with HCV, and 41 patients with chronic liver disease of other aetiology ranging from 19 to 74 years old. There are no PK data on the use of eltrombopag in patients &ge;75 years. Based on model estimate, elderly (&ge;65 years)&nbsp;patients&nbsp;had&nbsp;approximately&nbsp;41%&nbsp;higher&nbsp;plasma&nbsp;eltrombopag&nbsp;AUC(0-&nbsp;&nbsp; &nbsp;) &nbsp;as compared to younger patients (see section 4.2).</p><p><em><u>Paediatric population (aged 1 to 17 years)</u></em></p><p><!--[if gte vml 1]><v:shape id="_x0000_s1029"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:475.4pt;margin-top:99.55pt;width:6.25pt;height:7.6pt;z-index:-17014272;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="8" height="10" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /><!--[if gte vml 1]><v:shape id="_x0000_s1028"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:395.25pt;margin-top:128.8pt;width:6.25pt;height:7.6pt;z-index:-17013760;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="8" height="10" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" />The pharmacokinetics of eltrombopag have been evaluated in 168 paediatric ITP patients dosed once daily in two studies, TRA108062/PETIT and TRA115450/PETIT-2. Plasma eltrombopag apparent clearance following oral administration (CL/F) increased with increasing body weight. The effects of race and sex on plasma eltrombopag CL/F estimates were consistent between paediatric and adult patients. East-/Southeast-Asian paediatric ITP patients&nbsp;had&nbsp;approximately&nbsp;43%&nbsp;higher&nbsp;plasma&nbsp;eltrombopag&nbsp;AUC(0-&nbsp;&nbsp; &nbsp;) &nbsp;values as compared to non-Asian patients. Female paediatric ITP patients had approximately&nbsp;25%&nbsp;higher&nbsp;plasma&nbsp;eltrombopag&nbsp;AUC(0-&nbsp;&nbsp; &nbsp;) &nbsp;values&nbsp;as compared to male patients.</p><p>The pharmacokinetic parameters of eltrombopag in paediatric patients with ITP are shown in Table 11.</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1027"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:517.65pt;margin-top:64.6pt;width:4.65pt;height:5.3pt;z-index:-17013248;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="7" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />Table 11 Geometric mean (95% CI) steady-state plasma eltrombopag pharmacokinetic parameters in paediatric patients with ITP (50 mg once daily dosing regimen)</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Age</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong>max </strong><strong>(&micro;g/ml)</strong></p></td><td style="vertical-align:top"><p><strong>AUC</strong><strong>(0- )</strong></p><p><strong>(&micro;g.hr/ml)</strong></p></td></tr><tr><td style="vertical-align:top"><p>12 to 17 years (n=62)</p></td><td style="vertical-align:top"><p>6.80</p></td><td style="vertical-align:top"><p>103</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(6.17, 7.50)</p></td><td style="vertical-align:top"><p>(91.1, 116)</p></td></tr><tr><td style="vertical-align:top"><p>6 to 11 years (n=68)</p></td><td style="vertical-align:top"><p>10.3</p></td><td style="vertical-align:top"><p>153</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(9.42, 11.2)</p></td><td style="vertical-align:top"><p>(137, 170)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>1 to 5 years (n=38)</p></td><td style="vertical-align:top"><p>11.6</p></td><td style="vertical-align:top"><p>162</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(10.4, 12.9)</p></td><td style="vertical-align:top"><p>(139, 187)</p></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
 margin-left:372.6pt;margin-top:6pt;width:4.7pt;height:5.3pt;z-index:-17012736;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="7" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />Data&nbsp;presented&nbsp;as geometric mean (95%CI). AUC(0-&nbsp;&nbsp; &nbsp;) &nbsp;and&nbsp;Cmax &nbsp;based on population PK post-hoc estimates</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Safety pharmacology and repeat-dose toxicity</u></p><p>Eltrombopag does not stimulate platelet production in mice, rats or dogs because of unique TPO receptor specificity. Therefore, data from these animals do not fully model potential adverse effects related to the pharmacology of eltrombopag in humans, including the reproduction and carcinogenicity studies.</p><p>Treatment-related cataracts were detected in rodents and were dose and time-dependent. At &ge;6 times the human clinical exposure in adult ITP patients at 75 mg/day and 3 times the human clinical exposure in adult HCV patients at 100 mg/day, based on AUC, cataracts were observed in mice after 6 weeks and rats after 28 weeks of dosing. At &ge;4 times the human clinical exposure in ITP patients at 75 mg/day and 2 times the human exposure in HCV patients at 100 mg/day, based on AUC, cataracts were observed in mice after 13 weeks and in rats after 39 weeks of dosing. At non-tolerated doses in pre-weaning juvenile rats dosed from Days 4-32 (approximately equating to a 2-year-old human at the end of the dosing period), ocular opacities were observed (histology not performed) at 9 times the maximum human clinical exposure in paediatric ITP patients at 75 mg/day, based on AUC. However, cataracts were not observed in juvenile rats given tolerated doses at 5 times the human clinical exposure in paediatric ITP patients, based on AUC. Cataracts have not been observed in adult dogs after 52 weeks of dosing at 2 times the human clinical exposure in adult or paediatric ITP patients at 75 mg/day and equivalent to the human clinical exposure in HCV patients at 100 mg/day, based on AUC).</p><p>Renal tubular toxicity was observed in studies of up to 14 days duration in mice and rats at exposures that were generally associated with morbidity and mortality. Tubular toxicity was also observed in a 2-year oral carcinogenicity study in mice at doses of 25, 75 and 150 mg/kg/day. Effects were less severe at lower doses and were characterised by a spectrum of regenerative changes.</p><p>The exposure at the lowest dose was 1.2 or 0.8 times the human clinical exposure based on AUC in adult or paediatric ITP patients at 75 mg/day and</p><p>0.6 times the human clinical exposure in HCV patients at 100 mg/day, based on AUC. Renal effects were not observed in rats after 28 weeks or in dogs after 52 weeks at exposures 4 and 2 times the human clinical exposure in adult ITP patients and 3 and 2 times the human clinical exposure in paediatric ITP patients at 75 mg/day and 2 times and equivalent to the human clinical exposure in HCV patients at 100 mg/day, based on AUC.</p><p>&nbsp;</p><p>Hepatocyte degeneration and/or necrosis, often accompanied by increased serum liver enzymes, was observed in mice, rats and dogs at doses that were associated with morbidity and mortality or were poorly tolerated. No hepatic effects were observed after chronic dosing in rats (28 weeks) and in dogs (52 weeks) at 4 or 2 times the human clinical exposure in adult ITP patients and 3 or 2 times the human clinical exposure in paediatric ITP patients at 75 mg/day and 2 times or equivalent to the human clinical exposure in HCV patients at 100 mg/day, based on AUC.</p><p>At poorly tolerated doses in rats and dogs (&gt;10 or 7 times the human clinical exposure in adult or paediatric ITP patients at 75 mg/day and&gt;4 times the human clinical exposure in HCV patients at 100 mg/day, based on AUC), decreased reticulocyte counts and regenerative bone marrow erythroid hyperplasia (rats only) were observed in short-term studies. There were no effects of note on red cell mass or reticulocyte counts after dosing for up to 28 weeks in rats, 52 weeks in dogs and 2 years in mice or rats at maximally tolerated doses which were 2 to 4 times human clinical exposure in adult or paediatric ITP patients at 75 mg/day and &le;2 times the human clinical exposure in HCV patients at 100 mg/day, based on AUC.</p><p>Endosteal hyperostosis was observed in a 28-week toxicity study in rats at a non-tolerated dose of 60 mg/kg/day (6 times or 4 times the human clinical exposure in adult or paediatric ITP patients at 75 mg/day and 3 times the human clinical exposure in HCV patients at 100 mg/day, based on AUC). There were no bone changes observed in mice or rats after lifetime exposure (2 years) at 4 times or 2 times the human clinical exposure in adult or paediatric ITP patients at 75 mg/day and 2 times the human clinical exposure in HCV patients at 100 mg/day, based on AUC.</p><p><u>Carcinogenicity and mutagenicity</u></p><p>Eltrombopag was not carcinogenic in mice at doses up to 75 mg/kg/day or in rats at doses up to 40 mg/kg/day (exposures up to 4 or 2 times the human clinical exposure in adult or paediatric ITP patients at 75 mg/day and 2 times the human clinical exposure in HCV patients at 100 mg/day, based on AUC). Eltrombopag was not mutagenic or clastogenic in a bacterial mutation assay or in two <em>in vivo </em>assays in rats (micronucleus and unscheduled DNA synthesis, 10 times or 8 times the human clinical exposure in adult or paediatric ITP patients at 75 mg/day and 7 times the human clinical exposure in HCV patients&nbsp;at&nbsp;100&nbsp;mg/day,&nbsp;based on Cmax).&nbsp;In&nbsp;the&nbsp;<em>in&nbsp;vitro&nbsp;</em>mouse&nbsp;lymphoma&nbsp;assay, eltrombopag was marginally positive (&lt;3-fold increase in mutation frequency). These <em>in vitro </em>and <em>in vivo </em>findings suggest that eltrombopag does not pose a genotoxic risk to humans.</p><p><u>Reproductive toxicity</u></p><p>&nbsp;</p><p>Eltrombopag did not affect female fertility, early embryonic development or embryofoetal development in rats at doses up to 20 mg/kg/day (2 times the human clinical exposure in adult or adolescent (12-17 years old) ITP patients at 75 mg/day and equivalent to the human clinical exposure in HCV patients at 100 mg/day, based on AUC). Also there was no effect on embryofoetal development in rabbits at doses up to 150 mg/kg/day, the highest dose tested (0.3 to 0.5 times the human clinical exposure in ITP patients at 75 mg/day and HCV patients at 100 mg/day, based on AUC). However, at a maternally toxic dose of 60 mg/kg/day (6 times the human clinical exposure in ITP patients at 75 mg/day and 3 times the human clinical exposure in HCV patients at 100 mg/day, based on AUC) in rats, eltrombopag treatment was associated with embryo lethality (increased pre- and post-implantation loss), reduced foetal body weight and gravid uterine weight in the female fertility study and a low incidence of cervical ribs and reduced foetal body weight in the embryofoetal development study. Eltrombopag should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus (see section 4.6). Eltrombopag did not affect male fertility in rats at doses up to 40 mg/kg/day, the highest dose tested (3 times the human clinical exposure in ITP patients at 75 mg/day and 2 times the human clinical exposure in HCV patients at 100 mg/day, based on AUC). In the pre- and post- natal development study in rats, there were no undesirable effects on pregnancy,&nbsp;parturition&nbsp;or&nbsp;lactation&nbsp;of&nbsp;F0 &nbsp;female&nbsp;rats&nbsp;at&nbsp;maternally&nbsp;non-toxic doses (10 and 20 mg/kg/day) and no effects on the growth, development, neurobehavioural&nbsp;or&nbsp;reproductive function of the offspring (F1).&nbsp;Eltrombopag was&nbsp;detected&nbsp;in&nbsp;the&nbsp;plasma&nbsp;of&nbsp;all&nbsp;F1 &nbsp;rat&nbsp;pups&nbsp;for&nbsp;the&nbsp;entire&nbsp;22&nbsp;hour&nbsp;sampling period&nbsp;following&nbsp;administration&nbsp;of&nbsp;medicinal&nbsp;product&nbsp;to&nbsp;the&nbsp;F0 &nbsp;dams, suggesting that rat pup exposure to eltrombopag was likely via lactation.</p><p><u>Phototoxicity</u></p><p><em>In vitro </em>studies with eltrombopag suggest a potential phototoxicity risk; however, in rodents there was no evidence of cutaneous phototoxicity (10 or 7 times the human clinical exposure in adult or paediatric ITP patients at 75 mg/day and 5 times the human clinical exposure in HCV patients at 100 mg/day, based on AUC) or ocular phototoxicity (&ge;4 times the human clinical exposure in adult or paediatric ITP patients at 75 mg/day and 3 times the human clinical exposure in HCV patients at 100 mg/day, based on AUC).</p><p>Furthermore, a clinical pharmacology study in 36 subjects showed no evidence that photosensitivity was increased following administration of eltrombopag 75 mg. This was measured by delayed phototoxic index.</p><p>Nevertheless, a potential risk of photoallergy cannot be ruled out since no specific preclinical study could be performed.</p><p><u>Juvenile animal studies</u></p><p>&nbsp;</p><p>At non-tolerated doses in pre-weaning rats, ocular opacities were observed. At tolerated doses, no ocular opacities were observed (see above subsection &#39;Safety pharmacology and repeat-dose toxicity&#39;). In conclusion, taking into account the exposure margins based on AUC, a risk of eltrombopag-related cataracts in paediatric patients cannot be excluded. There are no findings in juvenile rats to suggest a greater risk of toxicity with eltrombopag treatment in paediatric vs. adult ITP patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The other core ingredients are: magnesium stearate, mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, Calcium silicate and Isomalt (E 953).</p><p>ELBAG 25 mg and 50 mg film-coated tablets also contain coating ingredients which are: Hypromellose, titanium dioxide, Iron oxide red (E 172), Iron oxide yellow (E 172) and Triacetin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The film coated tablets are supplied in oPA/Al/PVC/Al blister in carton packs, containing 28 film-coated tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceutical Co. Ltd.
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>